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Abstract 
The development of novel therapies is essential to lower the burden of complex diseases. The purpose 
of this study is to identify novel therapeutics for complex diseases using bioinformatic methods. 
Bioinformatic tools such as candidate gene prediction tools allow identification of disease genes by 
identifying the potential candidate genes linked to genetic markers of the disease. Candidate gene 
prediction tools can only identify candidates for further research, and do not identify disease genes 
directly. Integration of drug-target datasets with candidate gene data-sets can identify novel potential 
therapeutics suitable for repositioning in clinical trials. Drug repositioning can save valuable time and 
money spent in therapeutic development of complex diseases.  
We used Gentrepid (www.gentrepid.org) as a candidate gene prediction tool to identify 
candidate genes for complex diseases. Gentrepid predicted 1,497 unique candidate genes for the seven 
complex diseases considered in the Wellcome Trust Case-Control Consortium (WTCCC) genome-
wide association study; namely Type 2 Diabetes (T2D), Bipolar Disorder (BD), Crohn’s Disease 
(CD), Hypertension (HTN), Type 1 Diabetes (T1D), Coronary Artery Disease (CAD) and Rheumatoid 
Arthritis (RA). We also used Gentrepid in specific case studies on CAD and HTN and identified a 
total of 647 candidate genes for CAD and 151 candidate genes for HTN. Further, we extended our 
methodology to identify potential known and novel therapeutic targets from predicted candidate gene 
dataset. 
Our study proposes a simplified approach to integrate drug-target datasets from three publicly 
available drug databases: the Therapeutic Target Database, the Pharmacogenomics Knowledgebase 
and DrugBank; with candidate gene predictions from Gentrepid at the systems level. Using the online 
available drug databases as sources of drug-target association data, we identified a total of 428 
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candidate genes as novel therapeutic targets and 2,130 drugs feasible for repositioning against the 
predicted novel targets for seven complex diseases considered in Genome-wide Association Studies 
(GWAS) conducted by the WTCCC. In our second specific case study on CAD, we found 184 
predicted candidate genes as novel therapeutic targets and 981 potential novel therapeutics for CAD. 
In our third and final research study on HTN, we identified 149 predicted candidate genes as novel 
therapeutic targets associated with 374 novel therapeutics. Our validation benchmarks based on known 
drug targets of seven complex diseases and the scientific literature showed that predicted therapeutic 
targets in all the three research studies were significant (p < 0.05). Hence, we have identified potential 
novel therapeutics which may be suitable for repositioning towards seven complex diseases, taking 
advantage of already known work in pharmaceutics to translate the results of genetic studies to suggest 
clinical treatments for further research. 
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Chapter 1: Introduction 
Deciphering the genetic basis of human diseases develops a better understanding of the phenotype and 
can play an important role in identification of new therapies. Mendelian diseases involve a single gene 
(monogenic), whereas complex diseases involve multiple genes (polygenic), and environmental 
factors. Be it monogenic or polygenic, genes themselves are not responsible for a disease but the 
occurrence of biological variations in them is (Piro & Di Cunto 2012). During the last two decades, 
great efforts have been made in understanding the human genotype-phenotype relationship particularly 
for Mendelian diseases (Botstein  & Risch 2003). Over the last ten years, complex diseases have 
finally begun to be analysed using association studies (Wellcome Trust Case Control Consortium 
2007, Bush & Moore 2012). These studies revealed that complex diseases are far more genetically 
heterogeneous than was previously appreciated, but they are beginning to reveal the genetic basis of 
these diseases. As will be described below, by integrating a high throughput genomic approach with 
bioinformatic methods, it is now possible to map genetic data associated with diseases to therapeutics, 
allowing a precision medicine approach to therapy.  
In this section, firstly, we will describe different approaches of drug development, the 
economics of drug development, and publicly available drug repositories known as drug databases. 
Secondly, we discuss genetic methods to identify disease genes and bioinformatic tools such as 
candidate gene prediction platforms including our in-house platform Gentrepid (www.gentrepid.org). 
Thirdly, we will compare Gentrepid performance with other candidate gene prediction platforms. 
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Finally, we will discuss the purpose of this thesis to identify potential novel therapeutics for complex 
diseases using existing genetic and drug data. These novel therapeutics are suitable for further 
investigation to develop treatments for complex diseases. 
1.1 Drug Development 
The modern era of drug development began following the compound-centric industrial revolution with 
the increased ability to isolate chemical substances. Using a growing drug knowledge base, 
compounding chemists began isolating and dispensing drugs from their own chemist shops. Following 
a series of tragedies, the need for regulation became increasingly apparent. In response, the foundation 
of Food and Drug Administration (FDA) in 1906 provided a regulatory framework to ensure the safety 
and efficacy of drug compounds through clinical trials (Phase I, II and III) (Dickson & Gagnon 2004; 
Gallin & Ognibene 2012). During the late 1960s and early 1970s, drug discovery moved from 
university laboratories to the commercial sector as industries started developing new drugs (Pina, 
Hussain & Roque 2009). During this time frame, pharmaceutical industries discovered new molecules 
with similar properties to penicillin - Beecham discovered clavulanates and Pfizer produced semi-
synthetic molecules known as sulfactams (Pina, Hussain & Roque 2009). While this drug-centric drug 
development undoubtedly saved many lives in 20th century (Li & Jones 2012), it was also an 
expensive, time consuming and stifling approach (PhRMA, 2012), resulting in increasing calls for its 
reform. 
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The traditional compound-centric approach for developing therapeutics involves three steps; 
the first is to test many compounds in animal models (e.g. mouse) in order to identify lead compounds. 
The second is to test the lead compounds in human clinical trials (phase I, II and III) to confirm safety 
and efficacy, and the third and final step is to acquire approval from FDA or European Medicinal 
Agency (EMEA) to bring the drug to market (Dickson & Gagnon 2004). The transition from the first 
step to the second step is crucial, and is the riskiest part of the process because it involves trials of lead 
compounds in real-life patients in controlled clinical settings.  
In this study, we utilized ‘drug repositioning’, an approach to identify new uses of already 
known drugs (Chong & Sullivan 2007). As these drugs have already passed phase I clinical trials, they 
can be utilized in a lower risk drug discovery approach. In order to explain this approach, we will 
review different approaches currently employed to develop drugs, with the focus on the target-centric 
approach. Further, we will provide an overview of the current methods in genetics that can be used in 
conjunction with the target-centric approach to identify novel therapeutics for complex diseases 
suitable for repositioning in clinical trials. 
1.1.1 Compound-centric drug discovery  
Compound-centric drug development focuses on de novo identification of drug compounds. It involves 
testing thousands of compounds first in animal models such as the mouse to identify a lead compound, 
then testing the lead compound in diverse group of human subjects, and finally acquiring approval 
Novel therapeutics for complex diseases from genome-wide association data 
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from the FDA/EMEA to bring the drug to the market (Figure 1.1) (Ashburn & Thor 2004; Dickson & 
Gagnon 2004).  
Compound-centric drug development is a multistep process, which can be divided into following five 
steps: 
a) Preclinical testing  
b) Investigational New Drug (IND) application 
c) Clinical research: Phase 1, Phase 2, Phase 3 
d) New Drug Application (NDA)  
e) Phase 4 - Post-marketing surveillance – Pharmacovigilance 
a) Preclinical Testing 
Preclinical testing is a ‘bottleneck step’ of drug development which involves selection of five chemical 
compounds from 250 compounds by testing on animal models (Dickson & Gagnon 2004) (Figure 1.2). 
In this test, laboratory animals such as Mice, Guinea pigs are used to evaluate the toxicity and 
pharmacology of compounds both in vivo and in vitro (Dickson & Gagnon 2004). It takes 
approximately 1 - 3 years for completion of animal-based testing to find promising five lead 
compounds (Dickson & Gagnon 2004; PhRMA 2013). Finally, the five selected compounds are 
considered for further clinical evaluation in human subjects (PhRMA 2012, PhRMA 2013). 
Mani Grover 
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Figure 1.1– Compound-centric and Target-centric drug development approaches. Compound centric approach involves 
scanning thousands of chemical compounds first into animal models, then human clinical trials and final review and 
approval. On the other hand, target centric approach involves identification of disease gene as the first and foremost step. If 
the identified disease gene is the potential drug target, then already known approved drug compounds can be utilized to 
repurpose as potential drug compounds directly in phase II clinical trials. 
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b) Investigational New Drug Development (IND) 
After successful animal testing, the investigator will file an Investigational New Drug Application 
(IND) with the Food and Drug Administration (FDA) describing the pharmacological profile and 
toxicity testing results of the five drug compounds (Figure 1.2). The FDA usually conducts a safety 
review of a compound to approve an IND application (PhRMA 2012). Hence, the investigator can 
usually start clinical trials of compounds on human subjects about after a month of filing IND 
application. 
c) Clinical Research 
Clinical research involves prospective, organized and systematic exposure of patients to drugs, 
surgical procedures and dietary change. This step in drug development differentiates between the old 
method of trial and error and the present day scientifically proven approaches. It is the most significant 
and sensitive phase which also involves many limitations unlike other stages of drug development. It 
generally requires 6 -7 years to successfully complete clinical trials of a new compound (Dickson & 
Gagnon 2004; PhRMA 2012) (Figure 1.2). Clinical research involves following three phases – 
i) Phase 1 - This is the first clinical test of a new compound in healthy human volunteers. At this stage, 
the investigator selects 10 - 20 healthy human subjects to test the five promising drug compounds 
(PhRMA 2012). This phase determines the safety and toxicity effects of a new compound inside a 
healthy human body, and if it can be considered suitable for the next testing phase.  
Mani Grover 
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ii) Phase 2 - If a compound passes phase 1, then it requires testing in 100 - 500 human volunteers with 
the disease for which drug is under investigation (PhRMA 2012). Phase 2 investigates safety and 
efficacy of a drug compound only on a small group of human subjects. 
iii) Phase 3 - After successful completion of the phase 2 step, the compound undergoes phase 3 before 
filing of the drug approval application. It is the costliest, longest and the most crucial step of clinical 
research. This step confirms both safety and efficacy of the compound on a large group of diverse 
patients (1,000 - 5,000) to ensure capturing the possibility of any adverse side effects of the drug 
(PhRMA 2012). It requires a huge effort to monitor phase 3 clinical trial of a compound in a diverse 
group of patients around the world. 
d) New Drug Application (NDA) 
After the efficacy is confirmed in phase 3 clinical trials, manufacturers can submit a New Drug 
Application (NDA) to the FDA (Figure 1.2). The NDA advisory committee reviews the report 
obtained from the pharmaceutical company before approval for post marketing surveillance (Dickson 
& Gagnon 2004).  
e) Post-marketing surveillance – Pharmacovigilance 
In this last step, pharmaceutical companies perform post-marketing surveys in hospitals as a final 
assessment to approve a marketed drug compound in patients outside clinical studies (Figure 1.2). This 
process is also known as the “phase 4” step. This post-marketing monitoring known as 
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Pharmacovigilance, is designed to gather additional information and any adverse side effects of a drug 
in the general public. 
 
Figure 1.2 – Drug development pipeline with description of compound success rate (PhRMA 2012). The pipeline starts 
with the initial screening of 250 compounds to identify five potential compounds for further clinical research in phase I, II 
and III. Finally, a safe and effective compound is approved by FDA towards a disease. This complete pipeline takes 10-15 
years (PhRMA 2012). 
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1.1.2 Economics of drug development 
Drug development is a costly and time consuming business. It costs on average 1.2 billion U.S. dollars 
and takes 10-15 years to develop a single FDA-approved drug compound (PhRMA 2012) (Figure 1.1 
& Figure 1.2). As shown in Table 1.1, in the past 60 years (1979 - 2011), there was more than eight-
fold increase in drug development costs. Among all the stages of drug development, described in 
section 1.1.1, preclinical tests and clinical trials consume the largest amount of time and money. 
Pharmaceutical companies spend 21% of the average cost of drug development on preclinical studies 
and 31% on phase III clinical trials (PhRMA 2012). Despite such a high investment, a pharmaceutical 
company usually obtains enough revenue from only two out of ten FDA-approved and launched drugs 
(PhRMA 2012). Hence, there is a constant demand in pharmaceutical companies to reduce time and 
money spent on confirming the safety and efficacy of drugs. 
 In recent years, crowdfunding campaigns for clinical trials have begun as new 
initiatives to cover the cost of clinical trials involved in drug development. For example, a recent 
crowdfunding campaign for clinical trials of a potential anticancer drug “ADVince”, collected 2 
million pounds from 2,000 supporters in eight months (icancer.org.uk). This is the most successful 
medical crowdfunding campaign in web history, as of now. Such campaigns not only reduce the cost 
of clinical trials to companies but also create a direct connection between scientists, patients and 
society. However, crowdfunding campaigns are not accountable to the public because these campaigns 
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are unregulated (Cheah, PY et al. 2015). Not all crowdfunding campaigns have clearly set research 
priorities, and online media can also attract emotional donations from society (Cheah, PY et al. 2015). 
Hence, crowdfunding campaigns for clinical trials should be regulated to tackle associated risks 
(Cheah et al. 2015). 
Table 1.1: Description of different estimation of the average cost of drug development made by authors in different studies 
in different time periods. 
S. No. Year  Authors Average cost of drug 
development* 
1 1979 Hansen (Hansen 1979) $137  
2 1987 Woltman (Dickson & Gagnon 2004) $149  
3 1987 Wiggins (Dickson & Gagnon 2004) $173  
4 1991 Dimasi (DiMasi et al. 1991) $319  
5 2003 Dimasi (DiMasi, Hansen & Grabowski 2003) $802  
6 2011 PhRMA (PhRMA 2012) $1200  
        - amount in million US dollars. 
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1.1.3 Repositories of drugs  
Drug Databases 
Hard-won information discovered using the drug-centric approach has been deposited in online 
repositories known as “drug databases”. These drug databases are an easy and efficient way to access 
information on a drug and its mechanism of action. Drug databases provide detailed information 
regarding dosing, in vivo pharmacokinetics and toxicity of available drugs. Table 1.2 lists three major 
types of drug databases. 
Drug databases can be classified into three different types –  
1. Chemical databases - Chemical drug databases contain a broad coverage of compounds but less 
depth of information. They describe the nomenclature, structural and physical properties of 
compounds but do not provide information regarding the mechanism of actions of these compounds. 
An example is the Therapeutic Target Database (TTD) (bidd.nus.edu.sg/group/cjttd/), a freely 
available online drug database that integrates drug data with therapeutic targets. The Therapeutic 
Target Database currently contains 2,025 total drug targets, including 364 successfully approved by 
the FDA, 286 currently in clinical trials, 44 discontinued and 1,331 research targets; and 17,816 drugs, 
including 1,540 approved, 1,423 in clinical trials, 14,853 experimental drugs and 3,681 multi - target 
agents (14,170 small molecules and 652 antisense drugs with available structure or oligonucleotide 
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sequence). Targets and drugs in this database cover 61 protein biochemical classes and 140 drug 
therapeutic classes respectively (Chen, X, Ji & Chen 2002). 
2. Clinical databases - Clinical drug databases contain fewer compounds but a broader depth of 
information regarding the pharmacology and pharmacokinetics of compounds. An example is the 
Pharmacogenomics Knowledge Base (PharmGKB) (http://www.pharmgkb.org). PharmGKB 
captures information about drugs, diseases/phenotypes and targeted genes. It contains information 
about target genes as well as genes involved in modulating the response to drugs. This latter group of 
genes are known as pharmacogenes. Such genes may be involved in the pharmacokinetics of a drug 
(absorption, distribution, elimination) or the pharmacodynamics of a drug (mechanisms of action). 
PharmGKB compiles information regarding target genes and pharmacogenes, their variations and their 
pharmacokinetics and pharmacodynamics. The current release of PharmGKB contains information on 
more than 20,000 genes, 3,000 diseases, 2,500 drugs, 53 pathways, 470 genetic variants with primary 
experimental genotype data (Altman 2007; Hernandez-Boussard et al. 2008).  
3. Chemical and clinical databases - Chemical and clinical drug databases contain both a broad 
coverage of compounds and also attempt to include a broad depth of information. An example is Drug 
Bank (www.drugbank.ca/). Drug Bank is a freely available online database that combines detailed 
drug data with comprehensive drug-target and indication information. It contains 6,711 drug entries 
including 1,576 FDA-approved drugs and 5,083 experimental drugs. In addition, another 14,000  
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protein or drug target sequnces are linked to these drug entries. Each drug-target information entry in 
Drugbank is known as a Drug Card. For each drug card, half of the information relates to the drug data 
and the other half relates to the target data. Many data fields are linked to other data bases such as 
Drug 
Database 
Description Drug-target 
information 
Shortcoming Web link 
Drug Bank A chemical and clinical 
database with blended 
bioinformatics and 
cheminformatics 
resources that combine 
detailed drug data with 
comprehensive drug 
target information.  
6,700 drug 
entries 
including 1,576 
FDA-approved 
drugs, 5,083 
experimental 
drugs and 
14,000 drug 
targets 
This database has large 
number of compounds but 
broad information related 
to compounds. 
However, it does not have 
detailed information 
related to pharmacokinetic 
and pharmacogenetics of 
drug compounds like 
clinical drug databases. 
http://www.drugbank.ca 
(Knox et al. 2011;Wishart, 
David S et al. 2008; 
Wishart, David S. et al. 
2006). 
Therapeutic 
Target 
Database 
(TTD) 
A chemical drug 
database designed to 
provide information 
about the known 
therapeutic protein and 
nucleic acid targets and 
the corresponding 
drugs/ligands directed 
at each of these targets.  
1,535 targets 
and 2,107 
drugs. 
This database has more 
number of compounds but 
less depth of information 
related to compounds. 
http://bidd.nus.edu.sg/group
/cjttd/ 
(Chen, X, Ji & Chen 2002). 
PharmGKB A clinical repository of 
drug compounds with 
genetic, pharmaco- 
genomic, 
pharmacokinetic, 
molecular, cellular and 
clinical data. 
 
20,000 genes 
3,000 diseases 
2,500 drugs 
53 pathways 
470 genetic 
variants 
 
This database has less 
number of compounds but 
broad depth information of 
compounds 
https://www.pharmgkb.org/ 
(Altman 2007; Hernandez-
Boussard et al. 2008). 
Table 1.2 Overview of three major drug databases 
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KEGG, PubChem, ChEBI, PDB, Swiss-Prot and GenBank (Knox et al. 2011;Wishart, David S et al. 
2008; Wishart, David S. et al. 2006). 
1.1.4 Drug repositioning/Drug repurposing 
Drug repositioning is an approach to identify new uses of approved or withdrawn drugs or even those 
drugs which are currently in clinical trials (Chong & Sullivan 2007; Emig et al. 2013). Drug 
repositioning is also known as a drug repurposing, redirecting, reprofiling, retasking, and indication 
expansion. This process of “drug repurposing” aims not to develop new drugs but associate existing 
therapeutics with new phenotypes. 
In recent years, the pharmaceutical regulatory environment has become restrictive, leading to 
newer and more stringent regulations to launch a new drug into the market. These regulations have 
also led to a significant increase in the time and cost of new drug development (Kaitin 2010). 
Therefore, pharmaceutical companies have adopted drug repositioning as a strategy to save time and 
money by exploring drugs whose targets have already been discovered. The estimated time to develop 
a repurposed drug varies between 3 to 12 years compared to 10-17 years for de novo drug 
development, and it takes only ~8.4 million US dollars to relaunch a repositioned product, hereby 
ensuring the pharmaceutical companies significantly save time and money in drug development 
projects (Figure 1.3) (Ashburn & Thor 2004; Persidis 2011). For scientific researchers, the concept of 
drug repositioning is applied in the early stage of target-centric drug discovery to evaluate the 
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usefulness of action of the drug compound on a targeted gene product of interest. Hence, drug 
repositioning is an approach that not only involves development of an active drug compound for a new 
purpose but also identifies whether a drug target is involved in new indication. 
 
Figure 1.3 - Drug development process using drug repositioning - Drug repositioning saves time and risk as 
repositioning can reduce drug development time only to 3 - 12 years compare to conventional 10 - 17 year timeframe. 
Abbreviations - FDA - Food and drug administration, EMEA - European Medicianl Agency, MHLW - Ministry of health, 
labor and welfare (Reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews Drug Discovery] (Ashburn 
& Thor 2004), copyright (2004)). 
Drug repositioning identifies new indications for the following drugs -  
a. Drugs undergoing clinical research - Drugs which are under clinical trial for one disease but 
whose mechanism of action is relevant to more than one disease, can be used in clinical trials of 
more than one disease simultaneously (Padhy & Gupta 2011). For example, a clinical trial of 
the drug “duloxetine” was simultaneously carried out for depression and stress urinary 
incontinence (Ashburn & Thor 2004). 
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b. Failed drugs - Drugs which failed to demonstrate efficacy in phase II or III clinical trials but 
have no major safety concerns during phase I trials can be repositioned towards another disease 
(Padhy & Gupta 2011). For instance, at any one time, a pharmaceutical company typically has 
around 2,000 compounds lying on the shelf after failing phase II and phase III clinical trials. 
These compounds can be repositioned to treat new diseases (Tartaglia 2006). For example, 
blockbuster drugs, such as, Viagra (sildenafil citrate), and Evista (raloxifene hydrochloride), 
have been successfully repositioned after failed human clinical trials (Tartaglia 2006). 
c. Discontinued or withdrawn drugs - Drugs that have been discontinued or withdrawn for 
commercial reasons like financial issues, duplicate projects, or a change in portfolio strategy 
can be repositioned for a different disease in a new drug development project (Padhy & Gupta 
2011). For example, Thalidomide, a drug originally approved for treatment of nausea and 
insomnia in pregnant women, was withdrawn because of its severe birth defects in children. The 
FDA later approved thalidomide as a treatment for leprosy because of its antiangiogenic and 
immunomodulatory effects (Stephens & Brynner 2009). 
d. Marketed and Launched drugs – This category includes various types of marketed and 
launched drugs. Marketed drugs for which patents are about to expire or have already expired for 
the originally patented indications can potentially be repurposed (Padhy & Gupta 2011). Others 
are drugs which have been launched in emerging markets like India and China but are not yet 
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launched in developed markets like the USA and Europe can also be repositioned (Padhy & Gupta 
2011; Sleigh & Barton 2010). 
In recent years, various techniques including natural product (NP) data mining, drug compounds 
data mining and other bioinformatic tools have been used for identification and screening of potential 
drugs suitable for repositioning. NPs have special selectivity to cellular targets and can play an 
important role in drug development (Gu et al., 2013). Researchers have recently started exploring the 
mechanism of action of NPs in the context of biological networks such as protein-protein interactions, 
metabolic networks and drug-target interaction networks by performing statistical tests on large 
quantities of already available data (Gu et al., 2013). Similarly other methods collect 
pharmacokinetics, toxicology, and safety data for drugs suitable for repositioning (Tobinick 2009). As 
the clinical safety data, pharmacokinetics, and the viable dose are available at the start of a drug 
development project, the risks associated with clinical research on patients are significantly reduced 
with fewer failures in the later stages (Sleigh & Barton 2010). This enables pharmaceutical companies, 
academic institutions, public sector laboratories and regulators to efficiently identify novel uses of 
already known drugs suitable for repositioning against human diseases (Chong & Sullivan 2007; 
O'Connor & Roth 2005; Sleigh & Barton 2010; Tobinick 2009). 
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1.1.5 Target-centric drug discovery 
In recent years, a new approach has emerged to reduce the cost and time involved in drug 
development, known as the ‘target-centric’ approach (Bowman & Zon 2010). In the target-centric 
approach, identification of a disease gene is the first and foremost priority in the drug development 
pipeline (Figure 1.1). If the identified disease gene is a potential drug target, then already known drug 
compounds associated with the target can directly be used in animal and human clinical testing to 
evaluate potential therapeutic effects (Figure 1.1). As described in section 1.1, identification of 
suitable disease genes is part of preclinical testing in drug development. Therefore, the target-centric 
approach connects itself with the drug-centric approach via the preclinical step of drug development. 
Here, we will describe methods to identify disease gene candidates, repositories of known disease 
genes and bioinformatics tools to identify candidate gene as potential disease genes for human 
diseases. 
A) Identification of causal genes for inherited diseases 
Identification of disease genes underlying the phenotype is essential to understanding the mechanism 
behind pathogenesis of disease. Diseases may be caused by a single gene or multiple genes. Many of 
the rare diseases in nature for which genetic causes have been identified are caused by a single gene 
(Hamosh, Ada et al. 2005; Motulsky 2006). Such diseases are known as “Mendelian” or “Monogenic” 
diseases. Mendelian diseases follow a specific pattern of transmission (dominant, recessive, X - 
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linked) known as a “Mendelian pattern of inheritance” (Motulsky 2006). Recently, some diseases that 
were initially characterized as monogenic have been shown to be either caused or modulated by the 
action of a small number of genetic loci (Badano & Katsanis 2002). These diseases are described as 
oligogenic diseases (Badano & Katsanis 2002). Oligogenic diseases have been shown to be a 
continuously evolving concept that encompasses a broad spectrum of phenotypes (Badano & Katsanis 
2002). Some of the genes involved in oligogenic diseases have Mendelian-like patterns of inheritance 
which result in the same or similar phenotypes when a small number of genes are mutated in an 
exclusive OR fashion, such as occurs in the eight genes implicated in Bardet-Biedl syndrome (Beales, 
PL et al. 2003). Other genes may only have a modifier effect on genes of Mendelian inheritance 
(Cutting, 2011). At the other end of spectrum are complex diseases, which are polygenic and 
multifactorial (Figure 1.4) (Motulsky 2006). They frequently arise as a consequence of interaction 
between multiple disease genes and the environment. The actual development of a complex disease 
depends in large part on the environment. Genetics plays only a smaller role than for monogenic and 
oligogenic diseases, but the heritable components of some complex diseases have been estimated to be 
as high as 70% by twin studies (Faraone SV & Khan SA, 2006). As the environment is a complex 
system and our understanding of the genetic intricacy of the human genome has increased with time  
(Lieberman-Aiden et al. 2009), the identification of disease genes for complex diseases has proved to 
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be much more complicated than for Mendelian diseases (Dempfle et al. 2008). We will further 
describe two major approaches to identify disease genes for Mendelian and complex diseases. 
 
 
I) Approaches for Mendelian traits 
Most Mendelian traits follow a simple inheritance pattern which determines whether a trait is 
dominant or recessive. For example, a trait X is a dominant trait when it appears at least in one 
offspring of every generation in a family tree. Another trait Y that appears to skip generations is 
known as recessive because two rare alleles must be present in the individual who is then homozygous 
for the rare allele to transfer the trait. The inheritance pattern of Mendelian traits is still studied using 
the linkage method described below. 
Figure 1.4 - Mendelian vs. complex diseases - 
Factors responsible for Mendelian and complex 
diseases (Strachan & Read 2004). Single gene 
diseases are also known as Mendelian diseases. 
Polygenic diseases are multi-factorial and 
caused by both genetic and environmental 
factors. 
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a) Linkage  
Linkage studies take advantage of the tendency of genes in proximity, to be inherited together during 
meiosis. In linkage, a simple relationship between genotype and phenotype is proposed as a model 
(Botstein & Risch 2003). Linkage studies rely on family genetic data because it can only identify loci 
associated with genetic markers within families (related individuals) (Borecki & Province, 2008). In 
linkage, genetic marker loci remain on the same gametic haplotype as a function of the distance 
between the 2 loci, which is described as the recombination frequency (Borecki & Province, 2008). 
The early success of linkage studies lead to identification of the gene causing cystic fibrosis in 1989 
(Botstein & Risch 2003). These studies have successfully identified 1,200 disease genes for Mendelian 
diseases (Botstein & Risch 2003). The size of regions defined by linkage studies can be large, 
containing hundreds of even thousands of genes (Soares & Gershon, 2003). In familial linkage studies, 
the region is inversely related to the number of family members studied and the number of cross-over 
events that have occurred within the region (Soares & Gershon, 2003). Linkage studies are not suited 
for complex diseases because they lack power for the discovery of low odds ratio (odds ratio = relative 
risks of disease in cases versus controls) genetic risk factors involved in complex diseases (Risch, N & 
Merikangas 1996).  
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II) Approaches for complex diseases  
II.1) Association studies 
Complex diseases follow a non-Mendelian inheritance pattern of transmission and and patients with 
the same phenotype may display a spectrum of symptoms. A major difficulty in studying complex 
diseases relates to disease heterogeneity. Disease phenotypes vary significantly among different 
patients based on their genetic background and environmental factors. For example, “Autism” is 
medically known as “Autism Spectrum Disorders” (ASDs) because the symptoms of ASDs manifest 
differently in each individual, and range from mild to severe impairments consisting of ‘Asperger 
Syndrome’ (mild), ‘High function autism’ (low severity) and ‘Low function autism’ (high severity) as 
part of the spectrum (Baron-Cohen, 2008; Gabriels & Hill, 2007, Mayes et al., 2011). In recent years, 
ASDs have also been described as a spectrum of impairment in communication, social interactions, 
interests and behavior due to diversity in clinical presentation (La Malfa, Lassi, Bertelli, Salvini, & 
Placidi, 2004; Saulnier & Klin, 2007). Similar levels of heterogeneity are present in other complex 
diseases such as Hypertension (HT) and Bipolar disorder (BD). Because of such difficulties, it is a 
challenging task to identify the genes responsible for complex diseases and to even identify which 
individuals to include in a study, particularly with phenotypes like HT and BD for which there is no 
molecular marker. Unlike linkage, association studies can be performed in unrelated individuals as 
Mani Grover 
23 
 
 
 
 
 
 
well as families (related individuals) using both random and case-control sampling methods (Borecki 
& Province, 2008). 
Complex diseases have proved largely intractable to linkage studies and two competing 
theories evolved as to the reason for this: the common disease-rare variant scenario (CDRV) and the 
common disease-common variant scenario (CDCV). The CDRV hypothesis posits that DNA 
variations with minor allele frequencies less than 0.5% contribute to the disease (Manolio et al., 2009), 
but these rare variants make major contributions to the disease in individual patients. Examples are 
loci that contribute to salt-sensitive hyptertension (Liddle syndrome). The CDCV hypothesis posits 
that variations with minor allele frequencies of greater than 5% contribute to disease, based on the 
existing knowledgebase of diseases like Alzheimer’s and Diabetes (Manolio et al., 2009). Genome 
wide association studies (GWAS) are based on the ‘common disease, common variant’ hypothesis 
(Manolio et al., 2009). They attempt to find genetic loci with disease associations by comparing 
common genetic variants in a large number of affected individuals with those of controls (Lander, 
1996, Risch and Merikangas, 1996). The first large scale GWAS was studied for seven complex traits 
by comparing the genomes of 2,000 individuals against 3,000 case controls (Wellcome Trust Case 
Control Consortium, 2007). 
In recent years, large-scale association studies and sequencing analysis have successfully 
identified causal factors for complex diseases. GWAS studies are the first association studies to 
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resolve the genetics behind complex diseases, but they have not been as powerful as originally hoped. 
Next, we will describe GWAS and the first large scale GWAS conducted by the Wellcome Trust Case 
Control Consortium (WTCCC) in 2007 (Wellcome Trust Case Control Consortium 2007). 
II.2) Genome - Wide Association Studies (GWAS) 
Genome-wide association studies are based on the principle of ‘common disease-common variant’. 
This approach attempts to find disease makers associated with a specific phenotype by comparing 
common genetic variants in a large number of affected individuals with controls (Lander, ES 1996; 
Risch, N & Merikangas 1996). GWAS, unlike linkage analysis, test whether specific genetic loci are 
associated with a disease or not. In GWAS, a heterogeneous population rather than a family is used. 
This population must be effectively represented by a sufficiently large sample size to reflect the 
underlying genetic heterogeneity of the phenotype which may be difficult to estimate for initial 
studies, although allele frequencies of the common variants on the SNP chip allow an estimate to be 
made. While linkage is the most powerful method for identifying disease-associated alleles for 
Mendelian diseases, GWAS are considered to be the best method for identifying genetic variants 
related to common complex diseases (Hirschhorn, J & Daly 2005; Neale & Sham 2004). GWAS 
perform better than linkage and attempt to deliver precise results for common diseases by pinpointing 
the implicated locus to a haplotype block (Wellcome Trust Case Control Consortium 2007; Witte JS 
2010).  
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A common conundrum in linkage and GWAS is that genetic markers analysed and identified 
may be ‘tagging SNPs’ for a locus, and simply be in close proximity to the true aetiological gene 
(Deo, RC et al. 2014). A ‘tag SNP’ is a representative SNP of a group of SNPs in a genomic region 
which are in linkage disequilibrium (Deo, RC et al. 2014). This ‘Tag SNP’ can help to identify causal 
genes and associated with phenotypes without genotyping every SNP in a chromosomal region (Deo, 
RC et al. 2014). Subsequent sequencing studies within the affected population may then allow 
identification of variations that are associated with disease (Deo, RC et al. 2014). However, 
identification of the causal gene using sequencing-based methods (such as Sanger sequencing, 
Maxim–Gilbert sequencing, next generation sequencing) has been challenging because many 
variations in the genome have made it difficult to identify the causal gene and hence the target for a 
therapeutic strategy (Deo, RC et al. 2014).  
The majority of GWAS-identified genetic variants fall in noncoding regions of the genome 
(Edwards, SL et al. 2013). Approximately 88% of GWAS tag SNPs lie in intergenic regions and 
therefore are likely to influence gene regulation (Edwards, SL et al. 2013). However, the likely 
mechanisms affected by noncoding variants is still under investigation (Edwards, SL et al. 2013). 
Potential mechanisms include transcriptional regulation, noncoding RNA function, and epigenetic 
regulation (Edwards, SL et al 2013). These approaches have already accelerated progress from genetic 
studies to biological knowledge and novel therapeutic cures for complex diseases (Edwards, SL et al. 
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2013). Although GWAS have provided valuable insights into the genetic basis of several human 
diseases, such studies are still in their infancy, having explained only a small component of the 
heritability of complex diseases. Next, we will describe the first large scale genome-wide association 
study, the limitations of GWAS and their applications to identify disease genes and drug targets for 
complex diseases. 
 
II.2.1) WTCCC-GWAS study 
Over the past few years, GWAS have been employed to find genes contributing to complex diseases. 
The first large scale GWAS study was conducted by WTCCC in 2007 on the seven complex diseases: 
Type 2 Diabetes (T2D), Bipolar Disorder (BD), Crohn’s Disease (CD), Hypertension (HTN, HT), 
Type 1 Diabetes (T1D), Coronary Artery Disease (CAD) and Rheumatoid Arthritis (RA) using the 
 Figure 1.5 – Population based studies - 
Description of genome- wide association 
studies as population specific studies to identify 
disease associated locus. 
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genomes of ~2,000 individuals for each of the seven complex diseases against 3,000 case controls 
(Wellcome Trust Case Control Consortium 2007). A Manhattan plot obtained from this study 
describes the genome wide scan of the seven diseases (Figure 1.6) (Wellcome Trust Case Control 
Consortium 2007). Among the seven diseases, T1D, T2D, CD, CAD and RA, there were 7, 3, 9, 1 and 
3 significant peaks (p<5*10-7) (Figure 1.6) (Wellcome Trust Case Control Consortium 2007), 
indicating potential loci important in contributing to these diseases, but BD and HT provided no 
significant peaks at the highly significant level (p < 5*10-7) because the genotype - phenotype data was 
noisier compared to other five complex diseases (Figure 1.6) (Ballouz, S. et al. 2011; Wellcome Trust 
Case Control Consortium 2007). The WTCCC-GWAS study was the first GWAS study to identify 
statistically significant genetic loci for complex phenotypes. 
II.2.2) Limitations of GWAS 
Despite large investment, GWAS has identified far fewer genes than anticipated and the clinical 
benefit remains limited to date (Sanseau et al. 2012). Analysis of GWAS data using highly stringent 
thresholds for statistical significance by testing multiple isolated SNPs has limited the scope of gene 
discovery (Cantor, Lange & Sinsheimer 2010). Most GWAS studies used the “most significant 
SNPs/genes” approach to list only the top 20-50 significant SNPs and excluded other SNPs which did 
not reach this threshold (Saxena et al. 2007; Scott et al. 2007; Wang, Li & Bucan 2007; Zeggini et al. 
2007). The highly stringent significant threshold employed, which corrects for multiple testing of the 
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large number of SNPs on the array (e.g. Bonferroni correction), attempts to reduce the number of false 
positives. This conservative statistical approach, combined with the selection of the nearest- 
neighbouring gene (genes with SNPs adjacent or internal to genes or gene boundaries) to the 
significant SNP, identifies very few candidates. The lack of genetic signals recovered to explain the 
genetic heritability of many diseases implies that much has been missed due to the limitations of the 
GWAS methodology (Manolio et al. 2009). This “missing heritability” may partly be due to the 
heterogeneity of the population, for example – a disease may be caused by multiple rare variants or the 
effect size of each gene may be so small that a much larger population may need to be sampled. As 
shown in Manhattan Plots (Figure 1.6), GWAS data contain far more information than is encoded in 
the most significant peaks, and more work needs to be done to extract data from slightly less 
significant peaks (Wellcome Trust Case Control Consortium 2007). To address this deficit, 
bioinformatics tools such as candidate gene prediction platforms have been used to analyse the GWAS 
data. Next, we will describe major repositories to retrieve significant SNPs from GWAS studies and 
disease genes. 
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Figure 1.6 - Manhattan Plot showing 
significant SNPs for seven complex 
diseases identified in the WTCCC-
GWAS study (Reprinted by permission 
from Macmillan Publishers Ltd: [Nature],
(Wellcome Trust Case Control 
Consortium 2007) copyright (2007)). 
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B) Repositories of GWAS significant SNPs  
 
GWAS analysis has shown moderate success in the past decade, and there has been a dramatic increase 
in their utilization to identify GWAS hits for complex diseases, enabling a proportion of the genetic 
heritability to be explained (Lander, E & Schork 1994; Risch, NJ 2000). The increased number of 
GWAS being undertaken has also been fuelled by the decreasing cost and increasing resolution and 
availability of high density genotyping technologies. Here, we will describe two major repositories to 
search and explore known GWAS data for human diseases. 
I) The Database of Genotypes and Phenotypes (dbGaP) - The National Center for Biotechnology 
Information (NCBI) has created a freely available database known as ‘dbGaP’ 
(http://www.ncbi.nlm.nih.gov/gap, Access date: 18-09-2016) for individual-level phenotype data, 
genotype sequence data and the associations between them (Mailman et al. 2007).  The dbGaP catalog 
is sponsored by the National Institute of Health (NIH), USA to curate and distribute information from 
studies related to interaction of genotype and phenotype (Tryka et al. 2013). dbGaP assigns a unique 
identifier to each of the 737 studies catalogued (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/summary.cgi, Access date: 18-09-2016). The information recorded for each study includes 
individual phenotypic variables, a table of trait data, a set of genotype data and phenotype-genotype 
associations (Mailman et al. 2007). In addition to the SNP-trait association data, the catalog also has a 
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GWAS diagram of SNP-trait associations mapped to the SNPs’ chromosomal locations (Mailman et 
al. 2007). 
II) NHGRI-EMBL-EBI GWAS database – This database was originally created by the National 
Human Genome Research Institute (NHGRI) in 2008.  From September 2010 onwards, development of 
this database is a collaborative project between the European Bioinformatics Institute (EMBL-EBI) and 
NHGRI (https://www.ebi.ac.uk/gwas/, Access date: 18-09-2016). This database is a manually curated, 
literature-derived and quality controlled collection of all published GWAS, assaying at least 100,000 
SNPs, with all SNP-trait associations with p-values < 1.0 x 10-5 (Hindorff et al. 2009, Welter et al. 2014). 
This catalog has 1,751 curated publications of 11, 912 SNPs (https://www.ebi.ac.uk/gwas/, Access date: 
18-09-2016), and also provides pictorial representations of all the SNP-trait associations, with p-value 
≤ 5.0 x 10-8, mapped onto the human genome by chromosomal locations and displayed on the human 
karyotype (Welter et al. 2014). 
C) Repositories of known disease genes 
In the past few decades, far more progress has been made in identifying the underlying causes of 
Mendelian diseases, resulting in current repositories of known disease genes being heavily biased 
towards Mendelian diseases. Most disease mutations that have been identified to date occur in the 
coding regions of genes. As a result, available protein structures can provide an understanding about 
the effect of a mutation in a disease gene. The disease-causing abnormal gene may be translated into a 
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mutated protein causing a deficit in the protein activity in a number of ways such as: a structurally 
altered protein with abnormal catalytic properties; failure in synthesis of the protein, and indirect 
effects on the synthesis of other proteins by acting upon inhibitors or activators (Harris 1968). 
However, identification of the disease gene is essential to translate this knowledge to the level of 
proteins. Here, we will describe two primary repositories of known disease genes and disease-
associated mutations: The Online database of Mendelian Inheritance in Man (OMIM) and the Human 
Gene Mutations Database (HGMD), which together contain >10,000 annotated disease genes (Steward 
et al. 2003). 
I) Online database of Mendelian Inheritance in Man (OMIM) 
 OMIM, a database of inherited genetic disorders, contains 14,831 genes and 7,894 
phenotypes (Amberger et al. 2015). OMIM is a publicly-available online knowledgebase 
which stores information about genes and genetic disorders; combining expert-curated 
summaries of the literature with information on allelic variants, and is searchable by SNP 
identifier. It contains a total of 22,634 entries, consisting of either genetic or phenotypic 
descriptions, all of which are linked to other informative genetic databases such as DNA 
and protein sequence databases, PubMed references, general and locus-specific mutation 
databases, HUGO nomenclature, MapViewer, GeneTests, patient support groups and many 
others (Amberger et al., 2015). 
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II) Human Gene Mutation Database (HGMD)  
HGMD is a comprehensive collection of germ-line mutations in nuclear genes associated 
with inherited diseases. It includes cDNA reference sequences, splice junction data, as well 
as disease-associated and functional polymorphisms. It also provides links to data present 
in publicly-available online locus-specific mutation databases (Cooper, Stenson & 
Chuzhanova 2006). Unlike OMIM, it is not freely available for download for educational 
institutions. An older version can be searched online but the most recent version and a 
downloadable version requires a subscription. 
1.1.6 Candidate gene prediction tools 
Candidate disease gene prediction is a developing area of bioinformatics research assisting geneticists 
to identify good candidate disease genes. Bioinformatics tools such as candidate gene prediction 
platforms can help in silico identification of candidate genes for complex diseases. This area has been 
enabled by the completion of the Human Genome Project in 2001. Candidate gene prediction tools 
were originally designed for Mendelian disorders for use on one or more genetic loci. The need for 
good applications in the area of candidate gene prediction became increasingly important when SNP-
based association studies (e.g. GWAS) started producing valuable genetic information for further 
analysis. Despite the advent of GWAS, prediction and prioritization of disease genes in complex 
diseases is still difficult due to the weaker associations between genetics and the disease phenotype. 
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Hence, several candidate gene prediction tools were designed to prioritize genes from multiple loci 
implicated by the association studies rather than within a single locus.  
Candidate gene prediction tools with various underlying data sources, inputs, algorithms, and 
ranking strategies have been reviewed previously (Oti et al. 2011; Moreau and Tranchevent 2012). 
Some of these prediction tools have been designed to prioritize candidates from GWAS data (Holmans 
et al. 2009; Raychaudhuri et al. 2009; Duncan et al. 2010; Wang et al. 2010, Ballouz S. et al. 2011). 
Specific candidate gene prediction tools differ in the bioinformatic methods adopted for candidate 
gene prediction and the input data utilized to generate candidate gene predictions (Teber, ET et al. 
2009). Candidate gene prediction tools have been classified in a number of different ways. Below is a 
useful classification based on bioinformatic methods: 
I) Classification of candidate gene prediction tools: Candidate gene prediction tools may be 
classified based on bioinformatics methods into the following four types described below (Teber, ET 
et al. 2009). Figure 1.7 describes different bioinformatics methods used in candidate gene prediction 
tools and Table 1.4 provides brief descriptions and web-links of various candidate gene prediction 
tools (Table 1.4 is adapted from http://homes.esat.kuleuven.be/~bioiuser/gpp/tools.php web link and 
Oti, Ballouz &Wouters, 2011). 
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1. Gene clustering method-based tools   
Gene clustering methods use some common features of genes such as participation in the same 
biochemical pathways, protein functional domains or keywords associated with the genes to cluster 
them (Figure 1.7). Features may be associated with phenotypes using known disease genes (e.g. 
seeded method of Gentrepid) or by searching for enrichment of features across multiple disease 
intervals associated with the phenotype (e.g. ab initio method of Gentrepid) (George, RA et al. 2006, 
Teber, ET et al. 2009). Systems biology-based gene clustering approaches may use pathway and 
protein-protein interaction data from databases such as the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database, Reactome, Human Protein Reference Database (HPRD) e.g. Gentrepid 
Common Pathway scanning method (CPS). Alternatively, GO and InterPro-based keywords may be 
clustered to predict candidates e.g. the POCUS prediction tool uses keywords from InterPro domains 
to identify functional annotations among multiple loci associated with the disease of interest (Teber, 
ET et al. 2009). Domain-based methods utilize domain databases such as the Pfam library of Hidden 
Markov models (Finn RD et al. 2015) based on sequence alignments to predict candidates e.g. the 
Gentrepid Common Module Profiling method (CMP) (George, RA et al. 2006).  
2. Phenotype clustering method-based tools 
As the name suggests, phenotype clustering involves clustering of phenotypes rather than genes. In 
one tool, MimMiner (Van Driel, M.A. & Brunner, HG, 2006), this is done by text-mining of the 
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phenotypic description in OMIM. A feature vector for each phenotype is constructed from Medical 
Subject Headings (MeSH), a standardized vocabulary of hierarchical terms used by the National 
Library of Medicine (NLM). Terms are weighted according to the inverse document frequency 
measure so that rare terms shared by two phenotypes descriptions have more weight than a common 
keyword. Pairwise scores are calculated between phenotypes based on the number of non-common 
keywords their descriptions share. Disease genes can then be predicted for phenotypes that are not 
well characterized at the genetic level by using the disease genes for similar phenotypes.  
3. Machine learning method-based tools 
Machine-learning approaches use training sets of genes to produce classification rules that can 
distinguish genes in different subsets. The most common approach has been to divide genes into a set 
that are involved in diseases and those that are not to produce a profile of the two gene sets which 
enables training of a classifier (Teber, ET et al. 2009). A novel gene then submitted to the classifier is 
flagged as either "disease-causing" or "non-disease causing" (Teber, ET et al. 2009) (Figure 1.7). 
Because our knowledgebase is incomplete, this bipartite distribution is fraught with difficulties 
because the "non-disease" class may contain undiscovered disease genes (false negatives). Example 
ProDiGe (Priortization of Disease Genes) tool uses a machine learning algorithm for prioritization of 
candidate Genes. It integrates various data sources about the genes using a strategy based on learning 
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from positive and unlabeled examples (known disease genes and non-disease genes) and perform 
genome-wide searches to predict novel candidate genes. 
4. Transitive/hybrid method-based tools  
Transitive/hybrid methods employ a third quantity that can be linked to both genotype to phenotype to 
provide a mapping between the two entities. For example, the G2D tool uses keyword-based 
ontologies. It takes phenotype descriptions from the literature, maps them to Medical Subject 
Headings (MeSH) based keywords and then sequences are mapped to gene ontology (GO) based 
keywords. These two sets of keywords (GO keywords and MeSH keywords) are then matched using 
already known associations of phenotype of interest with Medical Subject Headings (MeSH) 
keywords to derive the relationship between phenotype of interest and sequence based functional 
keywords (van Driel, MA et al. 2003). The eVOC system uses literature-based ontologies. It uses text 
mining of biomedical literature to associate a phenotype with anatomy terms and links these with 
human expression data for each gene to produce a ranked list of disease genes (Tiffin N et al. 2005, 
Teber, ET et al. 2009).  
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 Figure 1.7 Prediction methods used in candidate gene prediction platforms. Gene clustering method 
associates a gene cluster with a phenotype e.g. Gentrepid. Phenotype clustering methods group related 
phenotypes into super-phenotypes e.g. MimMiner. Machine Learning methods are based on the concept that 
the genome consists of disease causing genes, and those not causing diseases. Hence, a candidate gene is either 
"disease-causing" or "non-disease causing" e.g. ProDiGe Transitive method simply maps phenotypes to genes 
using literature and keyword based ontology methods e.g. G2D, eVOC (Teber, ET et al. 2009). 
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II) Data sources utilized by candidate gene prediction tools: The data sources utilized by 
candidate gene prediction tools are the fundamental basis of gene prioritization (Tranchevent, LC et al. 
2010). Ideally, both high coverage and high quality data sources are required to predict candidate 
genes with accuracy (Tranchevent, LC et al. 2010). There are wide-range of data sources used by the 
candidate prediction systems such as literature mining, protein-protein interaction (PPI) and pathway 
based data sources, functional annotations, gene expression, and protein or DNA sequences. The most 
commonly used six data sources are systems-biology data sources (e.g. KEGG, Biocarta), domain 
classification libraries (e.g. Pfam), GO keywords, keywords obtained from literature searches or 
databases (eg MEDLINE, GO), transcription regulation related data source (e.g. m-RNA related data) 
and protein or DNA sequences (e.g. InterPro, BLAST) (Figure 1.8).  
The ability to make predictions is limited by the existing knowledgebase. The coverage of each 
data source is a basic limitation which constrains its ability to make predictions. For example, only 
10,000 human proteins, 25% of the human proteome, have manually curated GO-terms (George RA et 
al. 2006), coverage of pathways in currently available pathway databases (e.g. KEGG) is only 10-25% 
of existing pathways, while approximately 70% of the genes in the genome have at least one parseable 
functional domain and other regions of the protein sequence are completely unrepresented in the Pfam 
library (George RA et al. 2006, Finn RD et al. 2015). No a single data source currently has genome-
wide coverage but the use of several data sources may allow a prediction to be made for more loci. For 
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example, Gentrepid utilizes system biology-based (e.g. KEGG) as well as domain classification-based 
data sources (e.g. Pfam). 
 
Figure 1.8 – Data sources utilized by candidate gene prediction tools – Majority of data sources underlying candidate 
gene prediction tools are based on systems-biology (protein-protein interaction and pathways), functional annotations (GO 
keywords), literature (text mining), domain-homology, gene expression, transcriptional regulation and sequence analysis. 
Prediction tools described in this figure use at least two different type of underlying data resources (Tranchevent, LC et al. 
2010) (Reprinted with permission from Oxford University Press - Tranchevent, LC, A guide to web tools to prioritize 
candidate genes, 2010, Briefings in Bioinformatics, vol.12, issue no. 1, pp. 22-32). 
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Unfortunately, pooling data sources does not allow predictions to be made for all loci: there is 
much redundancy, with some regions being well-annotated and others having no information on which 
a prediction can be based. However, it is not desirable to include as many data sources as possible but 
rather to reach a critical number of data sources beyond which valid predictions can be made. Indeed, 
including many data sources can be detrimental if a meta-analysis approach is taken because data 
sources that are derivative of each other may suggest a prediction has better support when this is not 
true.  
Candidate gene prediction tools not only vary in underlying data sources as described above 
but also in the circumstances of their applicability. Some prediction tools only summarize the existing 
knowledgebase (Summarization tools), e.g. Bitola, while other tools can be used to investigate genetic 
data like GWAS (Analytical tools) e.g. Gentrepid. We will further discuss only about analytical tools. 
Different analytical prediction tools use different learning algorithms and weighting systems to predict 
and prioritize valid candidate genes. For example, Machine learning methods use a ‘learned classifier’ 
to predict and prioritize candidate genes. These methods involve binary classification approach, which 
is based on the assumption that genes can be divided as disease genes and non-disease genes for 
independent learning. ‘Support Vector Machine (SVM)’ is a widely-used machine-learning based 
technique which allows combination of protein interaction, sequence and protein functional 
information at the molecular level (Le, DH et al. 2015).  E.g. Endeavour prediction tool uses a support 
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vector machine algorithm trained with the already known disease genes of disease in question 
(Tranchevent LC et al. 2008). Underlying data sources in this tool are based on GO keywords, 
functional analysis (e.g. InterPro), pathway data (KEGG), literature, gene expression data, and 
sequence alignment (e.g. BLAST) (Tranchevent LC et al. 2008). It uses a set of known disease genes 
are used to gather information about a disease or pathway and rank test genes based on their similarity 
with the known disease genes. Finally, the ranks obtained using multiple data sources are fused by 
order statistic using the minimum and maximum ranks (Tranchevent LC et al. 2008). However, 
computing ranks based on order statistics causes selection problem because it is difficult to rank very 
long list of genes. Machine learning methods are useful in discovering patterns (Le, DH et al. 2015). 
However, binary classification of genes employed in these methods can not be ideal as we can never 
be completely sure which genes are non-disease as there are no evidences (e.g. literature, databases) 
available for such genes (Le, DH et al. 2015). 
Some candidate gene prediction tools cluster common features (e.g. domains, pathways) with 
known diseases genes, and the significance of each result is computed using a simple statistical test 
such as χ2-test (e.g. Gentrepid). In Gentrepid prediction tool, protein domain based gene predictions 
are filtered on the basis of two different chi-squared test score thresholds, depending on whether they 
were multi-domain or single domain proteins (George RA al, 2006). A threshold value of χ2min > 102 
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is used to filter single domain gene products and χ2max_unique > 105 is used for multi-domain gene 
products (George RA et al. 2006).  
Different data sources underlying candidate gene prediction tools are dependent on each other, 
and therefore, the redundant biological information present in different data sources can decrease the 
performance of prediction tools for e.g. MEDLINE, GO and KEGG. All information related to 
biomedical literature does not eliminate from a prediction tool after removing MEDLINE data source, 
because it is also present in GO and KEGG data sources (Bornigen D et al. 2012). Hence, the future 
research focus in this direction is the development of prediction methods to select useful features from 
various data resources and combine many data sources from different organisms to predict candidates.  
III) User inputs required for candidate gene prediction tools: Candidate gene prediction 
tools differ in the inputs required and users can supply two distinct types of inputs in candidate gene 
prediction tools:  the prior knowledge and the candidate search space. The prior knowledge represents 
already available knowledge about the disease in question, it can be represented either as a set of 
‘known disease genes’ or as a set of ‘keywords’ that describe the disease in question (Tranchevent LC 
et al. 2010). Gene products associated with the pathways already known to be involved in a disease 
can also be used as input. Many tools accept a disease name or a set of user defined keywords as 
inputs, for e.g. to identify candidates for diabetes, ‘diabetes’ keyword can be used in combination with 
diabetes related keywords such as ‘insulin’, ‘islets’, ‘glucose’ (Tranchevent LC et al. 2010). 
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The candidate search space defines genes as candidates using genetic loci and differentially 
expressed genes (DEG) list. A genetic locus is a set of neighboring genes (e.g. all genes from the 
cytogenetic band 8q11.22 or genes in a genetic interval) (Tranchevent LC et al. 2010). A genetic locus 
containing genes linked to a disease defined as a ‘Quantitative Trait Locus (QTL)’. Another user input 
using candidate search space is a list of genes which are not necessary from one chromosomal location 
but differentially expressed in a tissue associated with disease of interest (Tranchevent LC et al. 2010). 
Below is the detailed description of which tools can be utilized depending on type of input data is 
known to a user. Table 1.3 describes examples of which candidate gene prediction to use depending on 
input data supplied by user. Table 1.4 provides brief description and web-links of various candidate 
gene predictions tools described here in examples.  
1) If disease genes related data is known: Some tools prioritize candidate genes using a specific 
disease gene to be investigated for links to a disease phenotype. E.g. aGeneApart, BITOLA, 
and SNPs3D (Oti, Ballouz & Wouters 2011).  
2) If disease names related data is known: Some tools use disease names as an input data E.g. 
G2D (Oti, Ballouz & Wouters 2011). 
3) If phenotypic features related data is known: Some tools such as aBand apart, Gene 
Distiller allow the entry of disease-related phenotypic features such as phenotypic symptoms 
of inherited chromosomal aberration syndrome (e.g. Down syndrome). However, such 
information is still under-utilized by users (Oti, Ballouz & Wouters 2011) 
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4) If disease associated features related data is known: Some tools such as PosMed, 
SUSPECTS prioritize candidate genes using those disease-associated features as an input which 
are linked to a disease phenotype (Oti, Ballouz & Wouters 2011).  
5) If genetic loci related data is known: Some tools such as Gentrepid, G2D, Genewanderer can 
predict and prioritize candidate genes using genetic loci related data (chromosomal locations, 
SNP data) as an input (Oti, Ballouz & Wouters 2011). 
6) If differentially expressed genes (DEG) list related data is known: Tools such as ToppGene 
and PGMapper predict and prioritize candidate genes using DEG list (Oti, Ballouz & Wouters 
2011).  
 
 
Type of input data 
Single locus Multiple loci Single gene Multiple genes Whole genome 
Disease name 3.8, 3.10, 
3.19 
3.8 3.18  3.2, 3.7, 
3.13,3.15, 
3.16, 3.18,3.19 
Known genes 3.5, 3.6, 3.8, 
3.10, 
3.11, 3.19, 
3.20, 3.21 
3.5, 3.8,  
3.21 
 3.5, 3.6, 3.22    3.19, 3.20 
Phenotypic 
features 
3.1, 3.6, 3.9  3.1 3.6  
Disease- 
Associated features 
 
 
3.1, 3.4, 3.5, 3.6, 
3.14, 3.17,3.19 
3.4,  
3.5 
3.1,  
3.3 
3.5, 3.6, 3.14, 
3.12 
3.4, 3.7, 3.16, 
3.17, 3.19 
 None     3.12  
3.1, aBandApart and aGeneApart; 3.2, AlignPI and CIPHER; 3.3, BITOLA; 3.4, CANDID; 3.5, Endeavour; 3.6, GeneDistiller; 3.7, Gene Prospector; 3.8, 
Genes2Diseases (G2D); 3.9, GeneSeeker; 3.10, GeneWanderer; 3.11, Gentrepid; 3.12, GFINDer; 3.13, MimMiner; 3.14, PGMapper; 3.15, PhenoPred; 3.16, 
PolySearch; 3.17, PosMed; 3.18, SNPs3D; 3.19, SUSPECTS; 3.20, Syndrome To Gene (S2G); 3.21, TOM; 3.22, ToppGene (Oti, Ballouz & Wouters 2011).  
Table 1.3 Candidate gene prediction tools and input data required for such tools (Oti, Ballouz & Wouters 
2011). 
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 IV) Limitations of candidate gene prediction tools: There are following four limitations 
associated with candidate gene prediction tools. 
1. Annotation bias of prediction tools: Most candidate gene prediction tools rely on annotation from 
literature mining or manual curation (Oti, Ballouz & Wouters 2011). If a gene is better annotated and 
well-studied, it will be ranked highly in a prioritization method (Oti, Ballouz & Wouters 2011). The 
actual disease gene may fail to rank highly among predicted genes due to a lack of data rather than low 
functional relevance (Oti, Ballouz & Wouters 2011). 
2. Use of known disease genes for predictions: Some candidate gene prediction tools use known 
disease genes as training sets for their candidate disease gene prediction (Oti, Ballouz & Wouters 2011). 
It may be a disadvantage if the unknown disease gene differs substantially from the genes used in the 
training set (Oti, Ballouz & Wouters 2011). Most of these tools use Mendelian disease genes to predict 
genes for complex diseases (Oti, Ballouz & Wouters 2011). Thus they are not good knowledge discovery 
tools. 
3. Differences among multiple tools: There may be differences in prioritization performance among 
various candidate gene prediction tools, which also vary between disease types (Oti, Ballouz & Wouters 
2011). Higher performance tools and tools more appropriate for the disease in question should be given 
preference (Oti, Ballouz & Wouters 2011).  
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4. Candidate gene predictions as suggestions: The output of predicted candidate genes from 
prediction tools is only suggestions, regardless of any p-value assign for predictions (Oti, Ballouz & 
Wouters 2011). These predicted genes may not be representative for novel genes as these tools are 
usually benchmarked on known disease genes (Oti, Ballouz & Wouters 2011). There are various 
computational disease gene prediction methods already available, and candidate gene prediction tools 
are only extra tools to identify potential disease genes (Oti, Ballouz & Wouters 2011). 
V) Future directions for candidate gene prediction tools: In the recent years, candidate gene 
prioritization methods have highly improved and various candidate gene prediction platforms have 
been developed. However, in future some improvements described below are still necessary to develop 
better candidate gene prediction tools.  
1. Methodological improvements: Our current understanding to perform useful candidate gene 
predictions using multiple data sources and biological networks is still highly biased and rudimentary 
(Moreau & Tranchevent 2012). In future, more methodological improvement is needed to enhance 
data and network quality towards integrative predictions and to remove biases in predictive methods 
(Moreau & Tranchevent 2012). 
2. Improvements in benchmarking: Currently used benchmarks to compare various candidate gene 
prediction tools are not gold standard to evaluate the performance of prioritization methods, thus their 
quality should be improved in future (Moreau & Tranchevent 2012). There is a need for a large-scale 
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effort to compare multiple tools across common prospective benchmarks (Moreau & Tranchevent 
2012). It can also serve as a guide for further methodological improvements for candidate gene 
prediction tools (Moreau & Tranchevent 2012). 
3. Improvements in data standardization and update: Prioritization methods use data from                 
numerous databases and thus, there are several challenges of data standardization and data updates 
(Moreau & Tranchevent 2012). It will be highly useful to standardize ontologies across databases 
(Moreau & Tranchevent 2012). 
4. Improvements in underlying relationships: Further improvements are required for better 
explanation of predicted candidates. Methods should be improved to provide output rankings with 
more meaningful and reliable p values to increase confidence in the results (Moreau & Tranchevent 
2012). For example, the ToppNet tool displays a network view of candidate genes and seed genes with 
p values (Chen, J et al. 2009), which is a step in this future direction (Moreau & Tranchevent 2012). 
5. Prioritization of individual genes: Another important improvement is the prioritization of genomic 
variants using individual level next-generation sequencing data (Moreau & Tranchevent 2012). Full-
genome sequencing of any individual can identify around 4,000,000 variants, ~10,000 of which are in 
coding regions (Moreau & Tranchevent 2012). However, it is a challenging task to assess genetic 
variants which are associated with a phenotype (Moreau & Tranchevent 2012). Existing gene 
prioritization tools cannot handle information at the level of individual genetic variants (Moreau & 
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Tranchevent 2012). Therefore, approaches to analyse individual level genetic variant should be 
included in novel gene prioritization strategies (Moreau & Tranchevent 2012). 
6. Future method for prioritization: Edge prioritization methods can be developed in future to 
generate hypothetical potential interactions among top predicted candidates and seed known disease 
genes (Moreau & Tranchevent 2012). This would greatly increase the value of prioritization methods 
because it would generate hypotheses for further experimental validation (Moreau & Tranchevent 
2012). For example, if a top-ranked predicted candidate is a transcription factor and the corresponding 
seed disease gene carries potential transcription factor binding sites, the seed gene might be a direct 
target of this candidate (Moreau & Tranchevent 2012).  
7. Prioritization methods for alternative transcripts: The computational prioritization methods can 
also be developed for protein isoforms, peptides, non-coding RNAs, miRNA, metabolites and drugs 
(Moreau & Tranchevent 2012). It can be highly useful for the pharmaceutical industries to handle the 
large amounts of genomic and drug data (Moreau & Tranchevent 2012). 
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Prediction tool Description Method Web-links* 
aBandApart, 
aGeneApart 
Link genes to disease related features  
by literature mining of online available 
MEDLINE research abstracts. Uses 
specific genetic loci (aBandApart), or the 
whole genome (aGeneApart). 
. 
 
Gene clustering 
method http://tomcat.esat.kuleuven.be/
abandapart/, 
http://tomcatbackup.esat.kuleu
ven.be/sanger/ (Van Vooren et 
al. 2007) 
AlignPI, 
CIPHER 
Align PPI network with a phenotype 
network. AlignPI also identifies 
phenotype network that map to genetic 
network. Disease genes are predicted 
based on these mappings using network 
comparison method. 
Mapping method 
http://bioinfo.au.tsinghua.edu.c
n/alignpi 
http://rulai.cshl.edu/tools/ciphe
r/ (Wu X et al. 2008) 
BioGraph 
A data integration platform to explore 
and discover biomedical information. It 
prioritizes candidate genes based on 
functional hypotheses obtained by data 
mining. 
Data mining method 
to integrate various 
databases http://www.biograph.be (Liekens ML et al. 2011) 
Biomine 
Uses several publicly available 
biological databases to aid explorative 
discovery of connections between genes 
and phenotypes for prediction of 
candidate genes. 
Gene clustering based 
on integrated graph of 
PPI, gene-disease 
association and gene 
ontology. 
http://biomine.cs.helsinki.fi 
(Eronen L & Toivonen H, 
2012) 
  
BITOLA 
 
Uses literature mining method to link 
diseases and genes together. It identifies 
previously unrealized links between 
disease and genes to predict novel 
candidates. 
Machine learning 
http://ibmi.mf.uni-lj.si/bitola/ 
(Hristovski, D et al. 2005) 
CAESAR 
(CAndidatE 
Search And 
Rank) 
Uses ontologies to map the disease 
information to gene and protein 
information from several different public 
data sources. It also uses the knowledge 
of complex disease already available in 
literature. 
Machine learning 
http://visionlab.bio.unc.edu/cae
sar/ (Gaulton KJ et al., 2007) 
CANDID 
Uses a genome-wide candidate 
identification and prioritization 
algorithm that utilizes several 
heterogeneous data sources. 
Gene clustering https://dsgweb.wustl.edu/hutz/
candid.html (Hutz JE et al. 
2008) 
Table 1.4 Web-links and brief description of various candidate gene prediction platforms1 
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CGI 
Combines gene expression and PPI data 
to prioritize candidate genes associated 
with a disease. 
Integrative method to 
combine gene 
expression and 
protein interaction 
data 
Weblink not available. 
A software is implemented. 
(Xiaotu M et al. 2007) 
 
DGP 
Uses protein sequence properties to 
prioritize candidate disease genes 
associated with a disease. 
Machine learning http://maine.ebi.ac.uk:8000/ser
vices/dgp 
(Lopez-Bigas N & Ouzounis 
CA, 2004) 
DIR 
Integrates multiple heterogeneous data 
sources by using a unified graphic 
representation method. Uses the kernel 
measure approach to understand 
topology of network to define gene-
disease relationships and gene-gene 
relationships. 
Use of Unified 
graphic 
representation and 
diffuse kernel 
measure to integrate 
multiple data sources 
http://cbc.case.edu/dir/ (Chen 
Y et al. 2011) 
DomainRBF 
Uses a Bayesian regression approach to 
identify associations between protein 
domains and complex traits because 
proteins consist of one or more 
functionally independent domains. 
Mapping method 
http://bioinfo.au.tsinghua.edu.c
n/jianglab/domainRBF/ (Zhang 
W et al. 2011) 
Endeavour 
Combines several different data sources 
and prioritizes candidates by computing 
scores based on similarity to 
known disease genes using these data 
types. 
Machine learning 
http://www.esat.kuleuven.be/e
ndeavour 
(Tranchevent LC et al. 2008) 
eResponseNet 
Uses an extended version of 
ResponseNet algorithm to prioritize 
candidate disease genes based on cellular 
pathway data. 
Uses ResponseNet 
algorithm method to 
link pathways with 
genes. 
http://hanlab.genetics.ac.cn/eR
esponseNet (Huang J et al. 
2011) 
eVOC 
Associates a phenotype with anatomy 
terms by text mining of biomedical 
literature to prioritize candidate disease 
genes for a disease of interest. 
Machine learning 
http://www.sanbi.ac.za/evoc/ 
(Tiffin N et al. 2005) 
Genes2Diseases 
(G2D) 
Links candidate genes directly to a trait 
to prioritize positional candidate disease 
genes  
 
Transitive http://www.ogic.ca/projects/g2
d2/ 
(van Driel, MA et al. 2003) 
GeneDistiller 
Enables filtering and prioritization of 
candidates based on gene data integrated 
from different data sources.  
Computational 
method to check 
expression similarity 
http://www.genedistiller.org/ 
(Seelow D et al. 2008) 
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GeneFriends 
Uses a list of seed genes (known disease 
genes) to employ a gene co-expression 
network for candidate gene prioritization  
Co-expression 
analysis method 
using microarray data 
http://genefriends.org/ (van 
Dam S et al. 2012) 
Gene Ranker 
Combines PPI extracted from the 
literature with the gene-disease 
associations. It allows user to obtain a 
list of ranked genes for a specific disease 
of interest. 
Gene clustering based 
on graph theory http://cbioc.eas.asu.edu/genera
nker/ (Gonzalez G et al. 2008) 
GeneProspector 
Uses a highly curated and updated 
literature database of genetic association 
studies. It is a web-based gateway to 
search for evidences about human genes 
in relation to diseases. It also provides 
web links to published literature.  
Literature based 
evidence method to 
predict candidates 
http://www.hugenavigator.net/
HuGENavigator/geneProspecto
rStartPage.do 
(Yu et al. 2008) 
GeneRank 
Uses a modified version of PageRank 
algorithm to combine gene expression 
data with a network structure derived 
from gene ontologies or expression 
profiles. 
Google’s original 
PageRank algorithm 
based method used 
for Microarray data 
Web link not available. A 
software is implemented. 
(Morrison JL et al. 2005) 
GeneSeeker 
Maps gene expression patterns to disease 
related features to predict positional 
candidate disease genes  
Integrative method to 
combine positional, 
expression and model 
data 
http://www.cmbi.ru.nl/GeneSe
eker/ 
(Perez-Iratxeta, C. et al. 2002) 
GeneWanderer 
Uses different proximity measures to get 
proximity of candidate genes to known 
disease genes in a gene interaction 
network. 
 
Random walk method 
for PPI similarity http://compbio.charite.de/genewanderer (Kohler, S. et al. 
2008) 
 
Genie 
Uses a text-mining approach based on 
gene-related scientific abstracts. It 
processes a genome wide ranking in a 
few seconds. It is highly useful for 
researchers to rank genes for a specific 
topic. 
Text mining method 
using MEDLINE 
database 
http://cbdm.mdc-
berlin.de/~medlineranker/cms/
genie 
(Fontaine JF et al. 2011) 
Gentrepid 
Uses common biochemical pathways 
(CPS algorithm) or protein domains 
(CMP algorithm) to prioritize positional 
candidate genes. 
Gene clustering http://www.gentrepid.org/ 
(George, RA et al. 2006, 
Ballouz S. et al. 2011) 
GFINDer 
Uses microarray data to identify disease 
phenotypic features overrepresented 
within these up-regulated and down-
regulated genes. 
Functional 
evaluations of user-
classified sequence 
data 
http://www.bioinformatics.poli
mi.it/gfinder/ 
(Masseroli, M et al. 2004) 
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GLAD4U 
Uses existing resources available at 
NCBI to ensure computational efficiency 
and ranks candidates based on the 
hypergeometric test 
Text mining method 
which priortizes 
candidates based on 
publication count 
http://glad4u.zhang-
lab.org/index.php (Jourquin J 
et al., 2012) 
GPSy 
(Gene 
Prioritization 
System) 
A cross-species gene prioritization 
platform which is modular with regard to 
species, data sets and scoring strategies. 
It is enabled to predict gene function in 
conserved developmental processes e.g. 
meiosis, gametogenesis or sex 
differentiation. 
Gene clustering 
based on sequence, 
expression, 
annotation and 
association 
http://gpsy.genouest.org 
(Britto R et al. 2012) 
GUILD 
A network-based disease gene 
prioritization platform that uses four 
topology-based ranking algorithms. It 
uses already known gene-disease 
associations and PPI data to predict 
candidates. 
Mapping method 
A software is implemented 
http://sbi.imim.es/GUILD.php 
(Guney E & Oliva B, 2012) 
MedSIM/Funsim
mat 
Uses functional annotations of known 
disease genes to assess the disease 
relevance of candidates and similarity of 
diseases. It ranks candidates based on 
functional comparisons involving the 
GO keywords. 
Functional similarity 
matrix method http://funsimmat.bioinf.mpi- 
inf.mpg.de/qf.php (Schlicker A 
et al. 2010) 
MetaRanker 
Prioritizes the genome in relation to the 
disease in question by integrating 
complementary evidence layers of 
heterogeneous data sources  
Multiplayer evidence 
network method  http://www.cbs.dtu.dk/services/MetaRanker-2.0/ 
(Pers TH et al. 2011) 
PANDA 
(Prioritization 
ANalysis of 
Disease 
Association) 
It is an efficient method to narrow down 
a large set of genes into smaller subsets 
which are likely to be involved in a 
disease. 
Gene clustering 
http://www.h-
invitational.jp/panda/app 
(Taniya T et al. 2012) 
PGMapper 
Maps phenotype-related terms (available 
in OMIM or PubMed databases) to 
candidate genes. 
Mapping method to 
map phenotypic traits 
to genes. 
http://www.genediscovery.org/
pgmapper/index.jsp 
(Xiong, Q. et al. 2006) 
PhenoPred 
Uses a Support Vector Machine (SVM) 
algorithm on several different data types 
to predict gene-disease associations. 
Machine learning 
http://www.phenopred.org/ 
(Radivojac, P. et al. 2008) 
PINTA 
Identifies the candidates within a genetic 
locus by replacing sparse information 
available about the phenotype by 
Mapping method 
(Mapping gene 
expression with 
network model). 
http://www.esat.kuleuven.be/pi
nta/ 
(Nitsch D et al. 2012) 
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experimental data on differential gene 
expression (DGE). 
POCUS 
Uses a computational approach to 
prioritize candidate genes based on over-
representation of functional annotations 
between loci. 
Gene clustering 
A software is implemented. 
(Turner FS et al. 2003) 
PolySearch 
Uses text mining method to find 
relationships between genes, diseases, 
and various other biomedical concepts 
(e.g. drugs and metabolites) 
 
Text mining method 
http://wishart.biology.ualberta.
ca/polysearch/index.htm 
(Cheng, D. et al. 2008) 
PosMed 
 
 
Prioritizes genes in a genomic interval 
based on their links to phenotypic 
keywords in MEDLINE literature. These 
links are encoded in a neural network-
like structure. 
Artificial neural 
network 
method 
http://omicspace.riken.jp/PosM
ed/ 
(Yoshida, Y et al. 2009) 
PRINCE 
(PRIoritizatioN 
and Complex 
Elucidation) 
A network-based approach to predict 
causal genes and protein complexes that 
are involved in a disease in question.  
Gene clustering using 
protein interaction 
network 
Web link not available. A 
software is implemented 
(Vanunu O et al. 2010). 
ProDiGe 
(Prioritization of 
Disease Genes) 
Uses a machine learning strategy based 
on learning from positive and unlabeled 
examples (disease and non-disease 
genes), to combine various data sources 
to perform genome-wide searches for 
novel candidates. 
Machine learning 
http://cbio.ensmp.fr/~jvert/svn/
prodige/html/ 
(Mordelet F et al. 2011) 
ProphNet 
A method of prioritization that integrates 
and propagates information in a number 
of heterogeneous data networks. 
Network-based 
prioritization 
method 
http://genome2.ugr.es/prophnet
/ 
(Martnez V et al. 2012) 
 
SNPs3D 
Uses machine learning method of 
literature mining to link genes to 
diseases or to other genes, and also 
analyses effects of non-synonymous 
SNPs on protein functions.  
 
Machine learning 
http://www.snps3d.org/ (Yue, 
P et al. 2006) 
SUSPECTS 
Prioritizes candidate disease genes based 
on similarity to known disease genes 
using several different data types using 
data from 18 databases. 
Machine learning http://www.genetics.med.ed.ac.
uk/suspects/ (Adie, EA, et al. 
2006) 
Syndrome To 
Gene (S2G) 
Prioritizes candidate disease genes based 
on similarity to known disease genes 
underlying the disease in question. 
Phenotype clustering 
http://fohs.bgu.ac.il/s2g/ 
(Gefen, A. et al. 2010) 
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TargetMine 
Uses InterMine database to perform 
target prioritisation. It offers integration 
of custom annotations and experimental 
data. New data models such as protein-
DNA interactions can also be built and 
integrated to enable complicated 
searches. 
Gene clustering 
http://targetmine.nibio.go.jp 
(Chen YA et al. 2011) 
TOM 
Uses microarray co-expression data and 
functional annotations of genes to 
prioritize positional candidate genes 
based on similarity between  
candidate genes from one locus and 
known disease genes or between 
candidate genes from two loci. 
Gene-gene 
correlation method 
based on similarity in 
gene expression  
http://www-
micrel.deis.unibo.it/~tom/ 
(Rossi, S et al. 2006) 
ToppGene 
Uses many data types to prioritize 
candidate genes based on functional 
similarity of candidates to known disease 
genes. 
Gene clustering 
 http://toppgene.cchmc.org/ 
(Chen, J et al. 2009) 
UGET 
Uses known linkage interval of gene 
expression data to predict candidate 
genes. 
Gene-gene 
correlation method  http://genome.ucla.edu/projects/UGET (Day A. et al 2009) 
VAVIEN 
 
Uses an algorithm to understand the 
topological similarity of proteins in a PPI 
network to prioritize candidates. 
Topological 
similarity method 
using protein 
interaction network 
http://www.diseasegenes.org  
(Erten S et al., 2011) 
*At the time of thesis submission, only purple web links are working and blue web links are not working or outdated. 1 
Table adapted from Oti, Ballouz &Wouters, 2011 and http://homes.esat.kuleuven.be/~bioiuser/gpp/tools.php web link. 
1.1.7 Gentrepid, a candidate gene prediction tool 
The Gentrepid tool used in this study is one of many candidate gene prediction tools developed to help 
geneticists predict and prioritize candidate genes (Moreau & Tranchevent 2012; Oti, Ballouz & 
Wouters 2011; Teber, ET et al. 2009) (Table 1.4).  
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I) Prediction methods and input modes - The salient features of the Gentrepid bioinformatics 
tool and knowledge base are - it utilizes two independent methods - Common Pathway Scanning, a 
systems biology approach; and Common Module Profiling, a domain-based homology recognition 
approach, to prioritize candidate genes for human inherited disorders.  
x The Common Pathway Scanning (CPS) module is based on the assumption that 
common phenotypes are associated with proteins that participate in the same 
biochemical pathway (Badano & Katsanis 2002; George RA et al. 2006) (Figure 1.8, 
2.1). Systems biology methods are currently favoured in candidate gene prediction 
because of the attractiveness of their underlying thesis that alterations in specific 
metabolic and signalling pathways underlie particular phenotypes. Their weakness is 
the lack of coverage of the underlying systems biology knowledge bases. Many tools 
attempt to ameliorate the deficits of the knowledge base by extensive extrapolation of 
data from other species. Examples are GeneSeeker, ToppGene and Endeavour (Chen, J 
et al. 2009; Oti, Ballouz & Wouters 2011; Tranchevent et al. 2008; van Driel et al. 
2005). Gentrepid CPS uses only human data to reduce the number of predicted false 
positives i.e. it makes fewer predictions which are more often correct compared to other 
prediction systems (Teber, ET et al. 2009).  
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x The Common Module Profiling (CMP) is a novel sequence analysis approach based 
on the principle that candidate genes have similar functions to disease genes already 
determined for the phenotype (George RA et al. 2006; Jimenez-Sanchez, Childs & 
Valle 2001) (Figure 1.8). 
x Seeded and ab initio input modes: Two modes of input, referred to as “seeded mode” 
and “ab initio mode” were used to determine the common properties of phenotype-
specific genes within the gene sets for each disease (Figure 2.1). Seeded mode is 
assisted by phenotype-associated genes from OMIM database (Ballouz, S. et al. 2011). 
The “known” disease genes were defined as those determined prior to GWAS of these 
diseases, and therefore are restricted to OMIM entries. Ab initio mode, also known as 
blind mode, uses only genes pooled from the SNP-associated intervals, and no 
additional genetic data beyond the GWAS-implicated loci is required.  
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II) Mapping the associated SNPs to genes 
 
Although the implicated SNPs in GWAS are likely to be either the causal SNP, or in linkage 
disequilibrium with the causal SNP, the relevant locus may be distal to the gene it controls. Genomic 
architecture is still poorly understood and it is not clear if a ‘tagged locus’ is controlling the nearest 
gene, as is often assumed in these analyses, or one or more of the four genes surrounding it on the + 
and - strands or in the 5' or 3' directions, or possibly even a gene that is further away. Therefore, we 
assessed the ability of the two Gentrepid modules (CPS and CMP) to independently extract candidate 
genes from less significant data using two different mapping methods: Nearest Neighbour (NN) and 
Bystander (BY) (Figure 1.9). The NN approach contained three sets: the resident set mapped SNPs 
Figure 1.9 - Input modes of 
CMP and CPS - seeded and 
ab initio approaches of CMP 
and CPS. In seeded approach, 
known disease genes are 
considered as seeds while in ab 
initio approach, an exhaustive 
comparison of genes in the 
search space is made. 
Mani Grover 
59 
 
 
 
 
 
 
internal to gene boundaries to the resident gene, as is the case for the majority of mutations implicated 
in Mendelian disease; the nearest set mapped the implicated SNPs to the nearest gene, as is commonly 
done for GWAS studies; and the adjacent set mapped the implicated SNP to the four nearest genes in 
the 5'and 3' directions and on the + and - strand (Figure 1.9) (Ballouz, S. et al. 2011). The BY 
approach contained three sets of genes pooled from fixed-width intervals centered on the implicated 
SNP of  0.1 Mbp,  0.5 Mbp and and  1 Mbp widths (Figure 1.9) (Ballouz, S. et al. 2011).  
 
 
III) Gene Prioritization 
 
The statistical significance of Gentrepid-predicted genes is calculated in different ways for the CPS 
and CMP methods in seeded and ab initio mode. For CPS, both the seeded and ab initio predictions 
were filtered on the basis of a statistical significance threshold calculated for pathways using Fisher’s 
Figure 2.0 - Nearest Neighbour (NN) and 
Bystander (BY) approaches - Description of 
NN and BY approaches to create search space 
around SNPs (Ballouz, S. et al. 2011). 
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exact test (p < 0.05), and prioritized on the basis of the p-value score of the pathway. For the CMP 
module, candidate gene predictions were scored in different ways for the seeded and ab initio mode 
(George RA et al. 2006). For CMP seeded, predictions were filtered on the basis of a pairwise 
similarity score between a known disease gene template for the phenotype in question retrieved from 
the OMIM database and genes containing homologous domains in the search space (George RA et al. 
2006). Based on our previous benchmark, a pairwise similarity score greater than 0.4 was required for 
a gene to be predicted as a candidate gene (George RA et al. 2006). For CMP ab initio, gene 
predictions were filtered on the basis of two different chi-squared test score thresholds, depending on 
whether they were multi-domain or single domain proteins (George RA al, 2006). A threshold value of 
χ2min > 102 was used to filter single domain gene products and χ2max_unique > 105 to filter multi-
domain gene products (George RA et al. 2006). In summary, for each input search space generated 
from the six SNP to genome mappings, the Gentrepid web tool produced four separate lists of 
prioritized candidates obtained from the CPS and CMP modules in both seeded and ab initio modes. 
IV) Case studies 
 
We previously published our reanalysis of a series of data from the WTCCC case-control study of 
seven complex diseases (T1D, T2D, CD, CAD, RA, HT and BD) to select and prioritise valid 
candidate genes from the SNPs of GWAS (Ballouz S. et al. 2011) (Figure 2.1). We used following 
steps to select and prioritise valid candidate genes: 
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First step: From the 459,231 autosomal SNPs of the Affy500k SNP chip set, we extracted four sets of 
significant SNPs using the original Bonferroni corrected P-value and a series of three less stringent 
significant thresholds (p < 5*10-7, p ≤ 1*10-5, p≤ 1*10-4, p ≤ 1*10-3) for each of the seven diseases for 
further reanalysis (Ballouz S. et al. 2011).  
Second step: The four resulting SNP data sets from the first step were then mapped to genes in the 
genome in six different ways to create gene search spaces ranging in size from 2 to 4,431 genes (up to 
20% of the genome) for the seven phenotypes (Ballouz S. et al. 2011).  
Third step: The resulting 24 search spaces for each complex disease from the second step were further 
analysed using the CMP and CPS modules in seeded and ab initio input modes (Ballouz S. et al. 
2011). Genes involved in common pathways (CPS) or sharing common domains (CMP) within all 168 
search spaces for the seven complex diseases (24 search spaces/phenotype * seven phenotypes) were 
extracted by the Gentrepid system (Ballouz S. et al. 2011).  
Fourth step: Genes were further prioritized based on the likelihood of genes with common properties 
occurring randomly (see the above paragraph on page 55 for details of statistical methods used in 
prioritization) (Ballouz S. et al. 2011).  
Fifth step: Finally, a list of 1,497 predicted and prioritized unique candidate genes for seven complex 
diseases was retrieved. The number of predicted and prioritized candidate genes for each of the seven 
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phenotypes were: T2D - 291, BD - 212, CD - 378, HTN - 219, T1D - 358, CAD - 264 and RA - 200 
(Ballouz S. et al. 2011).  
Many candidate gene prediction systems combine the predictions of multiple modules using 
support vectors or other machine learning techniques based on a training set. Because we were using 
Gentrepid in discovery mode on data from complex diseases, but only initially had data largely from 
Mendelian diseases to benchmark the system, we chose to keep the predictions from the two modules 
separate but to check the performance of the two modules retrospectively. We compared the 
performance of CMP and CPS in our original benchmark using a set of nine oligogenic diseases with 
Mendelian inheritance (George, RA et al. 2006, Ballouz, S. et al. 2011). Most of the predictions were 
made by CPS based on pathways and protein-protein interactions.  In CMP, sequences are parsed at 
the domain level, linking them directly to function (George et al. 2006). CMP’s performance was 
disappointing in our original benchmark using 37 disease genes contributing to a set of nine oligogenic 
diseases with Mendelian inheritance (Turner, FS et al. 2003, George, RA et al. 2006). However, the 
CMP module produced a surprising number of statistically significant results when confronted with 
the GWAS data on seven complex diseases (Ballouz, S. et al. 2011). This result was robust when 
compared with simulations using random SNPs, and may arise from an underlying role for 
homologous genes specific to complex diseases (Ballouz, S. et al. 2011). In the reanalysis of the 
WTCCC-GWAS data, the CPS module was effective in replicating already known disease genes 
(seeds), including for some genetic loci where a disease gene has not been assigned yet (Ballouz, S et 
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al. 2011). Hence, we found that in seeded mode, where predictions are dependent on existing 
knowledge of the genetic basis of the phenotype, the CPS module was more effective and in ab initio 
mode where predictions are generated by finding patterns in the data rather than relying on existing 
knowledge of the phenotype, both the CPS and CMP modules made credible predictions (Ballouz, S et 
al. 2011). 
 
In summary, little attention has been paid to understanding the role of genomic architecture in 
interpreting data from GWA studies. This may have arisen from an early emphasis of the accuracy of 
GWA studies in pinpointing implicated genetic loci to the nearest haplotype block. However, the 
Figure 2.1 – Gentrepid prediction method - 
A genetic search space containing known 
disease genes (seeded method) or used stand-
alone (ab initio method). Common pathways 
(CPS) and common module profiling (CMP) 
methods are used to extract candidates and 
likelihood is calculated to prioritize candidates 
(Ballouz, S. et al. 2011). 
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implicated SNPs may be in the haplotype block of a control region which is further away from the 
gene whose transcription it controls. Using a nearest-neighbour mapping only 80% of the genome was 
covered by early 500K SNP chips, (Ballouz S. et al. 2011). In other words, 20% of the genome was 
invisible to the study. Our investigation showed that the adjacent mapping (where four genes on the 
plus and minus strands and in the 5’and 3’ directions are associated with the SNP), covered around 
90% of the genome and retrieved more disease genes with fewer false positives. The more generous 
1Mbp mapping, which was designed to capture genes which are near but not immediately adjacent to 
the significant SNP, covered 99.4% of the genome and retrieved disease genes with a larger number of 
false positives. We also found that both CMP and CPS modules in seeded and ab initio modes can 
successfully predict candidate disease genes (Ballouz S. et al. 2011). However, the predicted 
candidates remain dependent on underpinning knowledgebases and further research to resolve 
annotation bias is required to take complete advantage of the existing GWAS data (Ballouz S. et al. 
2011). Next, we will describe a comparison of Gentrepid’s performance with other currently available 
candidate gene prediction platforms.  
1.1.8 Comparison of candidate gene prediction platforms 
Because different candidate gene prediction systems use different methods and underlying data, a 
comparison of these systems is useful in understanding their utility. Comparison of different candidate 
gene prediction tools is crucial to understand the performance of these tools. In our previously 
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published work, we assessed the candidate gene prediction systems' ability to robustly select supported 
genes from the GWAS and filter noisy data from statistically less well supported genes to select 
candidates (Teber, ET et al. 2009). One metric calculated was the Enrichment Ratio (ER), which is the 
prediction system’s ability to accurately prune the search space. A perfect system has ER of 5, while a 
system that guesses randomly has a ER of 1. We used a set of 9,556 genes mapped to chromosomal 
intervals implicated in T2D as assessed by Tiffin et al. (2006) for all the seven candidate gene 
prediction systems available online at that time (DGP, Gentrepid, Geneseeker, eVOC, G2D, 
PROSPECTR and SUSPECTS) (Figure 2.2). We found that enrichment ratios ranged from 1 to 5 for 
the seven prediction systems (Teber, ET et al. 2009). The highest ERs were obtained by Gentrepid and 
GeneSeeker and the lowest were obtained by SUSPECTS and eVOC. These results were robust when 
the upper and lower confidence interval limits (95%) were taken into account. Overall, Gentrepid (ER 
= 5) performed better than other prediction tools. 
Moreover, we also compared the specificity and sensitivity of the different systems. Specificity 
of a system is a measurement of the prediction system’s ability to predict only phenotype specific 
genes and reject genes not associated with the phenotype. A perfect system has a specificity of 1, 
while a system that guesses randomly has a specificity of 0.5. Specificity scores among all seven 
systems ranged from 0.68 to 0.99, with a median of 0.92 (Figure 2.2) (Teber, E et al. 2009). Gentrepid 
showed the highest specificity (score = 0.99) and G2D showed the least (score = 0.68). Sensitivity is 
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the measurement ability of a tool to find the disease genes in the search space. It ranges between 0 and 
1, where ‘0’ represents the least sensitivity and ‘1’ represents the highest sensitivity. G2D showed 
highest sensitivity (score = ~ 0.78), Gentrepid and SUSPECTS showed the least sensitivity (score = ~ 
0.18). Overall, Gentrepid's sensitivity is on par with most of the other prediction tools but with higher 
specificity (Figure 2.1) (Teber, ET et al. 2009). Gentrepid’s high specificity is derived from the high 
quality of the data in the underlying genetic databases and lower sensitivity is because of 
incompleteness of these databases to cover the complete human genome (Teber, ET et al. 2009). 
In a later test, we compared two popular candidate gene prediction systems GRAIL and 
WebGestalt with Gentrepid using the WTCCC Medium highly significant (MHS) data sets for each of 
the seven diseases (Figure 2.3) (Ballouz, S. et al. 2011). GRAIL identifies relationships amongst 
genomic disease regions by text mining PubMed abstracts and assessing gene relatedness 
(Raychaudhuri S et al. 2009). WebGestalt performs gene set enrichment analysis given a list of genes 
or SNPs which it maps to genes using the array specific list of genes (Duncan D et al. 2010). GRAIL 
accepts a list of SNPs or disease regions and performs its own SNP-to-gene mapping based on 
Linkage Disequilibrium (LD). We used the gene set generated by GRAIL to perform the analyses and 
considered a result to be a prediction if the statistical significance of the annotation returned was p < 
0.05. This method allows the utility of the underlying datasets to be compared given the same genomic 
search space, but compromises the performance of Gentrepid's superior SNP mapping methods. 
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Overall, WebGestalt and GRAIL returned more candidate genes than Gentrepid (Figure 2.3). 
But many of the predictions made by GRAIL and WebGestalt were genes from the same locus, 
indicating a higher false positive rate. We calculated the sensitivity and specificity of the three 
different methods used for comparison. Specificity was high for all the three systems (Score = ~ 0.9), 
so we compared the sensitivity to gain more insights into performance. GRAIL showed the highest 
sensitivity using PubMed abstract (PUB) method. Gentrepid CPS had similar sensitivities in both ab 
initio and seeded modes, even when the p-value threshold was lowered (from p<0.05 to p < 0.01) 
(Figure 2.3). The sensitivity values were lower across all the three methods using genes selected by 
GRAIL based on LD compared to the Gentrepid's superior SNP mapping methods (see section 1.1.7 
for details of these mapping methods). 
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Figure 2.2 comparison of different candidate gene prediction platforms using Type2Diabetes (T2D) gene data sets. Top: 
Comparison is based on enrichment ratios, Bottom: Comparisons is based on sensitivity and specificity. Abbreviations: 
HS: Highly significant dataset; T2D: Type 2 Diabetes; MHWD: Moderately high weakly significant dataset (Teber, ET et 
al. 2009) 
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Figure 2.3 Comparison of the sensitivity of Gentrepid, GRAIL and WEbGestalt using WTCCC GWAS MHS data 
set (Ballouz, S. et al. 2011). CMP and CPS are Gentrepid methods. PUB, PUB2, GO-G, and HEA are GRAIL methods. 
PUB: PubMed abstracts up until 2006. PUB2: PubMed abstracts up until 2011. GO-G: gene ontology, HEA: human 
expression atlas. GO-W, KEGG, WIKI, PATHS, PPI, TF and MIR are WebGestalt methods. GO-W: gene ontology 
enrichment. KEGG: pathway enrichment from the KEGG (Kyoto Encyclopedia of Genes and Genome database). WIKI 
refers to pathway enrichment from Wikipathways. PATHS: pathway enrichment from Pathway Commons. PPI: protein-
protein interaction enrichment. TF: transcription factor enrichment. MIR: microRNA enrichment (Ballouz S et al. 2011). 
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1.1.9 Drug repositioning using candidate gene prediction systems 
 
There is a vast amount of public genomic and proteomic data available that may aid the discovery of 
disease genes for phenotypes and possible therapeutics. Recently, there has been extensive research to 
identify potential therapeutics and their targets by integrating publicly available genetic, bioinformatic 
and drug data. These methods involve repositioning of currently available drugs, and allow 
translational opportunities for drug testing (Sanseau et al. 2012). Several bioinformatics tools have 
been used to identify potential therapeutic targets for human diseases. For example, TARGET gene 
was used to identify and prioritize potential targets from hundreds of candidate genes for different 
types of cancer (Wu et al. 2012). Another study identified potential drug targets and drugs for three 
neurological disorders - Alzheimer’s disease, Parkinson’s disease, and Schizophrenia (Kaimal et al. 
2011). This study involved the prediction of candidate genes using the ToppGene and ToppNet 
prediction systems (Table 1.5) (Chen, J et al. 2009; Kaimal et al. 2011). Such repositioning tools could 
be used as an initial discovery tool to identify potential drug targets and drugs which can then be used 
for further evaluation (Wu et al. 2012). However, these studies were specifically applied to cancer and 
neurological disorders.  
Application of a similar strategy for many other common diseases prevalent in our society is 
essential but will require a significant investment of research time. As an effort in this direction, in this 
thesis I applied the Gentrepid system to the seven complex diseases studied by the WTCCC 
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(Wellcome Trust Case Control Consortium 2007, Grover, Mani P et al. 2014) to identify therapeutic 
targets and drugs suitable for repositioning. This work built on earlier candidate gene predictions for 
the seven complex diseases made by another lab member, Dr Sara Ballouz. This work is described in 
chapter 2. I then performed two more detailed studies on more recent data for CAD (chapter 3) and HT 
(chapter 4) (see page viii for abbreviations). This work involved prediction of candidates based on the 
new data as well as identification of therapeutic targets and drugs suitable for repositioning. More 
recent data from more powerful GWAS involves hundreds of thousands of patients rather than the 
thousands screened in the initial studies. Comparison of the results from the WTCCC data and the 
newer studies were also performed. 
Table 1.5 - Candidate gene prediction platform integrated with drug data - Description of three existing candidate 
gene prediction platforms integrated with drug data to identify novel therapeutics suitable for repositioning 
S.No. Study Candidate gene prediction 
platform utilized 
Drug database 
utilized 
Diseases studied 
1. Wu et al. 2012 TARGET DrugBank, TTD, 
PharmGKB 
Cancer 
2. Kaimal et al. 
2011 
Topp Gene - Topp Net DrugBank Alzheimer’s disease, Parkinson’s 
disease and Schizophrenia 
3. Grover et al 
2014 
Gentrepid DrugBank, TTD, 
PharmGKB 
T1D, T2D, CAD, CD, RA, HT, BD 
4. Grover et al 
2015 
Gentrepid DrugBank, TTD, 
PharmGKB 
CAD 
5. Grover et al 
2016 
Gentrepid DrugBank, TTD, 
PharmGKB 
HT 
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1.2 Research aims  
The primary aim of this thesis is to extend the Gentrepid candidate gene prediction system to identify 
targets amongst the candidates and predict novel therapeutics suitable for repositioning for complex 
diseases. The seven complex diseases selected in this study were - T1D, BD, CD, CAD, RA, T2D and 
HT (see page viii for abbreviations). These seven common diseases were selected from the first large 
scale WTCCC-GWAS study (see section 1.1.5 for details) reanalysed previously (Ballouz S et al. 
2011). This aim is addressed in the second chapter in which we performed integrative data analysis of 
genetic, bioinformatic and drug data.  
The secondary aim of this thesis is to make translational predictions on the most recent data on 
specific complex diseases. Hence, we performed in-depth case studies for two phenotypes: CAD and 
HTN. This should be of great interest to clinical researchers currently working in the field of CAD and 
HTN. The two case studies of CAD and HTN are described in chapter 3 and 4 respectively.    
Finally, we tested the system's performance retrospectively at both stages in each chapter by 
assessing the ability of system to replicate known therapeutics de novo from the genetic data and by a 
literature search of articles in PubMed. These chapters consist of research articles published or 
submitted for publication to peer-reviewed journals. The contributions of the first and executive 
authors made to each publication, and the contributions of each co-author, are detailed in each chapter. 
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Chapter 2: Research article 1 
Identification of novel therapeutics for complex diseases from genome-wide 
association data 
An important aim of this thesis was to extend the Gentrepid candidate gene prediction system to 
enable the identification of novel therapeutics suitable for repurposing in human clinical trials for 
seven complex diseases. We used Gentrepid as a bioinformatic platform to reanalyse the WTCCC 
genome-wide association study (GWAS) data for seven complex diseases. The diseases included in 
the WTCCC study were: T1D, BD, CD, CAD, RA, T2D and HT (Wellcome Trust Case Control 
Consortium 2007).  
 The WTCCC- GWAS study was one of the first large scale GWAS studies on a set of complex 
diseases. This study was conducted on the genomes of ~14,000 individuals (2,000 cases for each of the 
seven phenotypes) against 3,000 common case controls (see chapter one for details) (Wellcome Trust 
Case Control Consortium 2007). However, it has so far provided limited understanding of the genetic 
basis of these seven complex diseases (T1D, T2D, CAD, CD, HT, RA and BD) (Wellcome Trust Case 
Control Consortium 2007). We posited that the GWAS data was noisier than expected due to greater 
heterogeneity in the cases selected than was optimal (Ballouz, S. et al. 2011), although difficulty in 
control selection may also have played a part (Witte, JS 2010). We reasoned that the additional use of 
bioinformatic data in a candidate gene prediction system like Gentrepid would reduce the noise in 
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GWAS data (see chapter one section 1.1.5 for details about Gentrepid). We then extended the 
Gentrepid system by mapping our candidate gene predictions to therapeutic drugs. 
Our results suggest that the noise within the genotype-phenotype association data contributed 
to the "missing heritability" that was not detected by the WTCCC-GWAS study. The testing of 
multiple isolated SNPs also limited the manner of SNP-gene mapping. We addressed these issues in 
our reanalysis of GWAS data using the steps described below –  
Firstly, we used a series of four statistical thresholds (Cochran-Armitage association p-values: 
p < 10-7, p ≤ 10-5, p ≤ 10-4, p ≤ 10-3) to discriminate the signal from the noise in the more statistically 
significant GWAS data (Ballouz, S. et al. 2011). This resulted in a series of four SNP datasets for each 
of the seven phenotypes containing up to 1,064 SNPs per phenotype (Ballouz, S. et al. 2011). 
Secondly, we created six different search spaces around SNP-based genetic loci for analysis by 
Gentrepid (see section 1.1.5 and figure 1.9 of chapter one for details) (Ballouz, S. et al. 2011). These 
six search spaces were of two types: fixed-width intervals to identify genes associated with long range 
regulatory elements and proximity-based search spaces to identify short range regulatory elements 
(See figure 1.9 of chapter one). 
We used Gentrepid to reanalyze the WTCCC-GWAS data using a multi-locus approach that 
combines genetic and bioinformatic data for complex diseases. Gentrepid utilizes two bioinformatics 
modules: 1) Common Module Profiling (CMP) and 2) Common Pathway Scanning (CPS) to reanalyze 
the WTCCC-GWAS data for seven complex diseases (see chapter 1, section 1.1.5). We found that 
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Gentrepid replicated many known genetic loci and predicted a total of 1,497 unique candidate genes 
for the seven complex diseases targeted in the study (Ballouz, S. et al. 2011). Although this may seem 
like a large number, the small effect sizes of genes (<1%) identified for these phenotypes so far and 
consequent large "missing heritability" make this prediction entirely feasible. 
Further, we mapped the predicted candidate gene data set to therapeutics with the drug-gene 
target dataset extracted from three drug databases: TTD, Drug Bank and PharmGKB (Altman 2007; 
Chen, X, Ji & Chen 2002; Knox et al. 2011). These databases are described in detail in chapter one 
(section 1.1.3). The total number of unique targets from all the databases was 2,494 genes, which is 
8% of the entire human genome. These are the druggable genes in the genome. In our study, we 
identified 452 potential therapeutic targets from 1,497 candidate genes (30% of the predicted 
candidate genes) for the seven complex diseases. Nonetheless, despite the small coverage of targetable 
genes in the genome by the current arsenal of therapeutic drugs, the coverage of "disease" genes i.e. 
the predicted candidates, was remarkably good. This may be because there really is a subset of genes 
that are more likely to be involved in disease (Teber, ET et al. 2009), but it is more likely to arise from 
selection effects in the knowledgebases consulted i.e. druggable genes have been characterised better 
in pathway databases etc. 
 Not all of the seven individual phenotypes investigated were equally druggable. We calculated 
an empirical Targetability Index (TI), defined here as the ratio of the number of predicted targets to the 
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number of predicted candidate genes for each phenotype. We found that the TI distribution was 
bimodal with four phenotypes (CAD > RA >CD > HT) being more targetable (TI = 0.35-0.39) than 
the other three phenotypes (T2D > T1D ~ BD) (TI = 0.27-0.29). The higher druggability of heart-
related phenotypes (CAD, HT) may arise from more research dollars being spent in this area in the 
past whereas our knowledge of the less druggable phenotypes - diabetes and bipolar - is likely to be 
less complete. 
Finally, we validated our results using two different benchmarks. The first was based on 
replication of known drug targets in the drug databases for each of the seven phenotypes, and the 
second searched for association between the predicted candidate genes for each phenotype and that 
phenotype in the scientific literature. The first benchmark based on known targets showed that 24 
known targets i.e. true positives were replicated in this study (p<0.05) and the second benchmark 
based on literature search of studies related to seven diseases in PubMed, showed there was a 
significant association (p<0.05) between mentions of the phenotype and the predicted target gene in 
literature abstracts. The PubMed benchmark, however, is not conclusive because the association might 
be a negative one between the phenotype and the predicted target gene. 
In total, we were able to identify 29% of the predicted candidate genes as novel therapeutic 
targets (428 genes of 1,497 total predicted genes) and 29% of the extracted drugs from the databases 
were predicted to be suitable for repositioning towards at least one of the seven phenotypes as 
potential novel therapeutics (2,130 drugs of 7,252 total drugs). We utilized both FDA-approved drugs 
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and drugs currently in human clinical trials. However, further investigation is still required to verify 
the actions of these drugs in clinical settings. Hence, our approach allows immediate translational 
opportunities for drug testing in clinical trials. Gentrepid, thus, could be used as an initial screening 
tool for the identification of potential drugs in clinical trials towards the seven complex diseases 
studied.  
This chapter was chosen as a platform session at the Translational Bioinformatics 
Conference/International Society of Computational Biology conference – TBC/ISCB 2013, held at 
Seoul, South Korea and subsequently published in the peer reviewed BMC Medical Genomics journal. 
A copy of this publication is included here and it can also be freely accessed via following website: 
10.1186/1755-8794-7-S1-S8. Supplementary files of this publication are included after the published 
research article in the end of this chapter. 
This article is highly accessed with 1978 accesses, and has ten citations at the time of thesis 
revision (Oct 2016). Mani P Grover performed data mining and data extraction from the drug 
databases, the bioinformatic and statistical analyses using the Gentrepid platform and statistical 
software such as IBM-SPSS, GraphPad prism, and also wrote the first draft of the manuscript. Dr 
Merridee A. Wouters conceived the study, participated in its design, reviewed the results, and 
critically evaluated the complete manuscript. Dr Tamsyn M Crowley and Dr Craig D H Sherman 
provided technical and administrative support, and reviewed the manuscript. Kaavya 
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Mohanasundaram helped in technical discussions. Dr. Richard A. George helped in conception of 
project.  
Reproduced with permission from Mani P Grover, Sara Ballouz, Kaavya A. Mohanasundaram, 
Richard A. George, Craig D H Sherman, Tamsyn M. Crowley, and Merridee A. Wouters. 
"Identification of novel therapeutics for complex diseases from genome-wide association data." BMC 
Medical Genomics 7, no. 1 (2014): 1.  
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Identification of novel therapeutics for complex
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Abstract
Background: Human genome sequencing has enabled the association of phenotypes with genetic loci, but our
ability to effectively translate this data to the clinic has not kept pace. Over the past 60 years, pharmaceutical
companies have successfully demonstrated the safety and efficacy of over 1,200 novel therapeutic drugs via costly
clinical studies. While this process must continue, better use can be made of the existing valuable data. In silico
tools such as candidate gene prediction systems allow rapid identification of disease genes by identifying the most
probable candidate genes linked to genetic markers of the disease or phenotype under investigation. Integration
of drug-target data with candidate gene prediction systems can identify novel phenotypes which may benefit
from current therapeutics. Such a drug repositioning tool can save valuable time and money spent on preclinical
studies and phase I clinical trials.
Methods: We previously used Gentrepid (http://www.gentrepid.org) as a platform to predict 1,497 candidate genes
for the seven complex diseases considered in the Wellcome Trust Case-Control Consortium genome-wide
association study; namely Type 2 Diabetes, Bipolar Disorder, Crohn’s Disease, Hypertension, Type 1 Diabetes,
Coronary Artery Disease and Rheumatoid Arthritis. Here, we adopted a simple approach to integrate drug data
from three publicly available drug databases: the Therapeutic Target Database, the Pharmacogenomics
Knowledgebase and DrugBank; with candidate gene predictions from Gentrepid at the systems level.
Results: Using the publicly available drug databases as sources of drug-target association data, we identified a
total of 428 candidate genes as novel therapeutic targets for the seven phenotypes of interest, and 2,130 drugs
feasible for repositioning against the predicted novel targets.
Conclusions: By integrating genetic, bioinformatic and drug data, we have demonstrated that currently available
drugs may be repositioned as novel therapeutics for the seven diseases studied here, quickly taking advantage of
prior work in pharmaceutics to translate ground-breaking results in genetics to clinical treatments.
Background
The development of new therapeutics is essential to
improve the human condition and lower the burden of
disease. Due to our limited knowledge of the molecular
basis of complex diseases, comparatively few gene tar-
gets for therapeutics have been identified to date. The
standard approach to developing therapeutics involves
testing many thousands of compounds against a known
target in order to identify a lead compound. The lead
compound can then be further refined in silico and in
vitro before heading into the lengthy and costly clinical
trials pipeline. This process, which consists of phases I,
II, III and IV before final drug approval, involves 10-17
years of drug development, from target identification
until FDA/EMEA approval, with only a 10% probability
of success [1]. As a result, the pharmaceutical industry
spends an average of about 1.2 billion US dollars to
bring each new drug to market [2]. There is also a high
risk associated with de novo drugs due to unforeseen
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adverse side effects, as seen in the case of Thalidomide,
a drug used to treat morning sickness which resulted in
devastating birth defects [3].
A novel approach to therapeutic development is to
identify new applications for drugs that have already
been approved, or have successfully completed phase I
clinical trials which investigate toxicity [4,5]. This process
of “drug repositioning” aims not to develop drugs de
novo, but associate existing therapeutics with new pheno-
types. Here, we attempted to reposition existing drugs to
treat common complex diseases using recently acquired
Genome-Wide Association Study (GWAS) data.
Complex diseases are genetically intricate, polygenic
and multifactorial [6]; and frequently arise as a conse-
quence of interaction between genes and the environ-
ment. Recently, GWAS have begun to unravel the
complicated genetic basis of complex diseases. Sheer
statistical power has allowed GWAS to successfully
identify some associations between Single Nucleotide
Polymorphisms (SNPs) and complex diseases [7].
Despite high investment, far fewer genes have been
identified than can account for the heritable component
of complex diseases, and the clinical benefit remains
limited to date [8]. A factor that contributes to the miss-
ing heritability is likely to be noisy genotype-phenotype
association signals [9]. Also, analysis of GWAS data
using highly stringent thresholds for statistical signifi-
cance, by testing multiple isolated SNPs, has limited the
scope of gene discovery based on existing data [10]. As
shown in Manhattan plots, GWAS data obviously con-
tain far more information than the most significant
peaks, and more work needs to be done extracting data
from slightly less significant peaks [9,11].
Currently available gene discovery platforms can
enhance candidate gene identification from GWAS data
[9]. Candidate gene prediction tools are designed to find
a needle in the genetic haystack. These tools are based
on the assumption that genes with similar or related
functions cause similar phenotypes [12]. Specific candi-
date gene prediction tools differ in the strategy adopted
for calculating similarity, and the databases utilized for
prediction [13,14]. Gentrepid is one of the many bioin-
formatic tools developed to help geneticists predict and
prioritize candidate genes [9,15]. The Gentrepid tool
and its knowledge base utilizes two independent meth-
ods: Common Pathway Scanning (CPS), a systems biol-
ogy approach; and Common Module Profiling (CMP), a
domain-based homology recognition approach, to priori-
tize candidate genes for human inherited disorders (see
Methods for details). Compared to other prediction
systems, Gentrepid is designed to make fewer, more
conservative predictions which do not extensively extra-
polate existing bioinformatic data i.e. it tends to be
more specific than other systems [15].
We have previously developed protocols to analyze
GWAS data using a multilocus approach which com-
bines bioinformatic and genetic data [9,16,17]. To
demonstrate the usefulness of these protocols, we reana-
lysed the well-studied Wellcome Trust Case-
Control Consortium (WTCCC) data for seven complex
diseases [9]. Using a series of increasingly less conservative
statistical thresholds, we attempted to discriminate the sig-
nal from the noise in the more statistically significant data
(p ≤ 10-5, p ≤ 10-4, p ≤ 10-3). By incorporating bioinfor-
matic data, we were able to predict 1,497 candidate genes
for the seven complex diseases studied; namely, Type 2
Diabetes (T2D), Bipolar Disorder (BD), Crohn’s Disease
(CD), Hypertension (HT), Type 1 Diabetes (T1D), Coron-
ary Artery Disease (CAD) and Rheumatoid Arthritis
(RA) [9].
Here, we extend this pipeline to identify potential novel
drug targets among the predicted candidate genes by
associating drug information extracted from publicly
available drug databases. The three databases sourced in
this study were DrugBank [18], the Pharmacogenomics
Knowledgebase (PharmGKB) [19] and the Therapeutic
Target Database (TTD) [20]. The feasibility of this
approach is again illustrated for the seven complex dis-
eases investigated by the WTCCC [11]. This study shows
that it is possible to identify therapeutics for treatment of
specific complex diseases from genetic loci via the Gen-
trepid candidate gene prediction tool. Thus, in combina-
tion with drug target information, candidate gene
prediction systems can be utilized as drug discovery tools
to identify therapeutics which may be repositioned as
novel treatments for complex diseases.
Methods
We implemented a computational workflow to enable
repositioning of drugs by using Gentrepid as a bioinfor-
matic candidate gene discovery platform, with drug data
sourced from online databases (Figure 1). The two data
sets integrated were:
1. A candidate gene data set obtained by integration of
genotype-phenotype data from the WTCCC GWAS study
on seven complex phenotypes [11], with bioinformatic
data on structural domains and systems biology: identify-
ing proteins that share common features, or participate in
the same complex or pathway [21];
2. A drug-gene target association data set obtained
from three drug databases namely TTD, DrugBank and
PharmGKB [18-20].
Candidate gene data set
In previous work, we predicted a total of 1,497 candidate
genes for seven complex diseases by careful reanalysis of
the WTCCC GWAS data [11] using the Gentrepid candi-
date gene prediction system [9].
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In the original analysis, a highly stringent significance
threshold (p ≤ 5x10-7) was used in an attempt to correct
for multiple testing [11]. This conservative statistical
approach, combined with the selection of the nearest-
neighboring gene to the significant SNP, resulted in
identification of only a small number of loci associated
with each phenotype, with modest cumulative heritabil-
ity [9] (Additional file 1, Table S1).
We specifically addressed these two issues in our reana-
lysis of this noisy data by - (a) Considering a series of four
thresholds of decreasing stringency, starting with the
highly significant threshold used in the original study, and
decreasing to weakly significant(WS - p ≤ 10-3). This
resulted in a series of four SNP sets containing up to 1064
SNPs being considered for each phenotype [9]. The num-
ber of loci and SNPs considered in the four data sets for
each phenotype is shown in Table S1 (Additional file 1).
(b) Creating six different search spaces around each
SNP-based locus, three of fixed-widths and three proxi-
mity-based, for analysis by our candidate gene predic-
tion system [9].
Thus, for each of the seven phenotypes, twenty-four
search spaces were constructed; using four SNP signifi-
cance thresholds to obtain the loci, and six gene selection
methods to construct the gene search spaces. In total,
168 search spaces ranging in size from 2 to 4,431 genes
(up to 10% of the genome) were analyzed [9].
Gentrepid uses two modules: Common Pathway Scan-
ning (CPS) and Common Module Profiling (CMP) to
make candidate gene predictions.
The CPS module is based on the assumption that com-
mon phenotypes are associated with proteins that partici-
pate in the same protein complex or biochemical pathway
[22]. Such systems biology methods are currently favored
in candidate gene prediction because of the attractiveness
of their basic thesis. Their weakness is the lack of coverage
of the underlying systems biology knowledge bases [21].
Many tools attempt to ameliorate the deficits of the
human systems biology knowledge base by extensive
extrapolation of data from other species. Examples
are GeneSeeker, ToppGene and Endeavour [13,23-25].
Gentrepid CPS uses only human data to reduce the num-
ber of predicted false positives i.e. it makes fewer predic-
tions which are more often correct compared to other
prediction systems [15].
The other module, CMP, is a novel sequence analysis
approach based on the principle that candidate genes have
similar functions to disease genes already determined for
the phenotype [26]. Gentrepid CMP differs from most
candidate gene prediction systems which describe func-
tional similarity via keywords, a procedure which also
lacks good coverage of the human genome [21]. In CMP,
sequences are parsed at the domain level, linking them
directly to function [21]. Although CMP’s performance
was disappointing in our original benchmark using a set of
nine oligogenic diseases with Mendelian inheritance [12],
it produced a surprising number of statistically significant
results when confronted with the GWAS data on seven
complex diseases [9]. This result was robust when com-
pared with simulations using random SNPs, and may arise
Figure 1 Workflow. The complete workflow designed to predict novel therapeutic targets and identify novel therapeutics. We used Gentrepid as
a platform for candidate gene prediction and DrugBank, TTD and PharmGKB as drug repositories.
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from an important underlying role for homologous genes
in complex diseases.
Drug-gene target data set
We compiled the drug-gene target data set from three
publicly available drug databases: DrugBank [18],
PharmGKB [19] and TTD [20]. Snapshots of these data-
bases were taken in June 2012.
DrugBank is a freely available online database that
combines detailed drug data and indication information
with comprehensive drug-target associations [18]. From
this database, we retrieved Drugbank IDs and drug
names (generic and brand) to represent drugs, and the
unique gene symbols to represent protein targets. We
extracted 6,711 drug entries active against 3,410 unique
drug targets from several species. We used the G-profiler
conversion tool to separate human drug targets repre-
sented by official HUGO gene symbols [27], yielding
2,022 human drug targets associated with 3,910 drugs.
The Pharmacogenomics Knowledgebase (PharmGKB)
is a drug knowledge base maintained by Stanford Uni-
versity, USA and funded by the US National Institute of
Health (NIH). PharmGKB captures information about
drugs, diseases/phenotypes and targeted genes [19].
From this database, we extracted the “drug-associated
genes” field along with “description” which contains the
disease information. This database contains around
3,097 drugs and 26,961 human genes, but not all these
genes are associated with drugs. We retrieved 382 drugs
for 566 human drug targets. For the PharmGKB data-
base, the number of drug targets exceeds the number of
drugs because some drugs target multiple genes.
The Therapeutic Target Database (TTD) is also a
freely available online drug database which integrates
drug data with therapeutic targets [20]. This database
contains 17,816 drugs (approved, clinical and experi-
mental) and 2,025 human and non-human (bacterial
and fungal) drug targets. It describes synonyms of 3,167
drug names. We extracted “Drug names” along with
“Disease” information, and “Uniprot accession numbers”
for targets. UniProt accession numbers were replaced
with official HUGO gene symbols using the G-profiler
conversion tool [27]. Finally, we extracted 2,960 drugs
for 544 unique human drug targets from TTD.
Mapping of candidate gene data set with the drug-gene
target data set
We mapped the list of 1,497 candidate genes with drug-
gene target association files obtained from the three
drug databases. The candidate genes for each disease
were mapped with the three drug-target association files
obtained from the three drug databases, and the results
retrieved.
Identification of novel therapeutics and therapeutic targets
In the next step, we identified novel therapeutic targets
and therapeutics for all seven diseases. If an associated
drug is not registered as a therapy for the phenotype of
interest, it is predicted as a novel therapeutic for the new
phenotype, directed towards the predicted candidate
gene target. The novel drugs may be suitable for reposi-
tioning towards treatment of the phenotype in question.
Validation of predicted therapeutic targets
The predicted therapeutic targets were validated using
two benchmarks. In the first benchmark, the ability of
the system to replicate known therapeutics de novo
from the genetic data was assessed. This benchmark
tests the system’s ability to retrieve existing knowledge;
however, this does not give any idea about the validity
of the novel predictions. To test the system’s ability for
knowledge discovery, we performed an additional
benchmark in which the validity of the candidate gene
predictions for the phenotype were assessed using text
mining of the literature.
In the first benchmark, genes present in the six search
spaces were classified as “candidates” or “non-candi-
dates”. We considered genes which are currently known
as drug targets for the phenotype of interest as “true
positives”. Targets with currently registered therapeutics
for the phenotype of interest which were not predicted
by Gentrepid but present in the search space were desig-
nated “false negatives”. Genes which were not predicted
and not targetable by drugs were “true negatives"; and,
for the purpose of this benchmark, predicted novel thera-
peutic targets were considered “false positives”. Receiver
Operation Characteristic (ROC) Curves were plotted in
GraphPad Prism 6 software considering six thresholds
obtained from the number of targets present in the six
search spaces for each phenotype. Linear, as well as non-
linear regression analysis, was performed (see section
Validation of predicted therapeutic targets in Results and
Discussion).
In the second benchmark, all Pubmed IDs of literature
related to Bipolar disorder, Type 1 diabetes, Type 2 dia-
betes, Crohn’s disease, Coronary artery disease, Rheuma-
toid arthritis and Hypertension were extracted from
Pubmed in Feb. 2013. For each target, we calculated the
number of citations using both the gene name and the
phenotype, by mapping the extracted Pubmed IDs to the
gene citation information from Entrez Gene (ftp://ftp.ncbi.
nih.gov/). Further, ROC curves were created in GraphPad
Prism 6 software considering four thresholds of at least
one, five, ten and fifteen citations. Non-linear regression
analysis was also performed to fit the ROC curves (see sec-
tion Validation of predicted therapeutic targets in Results
and Discussion).
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Results and Discussion
Comparison of drug databases
Firstly, we assessed coverage of the human genome by
the three drug databases both individually and in toto.
We extracted the following therapeutic drug-gene target
association data from the three databases:
1. 3,910 drugs against 2,022 human targets from
DrugBank [18];
2. 382 drugs against 566 human targets from
PharmGKB [19] and;
3. 2,960 drugs against 544 human targets from
TTD [20].
For more details about the content of these databases
see Methods.
The total number of unique targets from all the data-
bases was 2,494 genes, which is 8% of the entire human
genome (Figure 2). Previously, it was estimated that
3,000-5,000 genes are druggable (able to be modulated by
a small-molecule drug [28]) which is 10-17% of the entire
genome [29-32]. The gap between extracted targets from
the three drug databases (8%) and the estimated number
of druggable genes (10-17%) exists because many drug-
gable genes have not yet been mapped to a phenotype
and thus there has been no imperative to develop drugs
for these targets [33]. The targets searched in our study
cover 50-83% of the possible druggable genes mentioned
in previous studies [29-32].
We compared raw data such as drugs and drug targets
across the three drug databases to determine the redun-
dancy of the information in these databases. With respect
to drug targets, only 4% of human drug target entries were
common to all three databases (Figure 3). When the data-
bases were compared in a pairwise fashion, the proportion
of common targets ranged from 9-18%. Each of the data-
bases contains a significant amount of information that is
unique to that database. TTD has the fewest unique tar-
gets (129), while DrugBank and PharmGKB have 1,495
and 326 unique targets respectively (Figure 3).
Figure 2 Coverage of the human genome by targets annotated in the three drug databases. The Venn diagram shows that gene targets
annotated in drug databases comprise 8% of the entire human genome. It also describes the percentage of the genome covered by each
database individually and upon pairwise comparison.
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We also compared the number of drugs present in
three drug databases (Figure 4). Of the combined total of
9,991 unique drugs, DrugBank contributes 50% of the
unique drug compounds, while TTD and PharmGKB,
contribute 18% and 15% of the unique drug compounds
respectively (Figure 4). Using pairwise comparisons to
check redundancy of drugs between the databases, we
observed TTD and PharmGKB share 15-19% of their
listed drugs with DrugBank. Although there is significant
overlap among the three databases, the high number of
unique drugs in each database show the databases are
fairly complementary. In summary, all three drug data-
bases contain unique and valuable data and were thus all
used in the subsequent analysis.
Identification of therapeutic targets
We identified potential therapeutic targets for the seven
complex diseases from the Gentrepid predicted candi-
date genes generated by our reanalysis of the WTCCC
data. In total, Gentrepid predicted 1,497 candidate genes
for all seven diseases; comprising by phenotype: Type 2
Diabetes (291), Bipolar Disorder (212), Crohn’s Disease
(378), Hypertension (219), Type 1 Diabetes (358),
Coronary Artery Disease (264) and Rheumatoid Arthritis
(200) (Additional file 1 Table S1) [9]. We searched for
these candidate genes in the drug-gene target files
obtained from all three drug databases and found 452
potential therapeutic targets for the seven complex dis-
eases (Table 1). This illustrates that almost 30% of the
total number of predicted candidate genes by Gentrepid
are potential targets for therapeutic treatments using
currently available drugs (Figure 5). The disparity
between the 8% of the human genome that is targettable
(2,494 extracted targets - Figure 2) and the 30% of pre-
dicted candidate genes that are targettable (452 pre-
dicted targets - Figure 5) is interesting and should be
investigated further. The enrichment of druggable tar-
gets in the candidate gene set might be a selection
effect: either at the SNP level; or at the knowledgebase
level: it might suggest that we already know more about
disease genes than the genome in general. Alternatively,
it has been previously suggested that the genome can be
Figure 3 Comparison of human drug targets from three drug databases. Comparison of three drug databases to identify unique and
common human drug targets extracted from DrugBank, TTD and PharmGKB. DrugBank has the highest number of unique human targets
followed by PharmGKB and TTD.
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partitioned into “disease genes” and “non-disease genes”.
While such a Boolean distribution is likely to be overly
simplistic, a spectrum of levels of disease association
with specific gene subsets might explain this disparity.
To drill a little further into the data, we assessed the
therapeutic potential of each phenotype using currently
available repositioned drugs. We calculated an empirical
Targetability Index (TI), defined here as the ratio of the
number of predicted targets to the number of predicted
candidate genes for each phenotype (Table 1). The distri-
bution was bimodal with four phenotypes (CAD > RA >
CD > HT) being more targetable (TI = 0.35-0.39) than the
other three (T2D > T1D ~ BD) (TI = 0.27-0.29). A factor
which is likely to influence the targetability is our underly-
ing knowledge of the phenotype. If the molecular path-
ways involved have been previously characterized, there is
more likely to be drug-target information in the existing
drug databases, even if the phenotype has not previously
been associated with the molecular system. The low TIs
for BD (0.28) and the diabetes phenotypes (0.27-0.29)
likely arises from lack of knowledge of underlying path-
ways. More basic research in this area is required.
All three drug databases made significant contributions
to target identification, with the highest contribution from
DrugBank (400), followed by TTD (156) and PharmGKB
(61). DrugBank is a chemical as well as a clinical drug
Figure 4 Comparison of coverage of drugs in three drug databases. Comparison of drug coverage of three drug databases to identify
unique and common drugs. DrugBank has the highest number of unique drugs followed by TTD and PharmGKB.
Table 1 Repositioning potential and known therapeutic
targets by phenotype.
PH ≠ TT TI RN RTT NTT NV RN
T2D 84 0.29 5th 7 77 0.92 5th
T1D 97 0.27 6th 2 95 0.98 2nd
RA 77 0.38 2nd 6 71 0.92 5th
HT 78 0.35 4th 5 73 0.94 4th
BD 59 0.27 6th 1 58 0.98 2nd
CD 135 0.36 3rd 0 135 1.00 1st
CAD 102 0.39 1st 4 98 0.96 3rd
Abbreviations - PH - Phenotypes; ≠TT - Number of Therapeutic Targets; TI -
Targetability Index; NTT - Novel Therapeutic Targets; RTT - Replicated
Therapeutic Targets; NV - Novelty; RN - Rank; T2D - Type 2 Diabetes; BD -
Bipolar Disorder; CD - Crohn’s Disease; HT - Hypertension; T1D - Type 1
Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis.
Description of therapeutic targets and novel therapeutic targets. Total 452
unique therapeutic targets and total 428 unique novel therapeutic targets
obtained for seven complex diseas
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database which contains broader coverage of drug targets
and broader depth of information compared to the chemi-
cal drug database TTD and the clinical drug database
PharmGKB. PharmGKB, being a clinical drug database,
has a lower coverage of drug-target associations, but
broader depth of information compared to TTD. To sum-
marize, the total coverage of the predicted targets from all
three databases was estimated to be 30% of the candidate
genes predicted by Gentrepid, with the maximum contri-
bution from DrugBank (Figure 5).
Discovery of novel therapeutic targets
For the seven diseases considered in our study, we per-
formed a binary classification of the 452 targets to dis-
tinguish therapeutic targets which were “rediscovered”
(or replicated) from novel potential therapeutic targets.
Novel genes are targeted by therapeutics registered for
other uses but not for the phenotype of interest. We
found 428 novel therapeutic targets accounting for
almost 94% of the targets identified in the previous sec-
tion. The remaining 24 targets have therapeutics which
either are approved, are in ongoing clinical trials, or
have been discontinued as therapeutics for the phenotype
of interest (Table 2). We considered these 24 known tar-
gets as “true positives” for the phenotypes of interest
in one of the benchmarks described below (see section
Validation of predicted therapeutic targets in Results and
discussion).
Figure 6 shows the number of novel therapeutic targets
obtained for each of the seven diseases, along with the
contribution from each drug database. The novelty of the
predicted targets for each disease was assessed by calcu-
lating the ratio of the number of novel therapeutic targets
to the number of therapeutic targets predicted for each
disease. The novelty ratio for all diseases was between
0.92 and 1.0 (Table 1). We observed the highest novelty
ratio for CD (1.0) and the lowest for RA (0.92). The high
ratio of novel targets for all phenotypes to predicted tar-
gets suggests repositioning could have a large impact on
clinical studies.
Identification of novel therapeutics
To identify novel drugs, we compared our phenotype of
interest (from the pool of seven diseases considered in our
Figure 5 Predicted therapeutic targets from three source databases. The Venn diagram represents the identified 30% of 1,497 candidates
are potential therapeutic targets for all the seven diseases. 17% of the targets were unique to one of the three drug databases (DrugBank), 1-2%
of targets were found in at least two databases (PharmGKB, TTD) and only 1.6% of targets are common to all the three drug databases.
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study) with indications associated with the drug. In total,
we retrieved 7,252 drugs associated with human drug tar-
gets from all three drug databases. We found 2,192 (30%
of the extracted drugs) unique drugs that target the 452
potential therapeutic targets.
We retrieved the maximum number of drugs from
DrugBank (1,618) and the remainder from TTD (735)
and PharmGKB (91). In order to identify the novel drugs
i.e. drugs not targeting our phenotype of interest, we fil-
tered the above list of 2,192 drugs to retrieve 2,130 novel
therapeutics. On a phenotype by phenotype basis, T1D
and CAD had the maximum number of novel predicted
therapeutics. Although CD had the highest number of
novel targets, it had comparatively few novel therapeutics
suggesting new drug development is needed for this phe-
notype. BD had the fewest therapeutics as expected based
on the small number of predicted therapeutic targets. We
found that the total percentage of drugs that may be
repositioned towards identified novel targets was around
29% of the total number of extracted drugs.
Table 2 shows the 24 replicated targets with examples of
replicated drugs found in our study. For example, the drug
“Aleglitazar” is in phase III clinical trial for the T2D target
PPARA, a predicted candidate gene for T2D. “Rosiglita-
zone” known to target PPARG as a therapeutic for diabetes
mellitus, has a potential use in the related phenotype T1D.
Examples of novel therapeutics for the seven phenotypes
are shown in Table 3. For example, “Pirenzepine”, which
acts upon the CHRM1 gene product, is approved as a
therapeutic drug for peptic ulcers. Our study predicts
CHRM1 is a predicted candidate gene and novel therapeu-
tic target for T2D, suggesting that the drug Pirenzepine
may be repositioned as a novel therapeutic for T2D.
Hence, the associated therapeutics for the novel therapeu-
tic targets may be repositioned against the phenotypes of
interest, accelerating the drug discovery process.
FDA-approved and clinical targets
Identification of therapeutic targets targeted by approved
and clinical trial drugs can help us to prioritize drugs for
Table 2 Predicted known therapeutics
PH Target *Drug name Status Action *Database
T1D PPARG Rosiglitazone Approved Agonist TTD
DGKA Vitamin E Approved Unknown DrugBank
T2D CTSD Insulin Regular Approved Unknown DrugBank
PPARA Aleglitazar Phase III Agonist TTD
NR3C1 ISIS-GCCR Preclinical Antisense TTD
TCF7L2 Repaglinide Unknown Unknown PharmGKB
PPARD Bezafibrate Approved Agonist DrugBank
RB1 Insulin, porcine Approved Unknown DrugBank
HSD11B1 INCB13739 Phase IIa Inhibitor TTD
RA TNF Infliximab Approved Inhibitor DrugBank
ITGA4 CDP323 Phase II Antagonist TTD
JAK2 INCB18424 Phase III Inhibitor TTD
IL15 AMG-714 Discontinued in phase I Inhibitor TTD
CCL2 MCP-1 Preclinical Inhibitor TTD
PRKCA Vitamin E Approved Unknown DrugBank
HT DRD1 Fenoldopam Approved Agonist TTD
AGTR1 Valsartan Approved Antagonist TTD
CNR1 AZD1175 Discontinued in phase I Antagonist TTD
AGT Benazepril Unknown Unknown PharmGKB
GUCY1A2 Isosorbide Mononitrate Approved Inducer DrugBank
BD SLC6A2 Imipramine Approved Inhibitor DrugBank
AGTR1 Valsartan Approved Antagonist DrugBank
CAD MYC AVI4126 Phase I/II Antisense TTD
PLG Urokinase Approved Activator DrugBank
NOS3 ACCLAIM Phase III Stimulator TTD
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; BD - Bipolar Disorder; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA -
Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Therapeutic targets with predicted known therapeutics for phenotypes of interest.
(* Drugs mentioned in the table are only examples as one target may have multiple drugs);
(* Drug databases in the table are only examples as one drug-target association may be present in more than one database).
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repositioning against phenotypes of interest. Both
approved and clinical targets are potential drug targets,
however, approved targets will undoubtedly be on the
priority list for further experimental studies. We classi-
fied the predicted targets as FDA-approved and clinical
targets for the seven complex diseases. An example
depicted in Figure 7 shows comparison between T2D tar-
gets from the TTD database and targets predicted by
Gentrepid for T2D. Of the 84 targets predicted for T2D
by Gentrepid (Table 1), 28 are listed in TTD (Figure 7).
Figure 6 Predicted therapeutic targets for each of the seven phenotypes. Abbreviations - T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD
- Crohn’s Disease; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis. For each phenotype, the
contributions of each of the three drug databases are shown in primary colours on the left, and the set of total unique targets is shown in
green on the right. The cross-hatched portion of the bar shows targets replicated by the system which are already targeted by therapeutics for
that phenotype. The solid portions of the bars are novel predictions, which may potentially be utilized in repositioning.
Table 3 Novel therapeutics suitable for repositioning for the seven diseases
PH Target *Drug name Status Current Indication Action *Database
T1D RARA Alitretinoin Approved Kaposi’s sarcoma Agonist TTD
GSK3B Lithium Unknown Bipolar disorder Unknown PharmGKB
T2D CHRM1 Pirenzepine Approved Peptic ulcer disease Antagonist TTD
LPL Gemfibrozil Approved Hyperlipidemia Activator TTD
CAD FLT1 Sorafenib Launched Advanced renal cell carcinoma Inhibitor TTD
KDR Sunitinib Launched Advanced renal cell carcinoma Inhibitor TTD
BD ESR1 Trilostane Approved Cushing’s syndrome aModulator DrugBank
ABCC1 Methotrexate Unknown Psoriasis Unknown PharmGKB
HT TACR1 GSK1144814 Phase I Schizophrenia Antagonist TTD
NRP1 Palifermin Approved Oral mucositis Unknown DrugBank
CD CRHR1 CRF-1 antagonist Phase II completed Irritable bowel syndrome Antagonist TTD
INSR Insulin Detemir Approved Type I and II Diabetes Agonist DrugBank
RA HLA - DRB 1 Glatiramer Acetate Approved Multiple sclerosis Binder TTD
ACE Ramipril Approved Hypertension Inhibitor DrugBank
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; BD - Bipolar Disorder; HT - Hypertension; CD -
Crohn’s Disease; RA - Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Examples of novel therapeutics suitable for repositioning towards cure of seven diseases. (* Drugs mentioned in the table are only examples as one target may
have multiple drugs); (* Drug databases in the table are only examples as one drug-target association may be present in more than one database); (a Allosteric
Modulator).
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Comparing these 28 targets with the 32 targets indicated
for T2D in TTD, we found products of three genes
(HSD11B1, PPARA, NR3C1) are targeted by drugs cur-
rently in clinical trials for T2D. In addition, PPARA is
already targeted by FDA-approved drugs. Hence, we pre-
dicted 25 novel therapeutic targets from the TTD data-
base for T2D. In total for the seven diseases, we found
291 approved therapeutic targets and 95% of these as
novel approved targets. We also found 334 targets in
clinical trials and 96% of these being novel (Table 4). To
summarize, both approved and clinical novel targets are
associated with therapeutics, which may be repositioned
as novel treatments towards the cure of complex diseases.
Validation of predicted therapeutic targets
To assess the validity of targets predicted by Gentrepid for
each phenotype, we used two different benchmarks. In the
first benchmark, validity of the association of the gene
with the phenotype was based on whether they are desig-
nated as targets in the drug databases or not. This was
repeated for all six search spaces investigated for each phe-
notype. In the second benchmark, the validity of the asso-
ciation of the gene with the phenotype was assessed by the
existence or the absence of abstracts in the literature citing
both the gene name and the phenotype.
For the first benchmark, we performed a binary classifi-
cation of genes in the six search spaces as “candidates” or
“non-candidates”. As described in Table 5, targets with
therapeutic drugs for the phenotype of interest were
Figure 7 FDA-approved and clinical therapeutic targets. Abbreviation - T2D - Type 2 Diabetes; Comparison of Gentrepid predicted targets for
Type 2 diabetes targeted by FDA-approved and clinical trial drugs with targets obtained from the TTD database for Type 2 Diabetes. Three
predicted therapeutic targets (HSD11B1, PPARA, NR3C1) targeted by drugs currently in clinical trials for T2D. In addition, PPARA is also targeted by
FDA-approved drugs.
Table 4 Approved and clinical targets for seven complex
diseases
PH AT NAT CT NCT
T2D 45 41 65 62
T1D 57 55 73 72
HT 71 68 43 40
RA 55 53 59 54
CD 93 93 135 135
CAD 63 61 80 76
BD 37 36 44 44
Unique sum 291 277 334 318
Abbreviations - PH - Phenotypes; AT - Approved Targets; NAT - Novel Approved
Targets; CT - Clinical Targets; NCT - Novel Clinical Targets; T2D - Type 2 Diabetes;
T1D - Type 1 Diabetes; HT - Hypertension; RA - Rheumatoid Arthritis; CD - Crohn’s
Disease; CAD - Coronary Artery Disease; BD - Bipolar Disorder.
Predicted therapeutic targets targeted by FDA-approved drugs and drugs in
clinical trials.
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considered “true positives”. Targets with currently regis-
tered therapeutics for the phenotype of interest which
were not predicted by Gentrepid, but were present in the
search space as “false negatives”. Genes which were not
predicted and not targetable by drugs as “true negatives”
and Gentrepid-predicted novel therapeutic targets were
considered as “false positives” (Table 5). ROC curves were
plotted considering targets based on the six search spaces
from the weakly significant data set (Additional file 1,
Figure S1). Area Under Curve (AUC) values obtained
from these ROC curves were significantly greater than 0.5
(p < 0.05) (Additional file 1, Table S2). This suggests that
our predictions of novel therapeutic targets for all the
seven diseases are significant.
For the second benchmark, ROC curves for the seven
complex diseases were created by considering four thresh-
olds for targets cited by at least one, five, ten and fifteen
article citations as true positives and targets without any
citations or less than five, ten and fifteen citations as false
positives. Figure S2 (Additional file 1) contains all the
ROC curves and Table S2 (Additional file 1) contains the
AUC values. The AUC values for all the seven diseases
were significantly greater than from 0.5 (p < 0.05) meaning
that our results were significantly better than by chance.
This also suggests that our predictions of novel therapeu-
tic targets for all seven diseases are significant.
Significance of the work
The primary purpose of our work was to identify poten-
tial therapeutics and their targets by integrating publicly
available genetic, bioinformatic and drug data using the
Gentrepid candidate gene prediction platform. As the
method involves repositioning of currently available
drugs, it allows immediate translational opportunities
for drug testing [8]. Other bioinformatic tools have been
used to identify potential therapeutic targets for com-
plex diseases and other conditions. For example,
TARGET gene was used to identify and prioritize poten-
tial targets from hundreds of candidate genes for differ-
ent types of cancer [34]. Another study identified
potential drug targets for three neurological disorders -
Alzheimer’s disease, Parkinson’s disease and Schizo-
phrenia. This study involved the prediction of candidate
genes using the ToppGene and ToppNet prediction
systems [24,35]. The repositioning tools could be used
as an initial screening tool for potential drugs which
can be used for further evaluation [34]. It is important
to note that not all repositioning opportunities will
be successful as there are always some limitations
[36,37].
Conclusion
There is a need to develop new approaches for the iden-
tification of therapeutic targets to accelerate the process
of therapeutic drug discovery which has not kept pace
with discoveries in genetics. In this study, we integrated
detailed drug data with predicted candidate genes for
seven complex diseases. We found 29% of the predicted
candidate genes could serve as novel therapeutic targets
and 29% of the extracted drugs are potential novel ther-
apeutics for at least one of the seven complex diseases
considered in our study. We have utilized both FDA-
approved drugs and drugs in clinical trials. Further
investigation is required to verify the action of these
drugs. This study enables efficient identification of pos-
sible novel therapeutic targets and alternative indications
for existing therapeutics. Hence, these drugs may be
repositioned against seven phenotypes of interest,
quickly taking advantage of already done work in phar-
maceutics to translate ground-breaking results in genet-
ics to clinical treatments. Gentrepid, thus can be utilized
as a drug screening tool to save time and money spent
on the initial stages of drug discovery.
Additional material
Additional file 1: Gentrepid annotated SNPs, ROC curves and AUC
values for seven phenotypes. Table S1 - Gentrepid annotated SNPs
(clusters) for four data sets, WTCCC study associated loci (HS - p ≤ 5 x10-7 )
and Gentrepid predicted candidate genes per phenotype. Figure S1 - ROC
curves for seven diseases based on six thresholds obtained from targets
present in six search spaces in weakly significant data set. Table S2 AUC
values for ROC curves. Figure S2 ROC curves for seven diseases based on
four thresholds obtained using four cutoff of Pubmed citations (at least one,
five, ten and fifteen).
Table 5 Binary classification of therapeutic targets
PH Total genes in all
search spaces
Binary classification
T2D 4,292 TP = 7 FP = 77
FN = 9 TN = 4,199
T1D 5,339 TP = 2 FP = 95
FN = 9 TN = 5,233
HT 8,427 TP = 5 FP = 73
FN = 15 TN = 8,334
RA 4,970 TP = 6 FP = 71
FN = 9 TN = 4,884
BD 5,667 TP = 1 FP = 58
FN = 6 TN = 5,602
CD 5,644 TP = 0 FP = 135
FN = 0 TN = 5,509
CAD 4,715 TP = 4 FP = 98
FN = 8 TN = 4,605
Abbreviations - TP - True Positives; FP - False Positives; TN - True Negatives;
FN - False Negatives; TN - True Negatives; PH - Phenotypes; T2D - Type 2
Diabetes; T1D - Type 1 Diabetes; HT - Hypertension; RA - Rheumatoid Arthritis;
CD - Crohn’s Disease; CAD - Coronary Artery Disease; BD - Bipolar Disorder.
Binary classification of therapeutic targets considering targets present in six
search spaces from weakly significant data set.
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Table S1 - SNPs per phenotype, WTCCC study associated loci (HS) and Gentrepid 
predicted candidate genes per phenotype 
 
Phenotype WS MWS MHS HS Loci in the Gentrepid 
p ≤ 1x10-3 p ≤ 1x10-4 p ≤ 1x10-5 p ≤ 5x10-7 original predicted 
SNPs SNPs SNPs SNPs WTCCC candidate 
(Clusters) (Clusters) (Clusters) (Clusters) Study genes 
        
CAD 757 (436) 134 (86) 43 (22) 25 (10) 1 264 
        
HT 799 (460) 110 (61) 5 (5) 0 (0) 0 219 
       
T2D 725 (421) 125 (70) 45 (15) 19 (2) 3 291 
       
T1D 966 (442) 276 (103) 162 (43) 92 (24) 7 358 
       
RA 699 (429) 104 (75) 27 (14) 11 (5) 3 200 
      
CD 1064 (501) 261 (112) 102 (23) 63 (10) 9 378 
BD 797 (513) 138 (94) 23 (10) 0 (0) 1 212 
 
Abbreviations - T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD - Crohn’s Disease; HT - Hypertension; T1D - Type 1 
Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis; SNP - Single Nucleotide Polymorphism; WTCCC - 
Wellcome Trust Case-Control Consortium; WS: Weakly Significant Set; MWS: Moderately-Weak Significant Set; MHS: 
Moderately-High Significant set; HS: Highly Significant Set. 
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Table S2 - AUC values for ROC curves 
 
 
 
 Phenotype AUC (figure S1) AUC (figure S2) 
    
 T2D 0.98 0.95 
 T1D 0.97 0.97 
 RA 0.95 0.97 
 HT 0.95 0.97 
 BD 0.98 0.98 
 CD 0.99 0.97 
 CAD 0.97 0.97 
    
 
Abbreviations - T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD - Crohn’s Disease; HT - Hypertension; 
T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis; AUC - Area under 
curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ROC curves for seven diseases based on four thresholds obtained using four cutoff of Pubmed citations 
(at least one, five, ten and fifteen). Abbreviations - T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD - 
Crohn’s Disease; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - 
Rheumatoid Arthritis 
 
 
Figure S2 – ROC curves for seven complex diseases based on PubMed citations 
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Chapter 3: Research article 2 
Novel therapeutics for coronary artery disease from genome-wide association 
data 
In the second research study, we specifically focused on CAD as a phenotype of interest. 
CAD, also known as Coronary Heart Disease, is a disease in which a waxy substance called plaque 
builds up on the inside of the coronary arteries resulting in heart-related disorders. It is one of the most 
common causes of deaths (12.2%) worldwide (Lopez et al. 2006; McCullough 2007). Hence, there is 
an urgent need to identify and develop potential targeted drug treatments. Heritability of CAD has 
been calculated to be between 40% and 50%, but only ~10% is explained by genetic variations 
discovered to date (Peden & Farrall 2011). 
Using the Wellcome Trust Case-Control Consortium GWAS data, we used Gentrepid to 
predict a total of 264 candidate genes and 104 potential therapeutic targets for CAD (see chapter 2 for 
details) (Grover, Mani P et al. 2014). In this expanded study, we used a similar pipeline as described in 
chapter 2, but we not only used the two bioinformatic modules previously used (i.e. pathways and 
protein domains (CMP &CPS), we also used three additional modules. These were: a Protein-Protein 
Interaction (PPI) module, a Common Regulatory Targets (CRT) module and a micro-RNA (MIR) 
module. (1) The Protein-Protein interactions (PPI) module is a systems biology method which is based 
on the assumption that common phenotypes are likely to be associated with proteins that partake in the 
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same complex or pathway (Badano and Katsanis, 2002, George RA, et al. 2006). PPI searches for 
genes by identifying interaction partners and protein interactions hubs using pairwise protein-protein 
interaction data (Ballouz, S. et al. 2013). In seeded mode, PPI searches for genes that interact with 
known disease genes in the interaction network. In ab initio mode, PPI searches for significant 
enrichment of interacting genes within the search space compared to remainder of the genome 
(Ballouz, S. et al. 2013). (2) The Common Regulatory Targets (CRT) module searches for genes in the 
implicated loci that bind transcription factors that are targeted by common regulatory factors (Ballouz, 
S. et al. 2013). In seeded mode, CRT uses regulatory elements in the seed genes to search for genes in 
the search space that regulated by the same transcription factors (Ballouz, S. et al. 2013). For the ab 
initio approach, CRT searches for enrichment of genes with common regulation among the loci in the 
gene search space (Ballouz, S. et al. 2013). (3) MicroRNA data (MIR) is a Micro-RNA based module 
which looks for genes among the implicated loci that are common miRNA targets and in regulatory 
hubs (Ballouz, S. et al. 2013). In seeded mode, MIR uses miRNA binding elements in the seed genes 
to search for genes in the search space that regulated by the same miRNAs. For the ab initio approach, 
MIR searches for enrichment of genes which are common miRNA targets among the loci in the gene 
search space (Ballouz, S. et al. 2013). The significance of the candidate gene predictions made by the 
PPI, CRT and MIR modules is calculated using a one-tailed Fisher’s test and a p-value is assigned to 
each gene for prioritization (Ballouz, S. et al. 2013).  
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Using the five bioinformatics modules, Gentrepid identified a total of 647 candidate genes and 
successfully replicated 16%, 17% and 55% of the candidate genes identified in the powerful 
CARDIoGRAM, C4D and CARDIoGRAMplusC4D meta-analysis studies of CAD respectively 
(Consortium 2011; Deloukas et al. 2013; Schunkert et al. 2011). These studies included 22,233 
(CARDIoGRAM), 15,420 (C4D), and 63,746 (CARDIoGRAMplusC4D) CAD patients (Consortium 
2011; Deloukas et al. 2013; Schunkert et al. 2011). Most of the identified genetic loci and candidate 
genes from these meta-analysis studies were limited to a highly significant statistical threshold (p < 5 
× 10-8) adjusted for multiple testing. Our study shows that the Gentrepid predictions align more 
closely with the more powerful CARDIoGRAMplusC4D meta-analysis study (55% of results 
replicated) which pooled cases and controls from both the CARDIoGRAM (16% of results replicated) 
and C4D studies (17% of results replicated)  (Consortium 2011; Deloukas et al. 2012; Schunkert et al. 
2011). 
Further, we used our pipeline to integrate drug-target data retrieved from three drug databases: 
the Therapeutic Target Database (TTD), PharmGKB and Drug Bank, with the 647 candidate gene 
predictions from Gentrepid. Our analysis identified a total of 192 predicted candidate genes as 
therapeutic targets for CAD associated with 993 therapeutics. 8 of the 192 Gentrepid-predicted 
candidates are known therapeutic targets for CAD. The successful replication of targets directly from 
the genetic data is not only an excellent test that the system is working, but also confirms the 
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importance of these genes in treatment of the phenotype. In total, Gentrepid predicted 184 novel 
therapeutic targets associated with 981 therapeutics suitable for repositioning in clinical trials towards 
treatment of CAD. 
We also calculated a Targetability Index (TI), the ratio of predicted therapeutic targets to 
predicted candidate genes, and found that TI for CAD in this 5-module based study the TI of 30% 
(Total number of targets = 192) was lower than our previous 2-module based study (TI of 39%, Total 
number of targets = 104). Although the TI is lower, this merely reflects that a larger fraction of the 
predicted candidates is not currently druggable but as the total number of targets increased from 104 to 
192, it still is a remarkable improvement.  
Finally, we validated our results using known CAD targets and the scientific literature to 
validate Gentrepid predictions for CAD. The first benchmark based on known CAD targets showed 
that eight of 12 known CAD targets i.e. eight true positives and four false negatives, were replicated in 
this study (p<0.05) and the second benchmark based on a literature search of CAD studies in PubMed, 
showed there was a significant association (p<0.05) between mentions of the phenotype and the 
predicted target gene in literature abstracts. The PubMed benchmark, however, is not conclusive 
because the association might be a negative one between the phenotype and the predicted target gene.  
We also compared the predicted therapeutic targets of CAD in this study with those targets 
identified in this study using CARDIoGRAMplusC4D meta-analysis candidate gene dataset 
(Schunkert et al. 2011). We mapped the 20 candidate genes for CAD obtained in the 
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CARDIoGRAMplusC4D study with the extracted drug-gene target dataset from the three drug 
databases (2,494 gene targets associated with 7,252 drugs) to identify ten therapeutic targets. 
Gentrepid independently predicted two (PLG and FLT1) of the ten therapeutic targets (20%) obtained 
using the CARDIoGRAMplusC4D study data. The remaining 8 targets were among the 45% of genes 
that were not confirmed by Gentrepid, either being outside our search space, or not having sufficient 
biological data to confirm their status as valid candidate genes. Thus, our methodology not only 
replicated some of the potential CAD therapeutic targets from the large-scale meta-analysis study, but 
also made 184 novel target predictions (Total targets = 192, known targets = 8) using the existing drug 
knowledgebase. Hence, Gentrepid can be utilized to identify potential candidate genes and novel 
therapeutic targets associated with novel therapeutics that can then be trialed in patients with CAD. 
The chapter was chosen as a platform session at the Translational Bioinformatics 
Conference/International Conference on Systems Biology – TBC/ISB 2014, held at Qingdao, China. 
and subsequently published in the peer reviewed BMC Medical Genomics journal. Mani P Grover 
extracted and processed the candidate gene dataset and the drug-gene target dataset, filtered the list of 
therapeutics suitable for repositioning, validated the results, drafted all sections of the manuscript, and 
critically revised the manuscript. Dr Merridee A. Wouters contributed to the conception of project, and 
critically reviewed all the results and the complete manuscript. Kaavya A. Mohanasundaram helped in 
technical discussions. Dr. Richard A George helped in conception of project. Craig D H Sherman and 
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Dr. Tamsyn M Crowley provided technical and administrative support, and reviewed the manuscript. 
Dr. Andrzej Goscinski provided computational support related to the Gentrepid database.  
This article has two citations and 189 access at the time of thesis revision (Oct 2016). A copy 
of this publication is included here and it can also be accessed via the following website: 
http://www.biomedcentral.com/1755-8794/8/S2/S1. Supplementary files of this publication are 
included after the published research article in the end of this chapter. 
Reproduced with permission from Mani P. Grover, Sara Ballouz, Kaavya A. 
Mohanasundaram, Richard A. George, Andrzej Goscinski, Tamsyn M. Crowley, Craig D H Sherman, 
and Merridee A. Wouters. "Novel therapeutics for coronary artery disease from genome-wide 
association study data." BMC Medical Genomics 8, no. Suppl 2 (2015): S1. 
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Novel therapeutics for coronary artery disease
from genome-wide association study data
Mani P Grover1, Sara Ballouz2, Kaavya A Mohanasundaram1, Richard A George3, Andrzej Goscinski4,
Tamsyn M Crowley1,5, Craig D H Sherman6, Merridee A Wouters1*
From The 4th Translational Bioinformatics Conference and the 8th International Conference on Systems
Biology (TBC/ISB 2014)
Qingdao, China. 24-27 October 2014
Abstract
Background: Coronary artery disease (CAD), one of the leading causes of death globally, is influenced by both
environmental and genetic risk factors. Gene-centric genome-wide association studies (GWAS) involving cases and
controls have been remarkably successful in identifying genetic loci contributing to CAD. Modern in silico platforms,
such as candidate gene prediction tools, permit a systematic analysis of GWAS data to identify candidate genes for
complex diseases like CAD. Subsequent integration of drug-target data from drug databases with the predicted
candidate genes can potentially identify novel therapeutics suitable for repositioning towards treatment of CAD.
Methods: Previously, we were able to predict 264 candidate genes and 104 potential therapeutic targets for CAD
using Gentrepid (www.gentrepid.org), a candidate gene prediction platform with two bioinformatic modules to
reanalyze Wellcome Trust Case-Control Consortium GWAS data. In an expanded study, using five bioinformatic
modules on the same data, Gentrepid predicted 647 candidate genes and successfully replicated 55% of the
candidate genes identified by the more powerful CARDIoGRAMplusC4D consortium meta-analysis. Hence, Gentrepid
was capable of enhancing lower quality genotype-phenotype data, using an independent knowledgebase of
existing biological data. Here, we used our methodology to integrate drug data from three drug databases: the
Therapeutic Target Database, PharmGKB and Drug Bank, with the 647 candidate gene predictions from Gentrepid.
We utilized known CAD targets, the scientific literature, existing drug data and the CARDIoGRAMplusC4D meta-
analysis study as benchmarks to validate Gentrepid predictions for CAD.
Results: Our analysis identified a total of 184 predicted candidate genes as novel therapeutic targets for CAD, and
981 novel therapeutics feasible for repositioning in clinical trials towards treatment of CAD. The benchmarks based
on known CAD targets and the scientific literature showed that our results were significant (p < 0.05).
Conclusions: We have demonstrated that available drugs may potentially be repositioned as novel therapeutics for
the treatment of CAD. Drug repositioning can save valuable time and money spent on preclinical and phase I
clinical studies.
Background
Coronary artery disease (CAD) or Coronary heart dis-
ease (CHD) is a complex disorder which is a leading
cause of death and disability (12.2%) worldwide [1]. In
CAD, a waxy substance called ‘plaque’ collects inside
the coronary arteries and other blood vessels which sup-
ply oxygen-rich blood to heart muscles [2]. Over time,
hardened plaque narrows the coronary arteries, reducing
the flow of oxygen-rich blood to the heart, resulting in
CAD [2].
Environmental and genetic risk factors play an impor-
tant role in the development of CAD. Lifestyle-related
environmental factors include smoking, drinking and
eating habits [3,4]. CAD is also inherited in families,
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suggesting the disease has a strong genetic basis [5].
CAD is thus a complex disease involving multiple risk
factors, and is characterised by low penetrance of
disease genes and non-Mendelian genetic transmission
patterns. Heritability of CAD is estimated between 30%-
60% by twin studies [6]. However, only a minor portion
of heritability is explained by conventional risk factors
such as decreased Low Density Lipoprotein (LDL) parti-
cle size and high Systolic Blood Pressure (SBP) [7,8].
Genome-Wide Association Studies (GWAS) are mak-
ing progress towards revealing single-nucleotide poly-
morphisms (SNPs) associated with CAD. The Wellcome
Trust Case Control Consortium (WTCCC) conducted
the first large-scale GWAS study of 2,000 cases of CAD
compared with white Europeans 3,000 controls [9]. The
WTCCC study identified one highly independent asso-
ciation signal for CAD (p < 5 × 10-7) in the genetic
locus 9p21 [9]. Another GWAS comparing 1,222 CAD
cases with European 1,298 controls identified a second
genetic locus (3q22) for CAD [10]. The typical effect
sizes for individual SNPs were fairly small (~1%) in
these studies.
In recent years, meta-analysis techniques have
emerged as a successful approach for increasing the
power of GWAS by pooling results from multiple
GWAS studies. The Coronary ARtery DIsease Genome-
Wide Replication and Meta-analysis (CARDIoGRAM)
consortium identified 13 new genetic loci (p < 5 × 10-8)
and 26 candidate genes in a meta-analysis study of 14
CAD GWASs comprising a total of 22,233 individuals
with CAD compared to European 64,762 controls [11].
Another meta-analysis performed by the Coronary
Artery Disease (C4D) Genetics Consortium identified
five genetic loci for CAD (p < 5 × 10-8) and six candi-
date genes using data from four CAD GWAS compris-
ing a total of 15,420 CAD cases (6,996 South Asians
and 8,424 Europeans) and 15,062 controls (7,794 South
Asians and 7,268 Europeans) which were replicated in
an independent sample of 21,408 cases and European
19,185 controls [12]. Together, the CARDIoGRAM and
C4D consortia (CARDIoGRAMplusC4D) scanned
63,746 CAD cases and 130,681 controls (South Asian
and European) identifying 15 novel genetic loci and 20
likely candidate genes for CAD [13]. In total, these
meta-analysis techniques successfully identified a further
32 genetic susceptibility loci for CAD beyond the two
identified by the original studies. However, most of the
identified genetic loci were limited to a highly significant
statistical threshold (p < 5 × 10-8) because the genotype/
phenotype data is inherently noisy.
Another approach to mining this inherently noisy data
is to filter less statistically significant data using an inde-
pendent data source. We previously developed protocols
to predict candidate genes for complex diseases by
reanalysing GWAS data using the Gentrepid candidate
gene prediction tool as the biological knowledgebase,
starting with data from a series of four lower statistical
thresholds (p ≤ 5 × 10-7, p ≤ 10-5, p ≤ 10-4, p ≤ 10-3)
[14]. Gentrepid utilizes five bioinformatic modules to
predict candidate genes for complex diseases: two sys-
tems biology modules - Common Pathway Scanning
(CPS) and Protein-Protein Interactions (PPI); one
domain-homology recognition approach - Common
Module Profiling (CMP) [14,15]; and two modules based
on identification of nucleic acid regulatory factors
involved in complex diseases - the common regulatory
targets (CRT) module, and the microRNA regulatory
module (MIR) [16]. Previously, we were able to predict
264 candidate genes for CAD [9,14] using two of these
modules: CMP and CPS over six search spaces. In an
expanded study, using a total of five bioinformatic mod-
ules: CMP, CPS, PPI, CRT and MIR [16], Gentrepid
replicated 204 of the 264 predicted candidate genes in
the previous two-module study, and identified an addi-
tional 443 candidate genes. In total, Gentrepid identified
647 candidate genes for CAD [16].
Compared to meta-analysis studies which have been per-
formed for CAD, Gentrepid predicted 16%, 17% and 55%
of the candidate genes identified in the CARDIoGRAM,
C4D and CARDIoGRAMplusC4D meta-analysis studies
respectively [11-13,16]. These data show that the Gentrepid
results are in better alignment with the more powerful
CARDIoGRAMplusC4D study which pooled cases and
controls from the CARDIoGRAM and C4D studies.
Recently, we extended our computational pipeline by
associating predicted candidate genes with drug-target
information extracted from three publicly available drug
databases: Drug Bank [17], the Pharmacogenomics
Knowledgebase (PharmGKB) [18], and the Therapeutic
Target Database (TTD) [19]. Applying this pipeline to
the predicted candidate genes obtained by reanalysing
WTCCC-GWAS data for seven complex diseases includ-
ing CAD [14], we showed 38% of the predicted candidate
genes (102 of 264 predicted candidate genes) are poten-
tial therapeutic targets for CAD, and predicted 743 novel
therapeutics suitable for repositioning in clinical trials to
accelerate the CAD drug discovery process [20].
In this study, we specifically focused on CAD, identify-
ing novel therapeutic targets among the 647 predicted
candidate genes for CAD by integrating drug-target
association data extracted in the previous study [16,20].
We also identified novel therapeutic targets and asso-
ciated novel therapeutics suitable for repositioning
towards treatment of CAD. These were benchmarked
using known CAD targets, the scientific literature, exist-
ing drug data and the CARDIoGRAMplusC4D meta-
analysis study. We have demonstrated that it is possible
to translate a large number of susceptibility genetic loci
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into clinical treatments of CAD using the Gentrepid
candidate gene prediction tool. Thus, Gentrepid can be
utilized as a drug discovery tool to identify novel treat-
ments for CAD.
Methods
We implemented a workflow to identify potential thera-
peutics for CAD by integrating the two following data
sets (Figure 1):
1. A predicted candidate gene data set for CAD,
obtained by reanalysing the WTCCC-GWAS data [9],
with Gentrepid using five bioinformatic modules: CMP,
PPI, CPS, CRT and MIR [15,16];
2. A drug-gene target data set retrieved from three
publically available drug databases namely TTD, Drug-
Bank and PharmGKB [17,19,21].
Candidate gene data set
In our previous work, we predicted a total of 647 candi-
date genes for CAD by careful reanalysis of the
WTCCC GWAS data on CAD [9] using the Gentrepid
candidate gene prediction system [16].
The WTCCC study used a highly stringent significance
threshold (p ≤ 5 × 10-7) to correct for multiple testing in
GWAS analysis [9]. While robust, this approach resulted
in association of only one genetic locus with CAD [14]. To
address the high false negative rate of GWAS studies, we
previously proposed a bioinformatics strategy to sift
through genes near the implicated loci of a large number
of SNPs of slightly lower significance thresholds. We con-
sidered four thresholds of decreasing stringency: a highly
significant set (HS - p ≤ 5 × 10-7), a Medium highly signifi-
cant set (MHS - p ≤ 10-5), a Medium weakly significant set
(MWS - p ≤ 10-4), and a weakly significant set (WS - p ≤
10-3). In total, we constructed a series of four SNP sub sets
comprising a total of 757 SNPs for CAD [14].
An additional problem arises when mapping these
SNPs to nearby genes. Although the causal SNPs are
likely to be in linkage disequilibrium with the implicated
SNPs, genomic architecture is still not well understood.
The implicated SNP may be in a control region distal to
the transcribed region of the gene. Six different search
spaces - three of fixed-widths and three proximity-
based, were created around each SNP-based genetic
locus, for analysis by the Gentrepid candidate gene pre-
diction system [14]. Thus, we utilized six gene selection
methods around each SNP to construct the gene search
spaces, using four SNP sets acquired by incrementally
Figure 1 Workflow. Computational workflow to identify therapeutic targets and novel therapeutics for CAD by integrating genetic,
bioinformatic and drug data. We used Gentrepid as a candidate gene prediction platform to predict candidate genes and DrugBank, TTD and
PharmGKB as databases to extract drug data. Abbreviations - TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics
Knowledgebase.
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lowering the significance threshold of the data, resulting
in a total of 24 search spaces [9,14].
For each of these 24 search spaces, we used the fol-
lowing five bioinformatic modules to predict and priori-
tize candidate genes for CAD using the Gentrepid
candidate gene prediction tool [16]: Two systems biol-
ogy approaches - a) Common Pathway Scanning (CPS)
and, b) Protein-Protein interaction module (PPI); one
domain homology module - c) Common Module Profil-
ing (CMP) and; two nucleic acid based regulatory mod-
ules - d) Common Regulatory Targets (CRT) and, e) the
Micro-RNA regulatory module (MIR) [16].
The two systems biology modules, CPS and PPI, are
based on the principle that common phenotypes are
associated with proteins that participate in the same pro-
tein complex or biochemical pathway [22]. The domain-
homology module, CMP, is a sequence analysis approach
based on the assumption that candidate genes are similar
in function to disease genes already determined for the
phenotype [23]. We have described these methods in
detail in our previously published work [14,15,20].
The two nucleic acid-based regulatory modules: CRT
and MIR are based on the assumption that disruption of
regulatory elements controlling gene expression can
cause diseases [24]. CRT searches for genes in the sus-
ceptibility genetic loci that bind with common transcrip-
tion factors. Regulatory information for genes of the
search space was retrieved from the Open REGulatory
ANNOtation (oRegAnno) database, a publically available
database of curated known regulatory elements from the
scientific literature [25]. The MIR module is based on
the assumption that dysfunction of micro-RNAs (miR-
NAs) plays a key role in the heart, central nervous sys-
tem, and immune system-related diseases [26]. MIR
searches the genetic susceptibility loci for genes which
are common miRNA targets and present in regulatory
hubs [16]. MicroRNA information for this module was
extracted from the mirBase database, an online reposi-
tory for microRNA sequences and annotations [27].
Drug-gene target data set
We used a drug-gene target data set compiled from
three online drug databases: DrugBank [17], PharmGKB
[21] and TTD [19], described in detail in our previously
published work [20].
DrugBank is a chemical and clinical drug database [18],
combining detailed drug data and disease information with
comprehensive drug-target associations [17]. Previously,
we retrieved 6,711 drug entries active against 3,410 unique
drug targets for several species from DrugBank [20]. We
used the G-profiler conversion tool to translate human
drug target information to official HUGO gene symbols
[20,28], resulting in a dataset comprising 3,910 drugs asso-
ciated with 2,022 human drug targets [20].
The Pharmacogenomics Knowledgebase (PharmGKB)
is a clinical drug database, combining information about
drugs, diseases and targeted genes [21]. This database
describes around 3,097 drugs and 26,961 human genes,
but not all of these genes are associated with drugs. We
obtained a licensed PharmGKB annotation dataset,
describing a total of 382 drugs associated with 566
human drug targets [20].
The Therapeutic Target Database (TTD) is a chemical
drug database, integrating drug data with therapeutic
targets [19]. TTD contains 17,816 drugs (approved, clin-
ical and experimental) associated with 2,025 human and
non-human drug targets. We replaced the UniProt
accession numbers with official HUGO gene symbols
using the G-profiler conversion tool [28], extracting
2,960 drugs for 544 unique human drug targets [20].
Pooling the data from DrugBank, TTD and PharmGKB,
we obtained a total of 2,494 unique gene targets from all
the databases, comprising ~ 8% of the entire human
genome [20]. A comparison of the extracted drug-target
datasets from the three databases revealed that only 4% of
human drug targets were common to all three drug data-
bases [20]. We retrieved the maximum number of unique
targets from DrugBank (1,495), followed by TTD (129),
and PharmGKB (326) [20]. In pairwise comparisons,
DrugBank and TTD share the maximal number of drug
targets (398), while TTD and PharmGKB share the fewest
(111) [20].
Of the 9,991 unique drugs contained in these three
drug databases [20], 50% of them are found only in
DrugBank, while the unique contributions from TTD
and PharmGKB were 15-18% [20]. In pairwise compari-
sons, TTD and PharmGKB share 15-19% of their
retrieved drugs with DrugBank [20]. DrugBank and
PharmGKB share the maximal number of drugs (1620),
while TTD and PharmGKB share the fewest (1352) [20].
In total, we retrieved a total of 7,252 unique drugs asso-
ciated with 2,494 human drug targets from all three
drug databases [20].
Identification of novel therapeutics and therapeutic
targets
We mapped predicted therapeutic targets from the pre-
dicted candidate genes with the extracted drug-gene tar-
get association files. A total of 647 predicted candidate
genes for CAD were mapped separately with the three
drug-target association files, and results were retrieved.
Within this set, we distinguished known and novel
therapeutic targets and therapeutics for CAD. If a drug
associated with a therapeutic target is not registered as a
therapy for CAD, it is designated as a novel therapeutic
directed towards a predicted candidate gene target for
CAD. Novel therapeutics may be suitable for reposition-
ing towards treatment of CAD.
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Comparison with previous studies
We compared therapeutic targets obtained in our pre-
vious study with this study to identify therapeutic tar-
gets for CAD using the WTCCC-GWAS data. In our
previous study, we utilised the CMP and CPS bioinfor-
matic modules to predict candidate genes and therapeu-
tic targets [14,20]. In this study, we integrated the
results from five bioinformatic modules: CMP, PPI, CPS,
CRT and MIR. Thus, we compared therapeutic targets
obtained from two different bioinformatic studies con-
ducted to reanalyse the same WTCCC-GWAS data [9].
The CARDIoGRAMplusC4D consortium meta-analysis
compared 63,746 CAD cases with 130,681 controls iden-
tifying 15 genetic loci and 20 candidate genes for CAD
[29]. Our previous reanalysis of this data with Gentrepid
replicated 11 of the 20 candidate genes and made three
novel gene predictions (LRPPRC, GUCY1B3, MAP3K4)
[16]. In this study, we identified potential therapeutic tar-
gets after mapping the 20 candidate genes obtained from
the CARDIoGRAMplusC4D study data and the three
novel genes predicted by Gentrepid with the extracted
drug-gene target dataset. We also compared the identi-
fied therapeutic targets from the CARDIoGRAMplusC4D
study with the Gentrepid-predicted therapeutic targets.
Validation of predicted therapeutic targets
We validated the predicted therapeutic targets using two
benchmarks as described in our previously published
work [20]. The first benchmark tested the ability of Gen-
trepid to replicate known therapeutics for CAD. How-
ever, this benchmark does not give any idea about the
validity of the novel predictions for CAD. Therefore, we
performed a second benchmark to assess the validity of
the candidate gene predictions using text mining of the
existing Pubmed literature for CAD.
In the first benchmark, we classified genes present in the
six search spaces as “CAD candidates” or “CAD non-
candidates”. We considered genes which are already
known drug targets for CAD as “true positives”. Targets
which were not predicted by Gentrepid, but present in the
search space and targeted by currently registered thera-
peutics for the CAD, were designated “false negatives”.
Genes, which were neither predicted for CAD nor targeta-
ble by CAD drugs, were designated as “true negatives";
and predicted novel therapeutic targets were selected as
“false positives”. Finally, we plotted a Receiver Operation
Characteristic (ROC) curve considering six thresholds
based on the number of targets present in the six search
spaces constructed (see candidate gene dataset section in
Methods for details). Non-linear regression analysis, was
performed to fit the ROC curves (see Validation of pre-
dicted therapeutic targets in Results and Discussion).
In the second benchmark, we extracted Pubmed IDs
of literature related to CAD from Pubmed in Feb. 2014.
We mapped the retrieved Pubmed IDs to the gene cita-
tion data downloaded from Entrez Gene (ftp//ftp.ncbi.
nih.gov/gene/) to calculate the number of article cita-
tions for each target, using both the gene name and the
phenotype name (CAD). Further, a ROC curve was
created considering four thresholds of article citations
(one, five, ten and fifteen). Finally, non-linear regression
analysis was performed to fit the ROC curve (see Vali-
dation of predicted therapeutic targets in Results and
Discussion).
Results and discussion
Discovery of novel therapeutic targets
Gentrepid identified 647 candidate disease genes for CAD
[16]. We searched for potential drug-targets in the
extracted drug gene-target files from the three drug data-
bases and found 192 candidate genes (30%) are potential
therapeutic targets for CAD (Figure 1). This may seem
like a large number, but as the typical effect sizes of the
most significant loci in the original WTCCC study was
~1%, and the estimated heritability of CAD is 30-60%, a
minimum of 30-60 genes are expected to underline the
disease. Therefore, it is not implausible that all of these
predicted genes are involved in aetiology of CAD.
Each drug database made significant contributions to
therapeutic target identification, with the maximum
contribution from DrugBank (173), followed by TTD
(57) and PharmGKB (15) (Figure 2). The enrichment of
druggable targets in the predicted candidate gene data-
set for CAD was 30% compared to the value of ~8% for
the entire genome which might be a selection effect,
either at the genome level or the knowledgebase level
[20]. For instance, at the genome level, it has been pos-
ited that a set of “troublemaker” or disease genes exists
[30]. Alternatively, at the knowledgebase level, we may
know more about drugs for the CAD phenotype-asso-
ciated genes as a subset of genes in the human genome,
than the remainder of the genes in the genome.
We performed a binary classification of the 192 pre-
dicted therapeutic targets to distinguish novel and repli-
cated therapeutic targets. Novel therapeutic targets are
genes targeted by therapeutics already approved, or still in
clinical trials for other diseases, but not for CAD. We
found 184 novel therapeutic targets, accounting for almost
95% of the targets identified in our analysis. A selection of
these are shown in Table 1. The remaining eight targets
have therapeutics which are either approved or in ongoing
clinical trials for CAD (Table 2). These eight targets are
Gentrepid-predicted therapeutic targets that are already
known to be associated with CAD (Table 1), and are thus
replicated directly from the genetic data de novo. These
eight replicated known targets are designated “true posi-
tives” in the first benchmark described below. We also
identified 30 known targets of drugs used in the treatment
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of CAD present in drug databases, which were not pre-
dicted by Gentrepid from the WTCCC GWAS data (Addi-
tional file 1 - Table S1). Most of these were not present in
the search spaces constructed from the genetic data: sug-
gesting that the genetic data is at odds with these currently
used therapeutics; or the genetic architecture is more
complicated than was assumed during construction of the
search spaces. However, four of these 30 targets are
present in all six of the search spaces constructed for the
weakly significant dataset, but were not retrieved by Gen-
trepid (Additional file 1 - Table S1). This may be failure of
the system at the knowledgebase level, possibly due to
incomplete coverage by the databases used. These four
targets are considered false negatives in the first bench-
mark described below (Validation of predicted therapeutic
targets in Results and discussion).
Figure 2 Predicted therapeutic targets for CAD by drug database. Therapeutic targets for CAD obtained from three drug databases. The
maximum contribution was from DrugBank (173). A further 19 unique targets were contributed by TTD and PharmGKB. We also identified seven
therapeutic targets common to all three drug databases. In pairwise comparisons, there were no common therapeutic targets between the TTD
and PharmGKB databases that were unique to these two databases i.e. not found in DrugBank. However, there were 34 targets common to TTD
and DrugBank, and five targets common to PharmGKB and DrugBank databases. Abbreviations - CAD - Coronary Artery Disease; TTD -
Therapeutic Target Database, PharmGKB - Pharmacogenomics Knowledgebase.
Table 1. Selected novel therapeutics suitable for repositioning for CAD
Target *Drug name Disease Action Status *Database
CHRM3 Tiotropium Chronic obstructive pulmonary disease Antagonist Approved TTD
HTR1A Fluvoxamine Depressive disorder Unknown Unknown PharmGKB
FLT1 Sorafenib Advanced renal cell carcinoma Inhibitor Launched TTD
ABAT Vigabatrin Epilepsy Inhibitor Approved TTD
GRIK2 Metharbital Epilepsy Antagonist Approved DrugBank
IL2RB Aldesleukin Metastatic renal cell carcinoma Agonist Approved DrugBank
ITGB1 Antithymocyte globulin Prevention of renal transplant rejection Unknown Approved DrugBank
PDGFRA Becaplermin Skin ulcers (from diabetes) Unknown Approved DrugBank
IL2RB Daclizumab Prevention of renal transplant rejection Antibody Approved DrugBank
VEGFA Bevacizumab Metastatic breast cancer Unknown Approved DrugBank
Selected novel therapeutics suitable for repositioning to develop potential treatment of CAD.
(* These drugs mentioned here are only selected examples because one therapeutic target may be associated with multiple drugs); (* Drug databases mentioned
here are only selected examples because one drug-target association may be described in more than one drug database). Abbreviations - PH - Phenotype; TTD -
Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase; CAD - Coronary Artery Disease.
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We further classified the novel targets into targets of
approved drugs vs targets of drugs in clinical trials. We
found 53 targets with approved drugs, 74 targets with
drugs in clinical trials, and 56 targets of both approved
drugs and drugs in clinical trials (Figure 3). Both
approved drugs, and drugs in clinical trials associated
with the novel targets, are suitable for repositioning
towards treatment of CAD. However, approved thera-
peutics associated with novel targets will be the priority
for further repositioning studies because of the lower
risk involved.
Identification of novel therapeutics
We identified novel therapeutics by comparing indications
of predicted drugs with our phenotype of interest i.e. CAD.
If a drug is neither approved nor in clinical trial for CAD,
it is predicted as a novel therapeutic suitable for reposition-
ing in clinical studies. Of the 993 identified unique drugs,
we found the maximum number of drugs from DrugBank
(821), and the remainder from TTD (234) and PharmGKB
(23). By comparing the indications of predicted drugs with
the phenotype (CAD), we determined 981 of the 993 pre-
dicted drugs are novel therapeutics. The percentage of
drugs that may be repositioned towards treatment of CAD
was around 14% of the total number of drugs extracted
from the databases (981 of 7,252 extracted drugs). In total,
we found 981 novel therapeutics: 331 of these were
approved, 636 were in clinical trials, and 14 were both
approved and in clinical trials for diseases other than CAD.
For example, the drug succinylcholine, which acts upon
the CHRM3 gene product, is approved as a therapeutic for
spasm (Table 1). Our study predicts CHRM3 as a predicted
candidate gene and novel therapeutic target for CAD, sug-
gesting that the drug succinylcholine may be repositioned
as a novel therapeutic for CAD.
Identification of known therapeutics
We replicated 12 known therapeutics for the eight
Gentrepid-replicated targets for CAD (Table 2). For
example, the approved drug anistreplase, retrieved
Table 2. Replicated therapeutics for CAD
Target *Drug name Status Action *Database
PLG Anistreplase Approved Activator TTD
ALOX5AP DG031 Suspended in Phase III Inhibitor TTD
PLAT Urokinase Approved Activator DrugBank
AGTR1 Losartan Approved Antagonist DrugBank
NOS3 ACCLAIM Phase III Unknown DrugBank
PLAUR Urokinase Approved Activator DrugBank
NID1 Urokinase Approved Unknown DrugBank
MYC AVI4126 Phase I/II Antisense TTD
Eight therapeutic targets with examples of replicated known therapeutics for CAD in this study.
* Drugs shown are examples. More than one therapeutic drug may be associated with each replicated target; * Drug databases shown are examples. One drug-
target association may be described in more than one drug database. Abbreviations - PH - Phenotype; CAD - Coronary Artery Disease; TTD - Therapeutic Target
Database.
Figure 3 Novel therapeutic targets with approved drugs compared to targets with drugs in clinical trials. A total of 110 therapeutic
targets with approved drugs were identified which may benefit the CAD phenotype, with a further 74 novel therapeutic targets in clinical trials.
Therapeutic drugs in the overlapping set are approved for one phenotype, and also in clinical trials for a second phenotype.
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from the TTD database, targets plasminogen, PLG: a
predicted therapeutic target for CAD. Losartan, an
antagonist of the type 1 angiotensin receptor, AGTR1,
is another known CAD therapeutic retrieved from
DrugBank (Table 2). Thus, the system is capable of
replicating known therapeutics for CAD directly from
the genetic data.
Validation of predicted therapeutic targets
We used two different benchmarks to assess the validity of
targets predicted by Gentrepid for CAD. In the first bench-
mark, we validated association of targets with CAD based
on whether they are designated as known targets for CAD
in the drug databases or not. This was performed for all
six search spaces created (see Methods for details). In the
second benchmark, we retrieved the number of Pubmed
citations, citing both the phenotype of interest (CAD) and
the gene name to validate the association of the predicted
gene-target with CAD.
For the first benchmark, we classified genes in the
six search spaces as “CAD candidates” or “CAD non-
candidates”. Targets with known therapeutic drugs for
CAD were considered “true positives” (Table 3). Tar-
gets which were not predicted by Gentrepid, but pre-
sent in any of the six search spaces, and targeted by
currently registered therapeutics for CAD were consid-
ered as “false negatives”. Genes that were not predicted
for CAD and not targetable by CAD drugs were
regarded as “true negatives”, while Gentrepid-predicted
novel therapeutic targets for CAD were considered
“false positives” (Table 3). A ROC curve was plotted
considering targets present in the six search spaces
constructed for the weakly significant data set (Table 3
Additional file 1 - Figure S1(A)). The Area Under
Curve (AUC) value of these ROC curves was greater
than 0.5 (p < 0.05) suggesting that our predictions of
therapeutic targets for CAD are significant (Additional
file 1 - Figure S1(A)).
For the second benchmark, a ROC curve for CAD was
created by considering four thresholds for targets with
at least one, five, ten and fifteen Pubmed citations as
CAD true positives and targets with less than five, ten
and fifteen citations or without any citations as CAD
false positives (Additional file 1 - Figure S1(B)). Genes
with at least one, five, ten and fifteen article citations
not predicted by Gentrepid, but present in the search
space were considered as “false negatives”. Genes neither
cited nor predicted for CAD were regarded as “true
negatives”. The AUC value for this ROC curve was also
significantly greater than 0.5 (p < 0.05) ensuring that
our results are not generated by chance and our predic-
tions of therapeutic targets for CAD are significant
(Additional file 1 - Figure S1(B)).
Comparison with previous studies
In our previous bioinformatic analysis of the WTCCC-
GWAS data, we identified 102 of 264 predicted candidate
genes as therapeutic targets for CAD using only the CMP
and CPS modules [20]. In this study, we identified 192 of
647 Gentrepid-predicted candidate genes of CAD as ther-
apeutic targets using a total of five bioinformatic modules
- CMP, PPI, CPS, CRT and MIR. We compared the ther-
apeutic targets obtained for CAD in both studies and
observed that more than half (59%) of the therapeutic
targets were not identified previously (Figure 4A). In
total, 113 therapeutic targets were not identified in our
earlier study, and 79 therapeutic targets are common to
both studies (Figure 4A).
We also sought to understand how druggable the can-
didate genes predicted in the newer study, based on 5
bioinformatic modules, were compared to our older 2-
module study. Among the 647 candidate genes utilised
in this study, 204 candidates were replicated from our
previous study. We calculated a Targetability Index (TI),
the ratio of predicted therapeutic targets to predicted
candidate genes. Although 443 additional candidate
genes were predicted compared to our previous study,
the proportion of these that mapped to therapeutic tar-
gets, TI5, was lower (30%, n = 192) for the 5-module
study compared to the value, TI2, for the 2-module
study, (39%, n = 102) [20]. This is likely a selection
effect due to better knowledge of genes in pathway data-
bases compared to those modules based on the high
throughput data (PPI, CRT, MIR).
The novelty of the predicted therapeutic targets for
CAD was also compared between this study and our pre-
vious study. A novelty ratio was calculated as the ratio of
number of novel therapeutic targets i.e. those that have
not been previously associated with CAD, to the number
of predicted therapeutic targets for CAD [20]. The
novelty ratio in this 5-module study for CAD was 0.95
(184/192) roughly the same as our previous 2-module
study (0.96) (98/102) [20]. This suggests that the relative
number of repositioning opportunities did not decrease,
despite the yield of therapeutic targets going down when
the additional bioinformatic modules were added, as indi-
cated by the TI [20].
Table 3. Binary classification of targets present in six
search spaces
Known Drug Targets Novel Drug Targets
CAD candidates T.P. = 8 F.P. = 184
CAD non-candidates F.N. = 4 T.N. = 4,519
Σ 4,715
Binary classification of therapeutic targets considering six thresholds based on
therapeutic targets present in six search spaces constructed in weakly
significant data set (WS). Abbreviations: CAD - Coronary Artery Disease; TP -
True Positives; FP - False Positives; TN - True Negatives; FN - False Negatives.
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We also compared our results with the most powerful
meta-analysis of CAD which has yet been performed. The
CARDIoGRAMplusC4D study improved the statistical
power of the genetic analysis by increasing the number of
cases and controls by a factor of 10 over the original
WTCCC study. We mapped the 20 candidate genes for
CAD obtained in the CARDIoGRAMplusC4D study with
the extracted drug-gene target dataset and identified ten
therapeutic targets. Gentrepid independently predicted
two (PLG and FLT1) of the ten therapeutic targets
obtained using the CARDIoGRAMplusC4D study data
(Figure 5). Thus, the Gentrepid system was able to suc-
cessfully retrieve 20% of the therapeutic targets obtained
using the CARDIoGRAMplusC4D study data. To sum-
marize, our analysis showed that the system not only
replicated already known targets, but also made novel
valid predictions using existing biological and drug
knowledgebases.
Limitations
Although Gentrepid was able to predict a list of 981
potential novel therapeutics suitable for repositioning
towards treatment of CAD, further clinical trials are
required to confirm the efficacy of these novel therapeu-
tics. Repositioning opportunities will not always be suc-
cessful due to the complexity, variability and sparsity of
currently available data in the biological knowledge
bases, and to the intrinsic nature of genetic data [31].
However, one successfully repurposed drug can signifi-
cantly impact the drug development for a complex
Figure 4 Comparison of therapeutic targets and candidate genes obtained after reanalysing WTCCC-GWAS data in 5-module study vs
our previous 2-module study. A) Comparison of therapeutic targets for CAD obtained in the two different studies by utilizing different
number of bioinforamtic databases to reanalyse the same WTCCC-GWAS data. In this study, 79 therapeutic targets were replicated from the
previous study (Grover et al, 2014), and 113 additional therapeutic targets were identified; B) Comparison of predicted candidate genes obtained
by reanalysing the same WTCCC-GWAS data in the two different studies (Green crosshatched portion - Ballouz et al, 2011, Yellow crosshatched
portion - Ballouz et al, 2014). In our recently published study for CAD (Ballouz et al 2014), 204 candidate genes were replicated from the
previous study (Ballouz et al, 2011) and 443 additional candidate genes were identified (Ballouz et al, 2014). Abbreviation - CAD: Coronary Artery
Disease.
Figure 5 Comparison of Gentrepid predicted therapeutic targets based on WTCCC-GWAS data vs CARDIoGRAMplusC4D study data.
Comparison of therapeutic targets predicted from CARDIoGRAMplusC4D study data with predicted therapeutic targets from WTCCC-GWAS data.
The system identified two (PLG and FLT1) of ten therapeutic targets obtained from CARDIoGRAMplusC4D study data.
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disease [31]. The results presented here can accelerate
drug discovery programs for CAD by translation of
already known compounds for novel therapeutic uses
towards CAD. Overall, our pipeline is an appropriate
methodology for generating potential therapeutics for
CAD from GWAS data.
Conclusion
CAD is a complex trait that has a major impact on
human morbidity and mortality. Identification of poten-
tial therapeutic targets is necessary to develop novel
treatments for complex diseases like CAD. In this study,
we integrated known drug data with predicted candidate
genes for CAD. We found 30% (n = 184) of the predicted
candidate genes could serve as novel therapeutic targets,
and 14% (n = 981) of the retrieved drugs are potential
novel therapeutics for CAD. Novel therapeutics include
both FDA-approved drugs and drugs currently in clinical
trials. Hence, these drugs may be repositioned towards
treatment of CAD. The lower effect sizes of individual
loci and large number of predicted targets suggest that
cocktails of repositioned drugs may be therapeutically
effective. Thus, Gentrepid offers new directions in reposi-
tioning of already known drugs to discover novel-cost
effective treatments for CAD.
Additional material
Additional file 1: Known targets and ROC curves for CAD. Table S1 - List
of 30 known targets of CAD retrieved from drug databases, not
predicted by Gentrepid. Four of these 30 known targets of CAD are
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Table S1 – Known targets of CAD 
 
Known targets of CAD not predicted by 
Gentrepid 
CYP2C19 
 
P2RY12 
 
ABCB11 
 
PLA2G2A 
 
MAPK12 
 
F9 
 
PCSK9 
 
ALOX5 
 
NPR1 
 
GUCY1A2 
 
ADRB1 
 
SERPINC1 
 
PRSS1 
 
PLAU 
 
SERPINE1 
 
SERPINB2 
 
SERPINA5 
 
LRP2 
 
ST14 
 
ADRB2 
 
ADRB3 
 
F10 
 
SELP 
 
CTRB1 
 
KLK1 
 
HMGCR 
 
ITGAL 
 
HDAC2 
 
DPP4 
 
AHR 
SERPINA5* 
  GUCY1A2* 
P2RY12* 
  PCSK9* 
(*Targets which are also present in six search spaces) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       
 
      A                                                            B 
 
 
  B 
Figure S1 A) - ROC curve for CAD based 
on known targets  
 
Figure S1 B) - ROC curve for CAD 
based on PubMed citations  
Figure S1 A) ROC curve for CAD based on six thresholds obtained from targets present in six search 
spaces in weakly significant data set (WS). Figure S1 B) ROC curve for CAD based on four thresholds 
obtained using four cut-off of Pubmed citations (at least one, five, ten and fifteen). Abbreviations: CAD – 
Coronary Artery Disease, ROC curve – Receiver Operation Characteristic curve. 
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Chapter 4: Research article 3 
Novel therapeutics for hypertension from genome-wide association data 
In this third chapter, we specifically focused on identifying novel therapeutics for Hypertension 
(HTN). HTN is a complex disease, where elevated blood pressure in the arteries results in increased 
risk for cardiovascular disorders (Ballouz, Sara et al. 2013). HTN is a growing epidemic world-wide. 
Hence, there is a need to develop potential new therapies.  
As described in chapter 2, we reanalyzed the Wellcome Trust Case-Control Consortium-
GWAS data (WTCCC-GWAS)  to identify 78 potential therapeutic targets for HTN associated with 
440 therapeutics using Gentrepid (www.gentrepid.org) as a candidate gene prediction platform 
employing two bioinformatics modules (CMP and CPS) (Grover, Mani P et al. 2014). However, 
Quantile-Quantile (Q-Q) plots of the original WTCCC GWAS data show that the genetic data for HT 
and BD deviated the least from random data compared to the other phenotypes examined (Ballouz, 
Sara et al. 2011). Neither of these phenotypes have molecular markers, so there may have been 
problems with patient selection. It is also possible that the HTN condition is highly heterogeneous. For 
example, although essential HTN is classified as a single phenotype by the OMIM database (see 
chapter one for details), it may consist of two or more sub phenotypes; a common variant sub 
phenotype and a rare variant sub phenotype that is salt induced (Gordon 1995).  
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In this research study, we used our computational pipeline already described in chapters 2 and 
3, to reanalyse GWAS data from the more recent ICBP meta-analysis study rather than the WTCCC 
GWAS data (Ehret et al. 2011; Grover, Mani P. et al. 2015; Grover, Mani P et al. 2014). We utilized 
Gentrepid to predict candidate genes as well as potential therapeutic targets for the HTN phenotype by 
reanalysing 6,244 autosomal SNPs extracted from the ICBP study below a significance threshold of p 
< 1*10-3. Of these 6,244 SNPs associated with high systolic blood pressure (SBP, >140 mm Hg, p < 
1*10-3), 2,323 SNPs were also associated with high diastolic blood pressure (DBP, >90 mm Hg, p < 
1*10-4). These SNPs were mapped to the human genome using the ‘adjacent approach’, where each 
SNP is mapped to four surrounding genes (+, -, 5’, 3’) which resulted in a search space consisting of 
1,016 unique genes (see section 1.1.5 for adjacent approach). 
 Gentrepid predicted a total of 151 candidate genes among 1,016 unique genes in the search 
space using both the CMP and CPS modules in seeded and ab initio modes (see section 1.1.5). The 
CMP and CPS modules in seeded mode identified 54 genes and in ab initio mode identified 134 genes. 
Highly-ranked (the top-five) predicted pathways in CPS seeded mode were also predicted in the CPS 
ab initio mode, indicating that at least some of the predictions made de novo from the genetic data 
were consistent with existing knowledge of genetic basis of hypertension. However, both modules 
failed to identify 23 known HTN disease genes retrieved from the OMIM database because these 
genes were not present in the search space. 
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Interaction networks from the CPS based predictions were visualised using the STRING 
database tool (http://string-db.org) for both the seeded and ab initio approach, to explore pathway 
redundancy and interconnectivity (Szklarczyk et al. 2011). Further, our bioinformatics pipeline 
identified 35 of the 151 candidate genes as potential therapeutic targets, 33 of which were novel 
therapeutic targets associated with 374 novel therapeutics feasible for repositioning in human clinical 
trials towards treatments of HTN. Two known targets of HTN therapy (ITPR1, ADRB2) were 
identified within the search space mapped from the SNPs for the study. Surprisingly, although 71 
candidate genes in 12 pathways previously implicated by 94 genes listed in OMIM were replicated in 
the study, the remaining 23 disease gene templates used in the seeded approach were not within the 
search space mapped from the SNPs in our study. We validated our results using two benchmarks 
based on known HTN targets from drug databases and published HTN literature in PubMed (see 
research articles of chapter 2 and 3 for detailed descriptions of benchmarks). The first benchmark 
based on known HTN targets showed that two known HTN targets i.e. true positives were replicated in 
this study (p<0.05) and the second benchmark based on literature search of HTN studies in PubMed, 
showed there was a significant association (p<0.05) between mentions of the phenotype and the 
predicted target gene in literature abstracts. The PubMed benchmark, however, is not conclusive 
because the association might be a negative one between the phenotype and the predicted target gene. 
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The novel therapeutics predicted in this study can potentially be repositioned in preclinical and 
clinical trials to develop potential treatments towards HTN phenotype. The research article is included 
in this chapter and is ready for submission to the peer reviewed Hypertension journal -American Heart 
Association. Supplementary files of this publication are included after the research article in the end of 
this chapter.  
Mani P. Grover designed the experiments, performed the bioinformatics and statistical 
analyses, and wrote the first draft of the manuscript. Dr Merridee A. Wouters contributed to the 
conception of project, and critically reviewed all the results and revised the manuscript. Dr. Sara 
Ballouz contributed to the collection of candidate gene dataset. Dr. Andrzej Goscinski provided 
computational support related to Gentrepid database. Dr. Stephen Harrap assisted in reviewing the 
manuscript. Dr. Tamsyn M. Crowley and Dr. Craig D H Sherman provided technical and 
administrative support. Dr. Richard A. George helped in conception of project. Kaavya A. 
Mohanasundaram helped in technical discussions.  
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Abstract 
Background 
Hypertension (HTN), a growing epidemic globally, is caused by both genetic and lifestyle 
risk factors. In recent years, meta-analysis studies involving genome-wide association 
studies (GWAS) data have been successful in identifying susceptible genetic loci of HTN. 
Candidate gene prediction tools, such as Gentrepid (www.gentrepid.org), can successfully 
reanalyse large numbers of susceptible genetic loci from GWAS data to predict candidate 
genes for HTN. By integrating drug-target data from drug databases with the predicted 
candidate genes, Gentrepid can also predict therapeutic targets and novel therapeutics 
suitable for repositioning towards HTN.  
Methods 
In this study, we used Gentrepid to reanalyse 6,244 SNPs (p < 1*10-3) from the 
International Consortium of Blood Pressure (ICBP) meta-analysis study to predict 
candidate genes. We used a bioinformatic approach utilizing pathways and functional 
domains to predict candidate genes before integrating drug-target data from three drug 
databases to identify novel therapeutic targets and therapeutics. We utilized known HTN 
drug targets and the HTN-related scientific literature to benchmarks the predictions. 
Results  
Gentrepid predicted a total of 151 candidate genes: 71 genes from 12 pathways previously 
associated with HTN as well as 11 novel pathways as well as 108 unique predictions from 
functional domains, 24 of which have some homology to known disease genes of HTN, 
while a further 88 were predicted de novo from the data. Several of the novel candidates 
look promising, having good genetic support. A major theme identified was inositol 
phosphate signalling.  
Conclusions  
Mapping these candidates to the drug data, 33 novel therapeutic targets were identified, as 
well as 374 novel therapeutics suitable for repurposing towards HTN in human clinical 
trials, saving time and money spent on preclinical and phase I human clinical trials and 
accelerating translational medicine for HTN.  
Keywords: Hypertension; Genome-wide association study; Candidate gene; Drug 
database; Drug target; Drug repositioning, Drug repurposing. 
3 
 
Background 
Hypertension (HTN) is a complex disease where elevated blood pressure in the arteries 
results in risk for cardiovascular, kidney and heart diseases [1]. HTN is responsible for 7 
million (12.8%) deaths per year worldwide [2, 3]. Blood pressure depends on the flow of 
blood pumped by the heart, and the resistance exerted by blood vessels against the flow. If 
the blood pressure is high, the heart works harder which results in HTN [4]. 
Interplay between genetic and environmental components regulates blood pressure 
[3]. Based on twin studies, genetic factors likely contribute around 30%-60% of the 
variation in blood pressure [4, 5]. Despite the significant contribution of genetics to blood 
pressure regulation, the heritability of HTN remains largely unexplained by conventional 
linkage and candidate gene studies [5, 6]. The genetic component is likely multifactorial, 
with non-Mendelian genetic transmission or low penetrance of disease genes involved in 
HTN. 
Recently, Genome Wide Association Studies (GWAS) have made progress in 
successfully identifying genetic loci associated with HTN [7]. In the first large scale 
GWAS conducted by the Wellcome Trust Case Control Consortium (WTCCC), 2,000 
cases of HTN were compared with 3,000 controls. Six other complex phenotypes were 
also included in this study [8]. Of the seven diseases of interest, HTN proved to be one of 
the most intractable studied, as there were no associations observed at the highly 
significant threshold (p ≤ 5*10-7).  
Several hypotheses have been promulgated to explain the poor results for the HTN 
phenotype in the WTCCC study. One of these suggested that the shared controls for the 
seven phenotypes studied were inappropriate for HTN because the average age of control 
subjects was 48 years, too young for HTN to have developed [8]. Likely some of these 
controls will develop HTN within the next two decades, and the effect of including such a 
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subgroup within the control group for HTN would be to significantly decrease the 
sensitivity of the WTCCC study to detect risk variants for HTN [7]. Measures of noise in 
the data suggested that the signal-to-noise ratio of the data was not as good as most of the 
other phenotypes such as coronary artery disease (CAD), although it was not as poor as 
Bipolar disorder (BD), which also had a dearth of significant associations [9]. 
In recent years, three additional GWAS studies with considerably more power than 
the original WTCCC GWAS study have been conducted to investigate the HTN 
phenotype. The Global Blood Pressure Genetics (Global BPgen) Consortium study 
conducted on 34,433 European Hypertension patients identified eight genetic loci (p ≤ 
5*10−8 ) [10]. The Cohorts for Heart and Aging Research in Genome Epidemiology 
(CHARGE) Consortium study conducted on 29,136 European HTN patients identified 10 
genetic loci (p ≤ 4*10−7). Finally, the International Consortium of Blood Pressure (ICBP) 
study, conducted on a very large sample size of 200,000 European patients, revealed 29 
genetic loci at a higher statistical threshold (p ≤ 5*10−9) compared to the previously 
conducted HTN GWAS studies [11]. However, in all these studies the combination of the 
noisy data and the high stringency of the statistical threshold required to adjust for 
multiple testing limited the number of identified disease genes. In toto, results from the 
GWA studies suggest that HTN is one of the more genetically heterogeneous of the seven 
phenotypes originally studied by the WTCCC, with many genes of small effect 
contributing to the development of the disease. Clearly many more contributing genes are 
lurking in the data. 
Candidate gene prediction platforms can enhance disease gene identification from 
GWAS data [9]. Unlike meta-analyses, which seek to increase the signal in the data by 
pooling large number of patients, candidate gene platforms, which filter against known 
biological data such as molecular pathways and functional data, suppress the noise. 
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Although the predictions are incomplete because some of the true signal is suppressed 
with the noise due to the lack of completeness of reference knowledgebases, valuable 
candidates can still be retrieved from the data. 
We previously used our candidate gene prediction tool, Gentrepid, as a gene 
discovery platform to identify potential disease genes from susceptibility genetic loci 
obtained from the WTCCC and International Consortium of Blood Pressure (ICBP) 
GWAS studies [1, 8, 9, 11]. We initially developed protocols to analyze the WTCCC-
GWAS data using a series of less stringent significant thresholds (p < 5*10-7, p ≤ 1*10-5, p 
≤ 1*10-4, p ≤ 1*10-3 ) [9, 12] to extract four sets of clustered SNPs. As there were no loci 
identified for the HTN phenotype at p < 5*10-7, we identified from 5 (p ≤ 1*10-5) to 460 (p 
≤ 1*10-3) loci in the genome potentially associated with HTN at the three lower 
significance levels [9]. These sets were then mapped to genes in the genome in six 
different ways to create gene search spaces ranging in size from 2 to 4,431 genes (up to 
20% of the genome) for the seven phenotypes [9]. For HTN, the search spaces contained 
from 5 to 799 SNPs, which mapped to 1,348 genes using the 'adjacent' approach, where 
up to four genes were mapped around each SNP; and 4,339 genes using the '1Mbp' 
approach, where genes were present within a fixed 1Mb window around each SNP [9]. 
These search spaces were analyzed with respect to pathway and domain-based data using 
the Common Pathway Scanning (CPS) and Common Module-Profiling (CMP) methods to 
identify 219 candidate genes belonging to the same pathways or containing domains that 
were significantly enriched in the search spaces for HTN [9]. 
We later reanalyzed a set of 29 significantly-associated loci from the ICBP GWAS 
study with Gentrepid, focussing on remapping the 29 loci associated with the highly 
significant SNPs [1]. Gentrepid identified 19 candidate genes from 15 of the 29 loci using 
the adjacent mapping method, where up to four genes were mapped around each SNP; and 
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a total of 108 candidate genes from 25 of the 29 loci using the 1Mbp mapping method, 
where genes were present within a fixed 1Mb window around each SNP [11]. The 
adjacent method, which has the highest specificity of the six mapping methods tested in 
our benchmarks [9], independently confirmed 12 of the ICBP gene predictions and 
produced 7 alternate gene predictions in 7 of the loci: AMPD3, CTNNB1, C20orf124, 
NFKB1, PRDM8, SLC391A2, and WNT9B [1]. The 1Mbp method, which produces larger 
search spaces than the adjacent mapping resulting in high sensitivity but at the cost of 
specificity, confirmed 15 of the candidates suggested by the original ICBP study and 
suggested 93 additional candidates [1].  
In other work, we recently published a protocol to integrate drug-target data with 
predicted candidate genes, using the WTCCC GWAS data as a case study [13]. As ‘target 
prediction’ is a key objective in genomic studies of human diseases, and is an essential 
component of target-centric drug discovery, we integrated the output of the Gentrepid 
candidate gene prediction system with three drug-target resources: Drug Bank [14], the 
Pharmacogenomics Knowledgebase (PharmGKB) [15] and the Therapeutic Target 
Database (TTD) [16]. This approach of “drug repositioning” or “drug repurposing” aims 
to find new uses of not only approved and withdrawn drugs but also of those drugs which 
are currently in clinical trials for other phenotypes, allowing immediate testing of drugs 
approved for other uses. 
In the drug-target study of the WTCCC data, we identified 428 novel therapeutic 
targets associated with 2,130 drugs suitable for repositioning towards the seven complex 
diseases [13]. Of these, 73 novel therapeutic targets associated with 423 novel therapeutics 
were predicted for HTN. Five known therapeutic targets already associated with HTN 
were replicated directly from the genetic data: AGTR1, AGT, CNR1, DRD1, and 
GUCY1A2 [13]; which are targeted by 17 known therapeutics for HTN [13]. 
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In the current study, we performed our full protocol on the ICBP data [11], 
reanalysing up to 6,244 SNPs (p < 1*10-3) to produce valuable new candidate gene 
predictions as well as identifying the subset of genes that are druggable and their 
corresponding therapeutics. Remapping and grouping of the genes with respect to 
biological pathways and protein domains resulted in identification of 151 candidate genes 
and 35 potential therapeutic targets associated with 392 therapeutics. 33 of these 
therapeutic targets were novel, while two known targets (ITPR1, ADRB2) associated with 
18 known therapeutics were replicated directly from the genetic data. We compared our 
results with previous GWAS and candidate gene predictions.
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Methods 
The ICBP-GWAS original study independently analysed 29 highly significant SNPs 
associated with high blood pressure at p < 5*10-9, and identified 44 candidate genes for 
HTN [11]. We previously reanalysed these 29 SNPs and identified 109 candidate genes 
for HTN (19 genes using the adjacent method and 108 genes using the 1Mbp method) [1]. 
In this expanded study, we performed reanalysis of 6,244 SNPs retrieved from the ICBP-
GWAS study at p < 1*10-3 to identify candidate genes, potential therapeutic targets and 
novel therapeutics for HTN using the following steps: 
Firstly, we mapped 6,244 SNPs to the human genome using the adjacent approach, 
resulting in a search space consisting of 1,016 unique genes. Secondly, we used Gentrepid 
to search for candidate genes among these 1,016 genes using pathway and domain-based 
bioinformatic modules: Common Pathway Scanning (CPS) and Common Module 
Profiling (CMP), as described in detail below [9]. Thirdly, we identified therapeutic 
targets by integrating predicted candidate genes with a drug-gene target association data 
set containing 2,494 unique drug targets associated with 7,252 drugs retrieved from the 
three drug databases namely DrugBank, TTD and PharmGKB [14, 17, 18]. Finally, a list 
of novel therapeutic targets associated with novel therapeutics was retrieved by separating 
known HTN therapeutic targets. 
Data Retrieval 
Candidate gene data set  
We used Gentrepid as a candidate gene prediction system, to predict candidate genes for 
HTN by careful reanalysis of significant SNPs from the ICBP GWAS study [11, 17]. 
We extracted a total of 6,244 autosomal SNPs associated with high blood pressure, 
consisting of 6,244 SNPs associated with high systolic blood pressure (SBP, >140 mm 
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Hg, p < 1*10-3), of which 2,323 SNPs were also associated with high diastolic blood 
pressure (DBP, >90 mm Hg, p < 1*10-4) [1]. We mapped these SNPs to the human 
genome on the plus and minus strands in both the 5′ and 3′ directions [9]. 
Our previously published reanalysis of the WTCCC GWAS data, associated only 
799 SNPs with the HTN phenotype at the p < 1*10-3 level [9]. These 799 SNPs were 
clustered into 460 genetic loci which mapped to a search space of 1,348 genes using the 
‘adjacent’ approach and 4,339 genes using ‘1Mbp’ approach [9]. Based on our experience 
with the system we choose to use only the more specific adjacent mapping to analyse the 
ICBP GWAS data as the 1Mbp approach has a higher rate of false positives [9]. Using the 
adjacent approach, we mapped the 6,244 extracted autosomal SNPs (p < 1*10-3) to a 
search space consisting of 1,016 unique genes. Significant SNPs were highly clustered in 
the human genome with on average 6 SNPs associated with each gene compared to the 2 
SNPs per locus for the HTN phenotype in the WTCCC GWAS data [9, 13]. 
We used Gentrepid to search for candidate genes among the 1,016 unique genes in 
the search space using two bioinformatics modules, Common Pathway Scanning (CPS) 
and Common Module Profiling (CMP). The CPS module is based on the principle that 
common phenotypes are associated with gene products that participate in the same 
complex or biochemical pathway [18, 19]. The second module, CMP, is a novel sequence 
analysis approach based on the assumption that candidate genes have similar functions as 
encoded in their domain structure [19, 20]. CMP and CPS modules were used in “seeded” 
and “ab initio” modes to determine the common properties of HTN-specific disease genes 
[9]. In seeded mode, existing genotype-phenotype information is used to aid the gene 
discovery process [9]. The “seeds” used were the 23 known disease genes identified prior 
to GWAS studies of HTN from the OMIM database (Supplementary Table 1). In ab initio 
mode, also known as blind mode, no a priori genotype-phenotype information is used [9]. 
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Candidates are extracted from the search space of 1,016 unique genes derived from the 
GWAS data using only molecular knowledge of the genes involved, finding significant 
groupings of genes in the same pathway or with the same domain structure. 
The CPS module utilizes pathway enrichment information from two databases: the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) and BioCarta to predict candidates 
[19, 20]. KEGG and BioCarta pathway databases contain pathway information on 
metabolic pathways, membrane transport, signal transduction and cell cycle pathways [19, 
20]. In seeded mode, the CPS module extracts all pathways containing the 23 HTN known 
disease genes and then searches for other genes of these pathways within the search space. 
For each pathway, genes of the genome are then bi-partitioned based on whether they in 
the pathway or not; and whether they are associated with the phenotype or not. In seeded 
mode, the seed gene as well as genes of the particular pathway are considered to be 
associated with the phenotype, whereas in ab initio mode, only genes in the search space 
constructed from the significant SNPs are considered to be associated with the phenotype. 
The CMP module utilizes the Pfam domain library of Hidden Markov models to 
predict candidates [21]. The strength of this approach is its large coverage. Using the Pfam 
library, domains can be assigned to approximately 69% of the human proteome [21], 
which allows functional annotation of 54% of the complete human genome [21]. In seeded 
mode, CMP module mapped pfam domain sequences associated with 23 HTN known 
disease gene products with pfam domain sequences associated with 1,016 gene products in 
the search space to predict candidates. In ab initio mode, CMP module predicts candidates 
by finding gene products with similar pfam domains within the search space without any 
known domain information of HTN phenotype. 
For CPS, both seeded (CPS s) and ab initio (CPS ai) predictions were filtered on 
the basis of statistical significance threshold calculated for pathways using Fisher’s exact 
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test (p < 0.05), and prioritised on the basis of lowest p-value score of the pathway (see 
Results and Discussion for details). 
In contrast, for the CMP module, candidate gene predictions are scored in different 
ways for the seeded (CMP s) and ab initio (CMP ai) mode [9]. For CMP seeded, 
predictions were filtered on the basis of pairwise similarity score between a HTN known 
disease gene and homologous genes in the search space. We adopted a previously 
determined pairwise similarity score greater than 0.4 for a gene to be predicted as a 
candidate gene [9, 22]. For CMP ab initio, gene predictions were filtered on the basis of 
two different chi-squared test score thresholds, depending on whether they were multi-
domain or single domain proteins as already described in our previously published work 
[9]. A threshold value of χ2min > 102 was used to filter single domain gene products and 
χ2max_unique > 105 to filter multi-domain gene products [9] (see Results and Discussion 
for details). Finally, a unique list of predicted and prioritised candidates of HTN 
phenotype was retrieved for further analysis. 
Drug-gene target data set  
To identify druggable genes and their therapeutics, we used a drug-target association data 
set already retrieved from the three drug databases in our previously published study [13]. 
Three drug databases considered were: DrugBank [18], Pharmacogenomics 
Knowledgebase (PharmGKB) [19] and Therapeutic Target Database (TTD) [20]. We 
extracted a total of 2,022 human drug targets associated with 3,910 drugs from DrugBank, 
2,960 drugs for 544 unique human drug targets from TTD and 382 drugs associated with 
566 human drug targets from PharmGKB [13, 23]. In total, we retrieved 2,494 unique 
drug targets with 7,252 drugs from the three drug databases [13]. 
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Mapping of candidate gene data set with the drug-gene target data set  
We mapped the list of 151 predicted candidate genes for HTN with drug targets retrieved 
from three drug databases. The 151 predicted candidate genes were mapped with extracted 
three drug-target association files separately and a list of predicted therapeutic targets 
associated with therapeutics for different phenotypes was retrieved. 
Visualisation of predictions  
We retrieved interaction network of CPS module based predicted gene products using the 
STRING database (http://string-db.org/) to identify interactions among predicted 
candidate gene products currently available in the database [21]. Interaction network 
retrieved from the STRING database consists of nodes and edges. Nodes are coloured 
gene products for visual aids and edges consist of up to eight lines with eight different 
colours referring to eight types of interaction evidences described in the STRING database 
[24] (See Results and Discussion for details). We used lists of both CPS s and CPS ai 
based predictions separately and retrieved two interaction networks from the STRING 
database (See Results and Discussion for details). 
CPS ai and CMP ai modules based predictions were also visualised on the human 
karyotype at specific chromosomal locations. In total, 436 significant SNPs were 
associated with CPS ai based predictions and 1,021 SNPs were associated with CMP ai 
based predictions. We mapped these SNPs at specific chromosomal locations of human 
karyotype using Ensembl genome browser [25], and labelled the predicted candidate 
genes associated with these SNPs at specific chromosomal locations (see Results and 
Discussion for details). 
We also created three Manhattan plots between chromosomal locations of 
predicted genes (X -axis) and p-values (Y -axis) associated with 436 significant SNPs for 
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CPS ai based module, 1,021 significant SNPs for CMP ai based module and 185 SNPs 
associated with 40 candidates for CPS s based predictions. Such plots identified highly 
significant candidate genes associated with low p-value SNPs (p value range: p <. 1*10-5 - 
p < 1*10-10) (see Results and Discussion for details). 
Identification of novel therapeutics and therapeutic targets  
In the next step, we identified novel therapeutics and novel therapeutic targets for HTN. A 
novel therapeutic target is identified by filtering potential targets associated with a drug 
which is neither approved nor currently in preclinical/human clinical trial for HTN. The 
predicted novel therapeutics are potential therapeutics suitable for repurposing in human 
clinical trials.  
Validation of predicted therapeutic targets  
We used following two benchmarks described in our previously published studies - [13, 
23]. 
1. Testing Gentrepid ability to replicate already approved drugs or drugs currently in 
human clinical trials for HTN.  
2. Text mining of research articles in Pubmed by citing gene name and phenotype (HTN). 
The first benchmark was based on binary classification of genes present in the 
search space (1,016 unique genes). We considered predicted candidates which are 
currently known as drug targets for HTN as “true positives”. Predicted targets with 
currently registered therapeutics for HTN which were not predicted by Gentrepid but 
present in the search space were designated “false negatives”. Genes, neither predicted nor 
targetable by drugs were considered “true negatives (TN)”; and, predicted novel 
therapeutic targets for HTN were considered “false positives”. Receiver Operation 
Characteristic (ROC) Curve was plotted in GraphPad Prism 6 software considering 
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thresholds obtained from the number of targets present in search space for HTN as 
described in our previously published studies [13, 23]. Non-linear regression analysis was 
performed to get the ROC curve. This benchmark checked the system’s ability to retrieve 
existing knowledge of HTN. However, this benchmark did not provide any idea about the 
validity of the novel predictions. 
In the second benchmark, we utilized Pubmed IDs of literature related to HTN 
already extracted in our previously published studies [13, 23]. We calculated the number 
of Pubmed citations by mapping the extracted Pubmed IDs to the gene citation 
information extracted from Entrez Gene (ftp//ftp.ncbi.nih.gov/gene/) [13, 23]. ROC curve 
was created in GraphPad Prism 6 software considering four thresholds of at least one, five, 
ten and fifteen citations [13, 23]. Non-linear regression analysis was performed to get the 
ROC curve. This benchmark tested the system’s performance to discover novel 
therapeutic targets by text mining of HTN articles in Pubmed. 
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Results and Discussion 
Prediction, prioritisation and visualisation of candidate genes 
We used Gentrepid to predict and prioritise candidate genes by reanalysing SNPs from the 
ICBP meta-analysis study [11] (Figure 1). Gentrepid predicted a total of 151 unique 
candidate genes using two bioinformatics modules: Common Pathway Scanning (CPS) 
and Common Module Profiling (CMP) in both seeded and ab initio mode. 
 
Figure 1 Workflow. Computational workflow to identify potential drug targets and novel therapeutics for 
HTN by integrating drug data from drug databases with predicted candidate genes obtained from reanalysis 
of ICBP GWAS SNPs (p < 1*10-3). We used Gentrepid as a bioinformatics platform to reanalyse ICBP 
GWAS SNP data and DrugBank, TTD and PharmGKB as drug databases to extract drug data. Abbreviations 
- TTD - Therapeutic Target Database; PGKB*- Pharmacogenomics Knowledgebase, DB* - Drugbank, ai - 
ab initio, s - seeded, CMP - Common Module profiling, CPS - Common Pathway Scanning. 
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CPS results 
At first glance, the results from the CPS module in seeded mode are rather daunting: none 
of the 23 already recognised HT genes listed in OMIM (Supplementary Table 1) were 
replicated by the study based on the ICBP genetic data; but encouragingly, nine of the 95 
pathways these genes participate in were. These are ranked in Table 1 by the significance 
of the pathway, calculated by Fisher’s exact test, using the fraction of genes in the 
pathway associated with the HTN phenotype, including the seed gene, even if it is not in 
the search space. Ranks for genetic support, as determined by the mean number of SNPs 
for each pathway gene in the search space are also shown. 40 genes in the search space 
were implicated by CPS seeded, supported by a total of 185 SNPs. The pathway 
candidates are listed on a gene by gene basis with the number of significant SNPs and all 
the pathways associated with each gene in Supplementary Table 2. The top genes in terms 
of genetic support, both from p-values and number of SNPs supporting are shown in 
Figure 2A. Three of these genes, CYP1A1, PLCE1 and GUCY1A3 were among the 44 
genes previously reported by the ICBP [11]. 
The ab initio mode is a powerful approach to discover novel candidates for 
complex diseases which requires no a priori information [9]. The CPS module in ab initio 
mode predicted 16 pathways associated with HTN at p < 0.05, containing 64 candidate 
genes. These are ranked by significance of the pathway in Table 2. The significance level, 
calculated by Fisher’s exact test, reflects the fraction of genes of the pathway in the search 
space. The top genes in terms of genetic support, both from p-values and number of SNPs 
supporting are shown in Figure 2B. The pathway candidates are listed on a gene by gene 
basis with the number of significant SNPs and all the pathways associated with each gene 
in Supplementary Table 3. 
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Shaded region in table: congruent pathways between ab initio and seeded approach. (1 describes total genes 
in the pathway, 2 describes ranking based on mean number of SNPs per gene in a pathway i.e. total number 
SNPs/number of predicted genes, 3 describes ranking based on p value associated with a pathway, 4 
describes number of predicted genes). Abbreviations: KEGG - Kyoto Encyclopedia of Genes and Genomes, 
Db IDs - Database Pathway Identifiers, CPS - Common Pathway Scanning. 
Pathways Db-IDs Genes1 Total  
SNPs 
SNP  
Rank2 
Genes 
(Num)4 
Seeds Genes in 
search space 
p-
values 
Path 
Rank 3 
cGMP-PKG 
signalling 
pathway 
KEGG - 
04022 
167 66 9 14 KCNMB1, 
NOS3, 
ATP1B1, 
AGTR1 
ADRB2, ATP2B2, 
AKT3, CALML6, 
GNAI1, GUCY1A3, 
ITPR3, INS,  
ITPR1, ITPR2, 
NPPB, PRKG1, 
PLCB1, VDAC2 
0.0007 1 
Steroid hormone 
biosynthesis 
KEGG - 
00140 
57 40 3 6 CYP3A5, 
HSD11B2, 
CYP11B2 
AKR1C1, CYP1A2, 
CYP21A2,  
CYP1A1, CYP17A1, 
HSD17B7 
0.0015 2 
Estrogen 
signalling 
pathway 
KEGG - 
04915 
100 28 11 11 NOS3 AKT3, CALML6, 
ESR1, GNAI1,  
HBEGF, HSPA1L, 
ITPR1, ITPR2,  
ITPR3, OPRM1, 
PLCB1 
0.0023 
 
3 
Salivary 
secretion 
KEGG - 
04970 
90 46 8 9 ATP1B1 ATP2B2, CALML6,   
GUCY1A3, ITPR1, 
ITPR2, 
ITPR3,DRB2, 
PLCB1, PRKG1 
0.0084 4 
Gastric acid 
secretion 
KEGG - 
04971 
75 20 10 7 ATP1B1 CALML6, CFTR, 
ITPR3, GNAI1, 
ITPR1, ITPR2, 
PLCB1 
0.0213 5 
Calcium 
signalling 
pathway 
KEGG - 
04020 
180 64 6 11 AGTR1, 
NOS3, 
NOS2A 
ADRB2, ATP2B2, 
CALML6, HTR4, 
ITPR3, ATP2B1 
ITPR1, ITPR2, 
PLCE1,  
PLCD3, PLCB1 
0.0310 6 
Corticosteroids 
and 
cardioprotection 
BioCarta-
100156 
25 13 5 3 AGT, 
NOS3 
ADRB2, NR3C1, 
NFKB1 
0.0314 7 
Circadian 
entrainment 
KEGG -
04713 
97 42 7 7 GNB3 CALML6, GNAI1,  
GUCY1A3, PRKG1, 
PLCB1, ITPR1, 
ITPR3 
0.0315 8 
Alk in cardiac 
myocytes 
Biocarta-
100244 
27 28 2 3 BMPR2 MYL2, NPPB, 
NPPA 
0.0390 9 
Small cell lung 
cancer 
KEGG -
05222 
86 14 12 6 NOS2A AKT3, BCL2,  
CCNE2, LAMB1, 
LAMA1,  
LAMA2 
0.0406 10 
Vascular smooth 
muscle 
contraction 
KEGG -
04270 
121 50 4 8 AGTR1, 
AGT 
CYP4A11, 
CALML6, 
GUCY1A3, PRKG1, 
ITPR3, ITPR1, 
ITPR2, PLCB1 
0.0452 11 
Ion channels 
and their 
functional role 
in vascular 
endothelium 
BioCarta-
100055 
43 34 1 3 NOS3, 
AGT 
ADRB2, GUCY1A3, 
PRKG1 
0.0491 12 
Table 1 Predicted biochemical pathways and candidate genes using CPS seeded approach 
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Figure 2 Manhattan plots of significant SNPs associated with predicted candidates using 
CPS s (A) CPS ai (B), CMP ai (C) methods. Manhattan plot of 185 SNPs associated with 40 candidate 
genes predicted by CPS s module (A), 436 significant SNPs associated with 64 candidate genes predicted by 
CPS ai module (B), 1,021 significant SNPs associated with 88 candidate genes predicted by CMP ai module 
(C). Blue colour gene symbols represent predicted candidate genes which are associated with less than 9 
significant SNPs, red colour gene symbols represent candidate genes associated with more than 9 significant 
SNPs (based on the SNP count). (* symbol shows candidate genes which are predicted as potential 
therapeutic targets). (p-values associated with significant SNPs are retrieved using original ICBP GWAS 
study dataset). Abbreviations: CPSai - CPS module in ab initio mode, CPS s - CPS module in seeded mode, 
CMP ai - CMP module in ab initio mode. 
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The specific chromosomal locations of the 64 CPS ai predictions and 40 CPS 
seeded predictions are depicted with respect to cytogenetic bands in supplementary figures 
(Supplementary data - Figures S1(A) and S1(B)). 
Congruency between ab initio and seeded results 
There was substantial congruency between the, the CPS ab initio results produced directly 
from the genetic data using the pathway information (Table 2) and results from the CPS 
seeded module which uses existing knowledge of HTN to extract information from the 
ICBP data (Table 1). Five of the pathways were predicted by both input modes. These 
were, in order of their seeded mode rank: 1st - the cGMP-PKG signalling pathway (cGMP-
PKG), 2nd - steroid hormone biosynthesis (steroid), 3rd - the estrogen signalling pathway 
(estrogen), 4th - salivary secretion (salivary), and 5th - gastric acid secretion (gastric) 
(Figure 3).  
As the seeded mode rank includes the seed genes in the p-value calculation based 
on their involvement proven in independent studies, it is instructive to see how these 
pathways are ranked by Gentrepid when only the genes in the search space are taken into 
account. These five pathways were ranked 5th, 10th, 3rd, 7th, & 11th respectively by the ab 
initio mode p-values in order of their seeded mode ranking. 
If the Gentrepid predictions are used only as a filter, the results from the seeded 
and ab initio modes pooled to give 23 unique pathways, and the genetic data subsequently 
used for ranking via the mean number of SNPs per gene in the search space, these five 
pathways are ranked 16th (cGMP-PKG - 4.7 SNPs/gene), 7th (steroid - 6.7 SNPs/gene), 
19th(estrogen - 2.5 SNPs/gene), 14h (salivary - 5.1 SNPs/gene) and 18th (gastric - 2.9 
SNPs/gene) (Supplementary Table 4). 
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Table 2 Predicted candidate genes for HTN based on CPS module in ab-initio mode 
Pathway Db-IDs Genes1 Total 
SNPs 
SNP 
rank2 
Candidates Candidate 
symbols 
p-
values 
Path 
Rank3 
Prion pathway BioCarta 
10062 
17 7 16 5 BCL2, DNAJB6, LAMA1, 
LAMA2, LAMB1 
0.0009 1 
Phosphatidyl 
inositol signalling 
KEGG 
04070 
81 62 5 10 CALML6, ITPR1, ITPR2,  
ITPR3, INPPL1, PIK3C3, , 
PLCE1, PLCD3, PIK3C2A, 
PLCB1 
0.0019 2 
Estrogen 
signalling 
pathway 
KEGG 
04915 
100 28 13 11 AKT3, CALML6, ESR1, 
GNAI1, HBEGF, HSPA1L, 
ITPR1, ITPR2, ITPR3, 
OPRM1,PLCB1 
0.0026 3 
Long-term 
depression 
KEGG 
04730 
60 39 12 8 CRHR1, GNAI1, GUCY1A3, 
ITPR1, ITPR2, ITPR3, 
PLCB1, PRKG1 
0.0034 4 
cGMP-PKG 
signalling 
pathway 
KEGG 
04022 
167 66 4 14 ADRB2, ATP2B2, AKT3, 
GNAI1, CALML6, 
GUCY1A3, ITPR3, INS, 
ITPR1, ITPR2, NPPB, 
PRKG1, VDAC2, PLCB1 
0.0072 5 
Gap junction KEGG 
04540 
89 44 10 9 ITPR1, ITPR2, ITPR3, 
GNAI1, GUCY1A3, PLCB1, 
PRKG1, TJP1, TUBB1 
0.0101 6 
Salivary secretion KEGG 
04970 
90 46 7 9 ATP2B2, CALML6, DRB2,  
GUCY1A3, ITPR1, ITPR2, 
ITPR3, PLCB1, PRKG1 
0.0107 7 
Oocyte meiosis KEGG 
04114 
113 69 3 10 CDC27, CALML6, CCNE2, 
ITPR3, , INS, ITPR1, 
ITPR2,MAD2L2,  
MAD2L1,PTTG2 
0.0155 8 
Adherens 
junction 
KEGG 
04520 
73 23 14 7 ACTN2, CTNNA3, CSNK2B 
FGFR1, PTPRJ, TJP1, 
WASL 
0.0277 9 
Steroid hormone 
biosynthesis 
KEGG 
0140 
57 40 11 6 AKR1C1, CYP1A2, 
CYP21A2, CYP1A1, 
CYP17A1, HSD17B7 
0.028 10 
Gastric acid 
secretion 
KEGG 
04971 
75 20 15 7 CALML6, CFTR, GNAI1, 
ITPR3, ITPR1, ITPR2, 
PLCB1 
0.0312 11 
Proteoglycans in 
cancer 
 
KEGG 
05205 
204 81 2 13 AKT3, CAV3, ESR1, FZD8, 
FGFR1, HBEGF, ITPR3, 
ITPR1, ITPR2, PTPN11, 
PLCE1, WNT9A, WNT2B, 
WNT3 
0.0313 12 
ABC transporter KEGG 
02010 
44 59 6 5 ABCG8, ABCG5, ABCC2, 
ABCC10, CFTR 
0.0334 13 
Inositol 
phosphate 
metabolism 
KEGG 
0562 
61 51 9 6 INPPL1, PIK3C3, PLCE1, 
PLCD3, PIK3C2A, PLCB1 
0.0364 14 
Tight junction KEGG 
04530 
138 54 8 10 AKT3, ACTN2, CTNNA3, 
CLDN20, CSNK2B, 
EPB41L2, GNAI1, MYL2, 
MAGI2, TJP1 
0.047 15 
Melanogenesis KEGG 
04916 
101 89 1 8 CALML6, FZD8, 
GNAI1,MITF, PLCB, 
WNT9A, WNT2B, WNT3 
0.0479 16 
Shaded region in table: congruent pathways between ab initio and seeded approach. 1 describes total genes 
in the pathway, 2 describes ranking based on mean number of SNPs per gene in a pathway i.e. total number 
SNPs/number of predicted genes., 3 describes ranking based on p-value associated with a pathway. 
Abbreviations: KEGG: Kyoto Encyclopedia of Genes and Genomes; CPS - Common Pathway Scanning, Db 
IDs - Database Pathway Identifiers. 
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Figure 3 Comparison of Db IDs of CPS ai and CPS s based predictions. Comparison of Db IDs 
of pathways predicted by CPS ai and CPS s modules shows that there are five overlapping pathway IDs 
between CPS ai and CPS s based predictions. Abbreviations: k - KEGG Db IDs, b - Biocarta Db IDs, CPSs - 
Common Pathway Scanning module in seeded mode, CPS ai - Common Pathway Scanning module in ab 
initio mode, Db IDs - Database Identifiers for predicted pathways, KEGG - Kyoto Encyclopedia of Genes 
and Genomes.  
In the pooled pathway list, the seven pathways implicated only be the seeded mode 
had the following rankings based on bioinformatic data alone: Ion channels and their 
functional role in vascular endothelium (ion channels - ranked 12th) , Corticosteroids and 
cardioprotection (corticosteroids - ranked 7th) , Calcium signalling pathway (calcium - 
ranked 6th), Circadian entrainment (circadian - ranked 8th), Alk in cardiac myocytes 
(cardiac myocytes - ranked 9th ), Small cell lung cancer (lung cancer - ranked 10th), 
Vascular smooth muscle contraction (vascular muscle - rank 11th). However, ranking of 
these seven pathways when genetic data (i.e. mean number of SNPs per genes) was used 
are: 1st Ion channels - (11.3 SNPs/gene), 3rd cardiac myocytes - (9.3 SNPs/gene), 7th 
corticosteroids - (6.5 SNPs/gene), 8th vascular muscle - (6.25 SNPs/gene), 11th calcium - 
(5.8 SNPs/gene), 13th circadian - (5.25 SNPs/gene) and 22nd lung cancer - (2 SNPs/gene). 
Clearly, based on the mean number of SNPs per gene, the seeded mode is still extracting 
valuable data based on other clinical studies which is missed by the ab initio mode when 
only the ICBP data is considered. 
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Novel pathways predicted by CPS ab initio  
Some important novel pathways were predicted by CPS de novo from the genetic data in 
ab initio input mode. Based on the mean number of supporting SNPs per gene, the top-
ranked pathway was melanogenesis (MG, ranked 1st with 11.1 SNPs per gene) and the 
related proteoglycans in cancer pathway (PC, ranked 5th with 6.2 SNPs per gene) (Table 
1). These pathways contain various WNT signalling genes WNT2B, WNT3, WNT9, FZD8, 
with the majority of SNPs supporting WNT2B on 1p13 (31 SNPs) and MITF on 3p13 (42 
SNPs), Supplementary Table 3.  
Another important theme is phosphoinositide signalling and metabolism. Ten 
genes involved in phosphatidyl inositol signalling (PIS) were predicted, of which 6 also 
belong to inositol phosphate metabolism (IPM). Furthermore, five additional genes 
associated with phosphoinositol were predicted by the CMP module, which will be 
discussed further below. The best supported genes in these pathways were PIK3C3 on 
18q12.3, supported by 23 SNPs and various phospholipases eg PLCE1 on 10q23 
supported by 14 SNPs (Supplementary Table 3).  
Finally, cell junctions were a recurrent theme in the CPS ab initio results with gap 
junctions, tight junctions and adherens junctions all being implicated. A potential role for 
gap junctions in HTN has been proposed via the regulation of vasomotor tone and arterial 
blood pressure [26, 27]. The expression of the proteins that form gap junctions, the 
connexins, have been implicated in vascular pathologies such as HTN in animal models. 
The connexins are not directly implicated by this study; instead, the role of gap junctions 
in passing small molecules such as prostaglandins like phosphatidyl inositol may be 
implicated. The top genes in gap junctions based on genetic data were PRKG1 (18 SNPs), 
ITPR2 (6 SNPs), TUBB1 (5 SNPs) and PLCB1 (5 SNPs). Alterations of both gap junctions 
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and tight junctions have been observed in animal models of HTN [28], suggesting poor 
responses to the onset of HTN in some genetic backgrounds might contribute to the 
development of the phenotype. The top genes of tight junctions were MYL2 (24 SNPs), 
EPB41L2 (7 SNPs), CTNNA3 (5 SNPs), and CLDN20 (5 SNPs). Most of the genes 
implicated in adherens junctions overlapped with the predictions of gap junctions and tight 
junctions with the exception of FGFR1, which was supported by 10 SNPs. FGFR1 is a 
cognate receptor of FGF5, which was previously implicated by the ICBP [11].   
Relationship between predicted pathways 
The pathways involved in HTN seem to form a larger network as shown in Supplementary 
figures S2 (A) and S2 (B). This can also be seen from the involvement of several genes in 
multiple pathways in Supplementary Tables 2 and 3. For example, as mentioned above, 
IPM is a subset of PIS; and MG & PC have substantial overlap, as do gap junctions and 
long term depression. Importantly, there are several genes linking two or more pathways 
including ITPR2 (6 SNPs), PLCB1 (5 SNPs), GUCY1A3 (4 SNPs), CALML6 (3 SNPs), 
and GNAI1 (3 SNPs). 
Pathway genes supported by literature 
Novel genes predicted by CPS with good genetic support and additional literature support 
include ADRB2, supported by 12 SNPs (ranked 11th for ab initio, 5th for seeded) with the 
most significant SNP at p < 3.25*10-4 (rs10075404); FGFR1, supported by 10 SNPs 
(ranked 12th by ab initio only) with the most significant SNP at p < 7.93*10-4 
(rs10958700), and CYP17A1, supported by 3 SNPs (ranked 33rd for ab initio, 17th for 
seeded) with the most significant SNP at p < 6.85*10-10 (rs3824755).  
The gene ADRB2 encodes the β2-adrenergic receptor that, along with ADRB1, is 
the target of a variety of endogenous and pharmacological agonists and antagonists, 
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including epinephrine and β-blocker and β-agonist drugs. It mediates important 
physiological responses, including vascular smooth muscle relaxation, lipolysis and 
possibly renin release from the kidney [29]. Association between ADRB2 polymorphisms 
and HTN and the response to antihypertensive treatments such as β-blockers and 
angiotensin converting enzyme inhibitors have been reported [30-32].  
FGFR1 is a member of the Fibroblast growth factor (FGF) family. FGFs are 
involved in various cellular functions and have been implicated in preserving normal 
vascular homeostasis (3). Of the 4 high-affinity tyrosine kinase receptors that mediate the 
biological effects of FGFs it has been demonstrated that FGFR1 is likely to be involved in 
cardiovascular disease through its regulation of TGFβ signalling (hsa05212). TGFβ 
contributes to proliferation of vascular smooth muscle cells and fibroblasts, deposition of 
extracellular matrix and neointima formation [29, 33].  
The gene encoding CYP17A1 is primarily expressed in the adrenal glands and 
gonads. It produces P450c17 proteins that catalyze reactions involved in synthesis of 
cholesterol, steroids and other lipids. It is also involved in drug metabolism. In 
relationship to blood pressure, its potential effects on mineralocorticoid metabolism 
(hsa04960) are relevant. The CYP17A1 gene has been associated with HTN in a number of 
studies and rare mutations causing hypertension have also been identified [34]. 
Other genes with literature support, but which are supported by only a single SNP 
in the data include: ESR1, BCL2, CRHR1 and CFTR. Higher than average blood pressure 
in men, the rise in pressure in women after menopause and the effects of the oral 
contraceptive pill have been attributed to hormonal effects including those of estrogen. 
Effects of estrogen on the vascular endothelial and smooth muscle cells are mediated by 
the estrogen receptor ERα encoded by the ESR1 gene. Variants of ESR1 have been 
associated with high blood pressure, often in a sex-dependent manner [35, 36]. BCL2 is a 
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factor that opposes apoptosis. It has been implicated in vascular remodelling through 
increased vascular smooth cells in pulmonary HTN. FGF2 from the vascular endothelium 
reduces the expression of BCL2, resulting in smooth muscle hyperplasia. Its possible role 
in systemic vascular hypertrophy and HTN has not been delineated, but is possible [37]. 
Corticotropin-releasing hormone and its receptor CRHR1 are part of the hypothalamic-
pituitary-adrenal pathway and are relevant to the regulation of diverse physiological 
processes including stress, reproduction, immune response and obesity. Genetic variants 
of CRHR1 have been associated with the complication of HTN with glucocorticoid 
treatment in children and with supine blood pressure control mechanisms in adults [38, 
39]. CFTR (cystic fibrosis transmembrane conductance regulator) is one of several 
proteins in the cell membrane of vascular smooth muscle cells involved in chloride 
transport. Chloride ion flux contributes to the physiological regulation of vascular tone 
and arterial pressure. Loss of function mutations in CFTR causes cystic fibrosis and 
patients with cystic fibrosis have decreased blood pressure. In addition, female carriers of 
cystic fibrosis mutation carriers show a reduced rise in blood pressure with age [40, 41]. 
CMP results 
The CMP module in ab initio mode identified 88 unique genes consisting of three single-
domain candidate gene products and 85 multi-domain candidate gene products. We used a 
threshold of χ2min > 100 for single domain gene products and χ2max_unique > 100000 for 
multi-domain gene products to filter CMP ai-based predictions (see Methods for details) 
[9]. The top genes among CMP ai predictions in terms of genetic support, both from p-
values and number of SNPs supporting are shown in Figure 2C. The value of these 
domain-based predictions is immediately apparent from the large number of SNPs 
supporting the top candidates. Predictions are listed on a gene by gene basis with the 
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number of significant SNPs associated with each gene in Supplementary Table 5. The top 
8 predictions by CMP ab initio have more SNPs supporting them than any of the pathway 
predictions. MTA3, which was ranked 1st with 86 SNPs supporting, contains a BAH 
domain (PF01426) in common with ORC1L (2 SNPs). These domains are involved in 
DNA methylation and may be involved in control of replication. DHX30, ranked 2nd with 
77 SNPs supporting, is an ATP-dependent helicase containing DEAD (PF00270) and 
Helicase_C (PF00271) domains in common with BLM (4 SNPs) & SKIV2L (3 SNPs) 
(Figure 4), and a Helicase_C domain in common with CHD6 (36 SNPs). The top ten CMP 
ab initio predictions are listed along with supporting information linking them to HTN in 
Table 3. 
Genes composed of tandem domains found repeatedly in the CMP ab initio 
predictions are depicted in Figure 4. The most common domains found in the predicted 
genes were the C2 domain (PF00168), a domain that targets proteins to the membrane by 
binding phospholipids, often in a calcium-dependent fashion; and PH or Pleckstrin 
homology domains (PF00169) which have a similar function (Supplementary Table 6). C2 
domains were present in eight CMP-predicted genes: PIK3C2A, PLCB1, PLCL2, DYSF, 
PLCD3, RASA1, PLCE1 and SMURF2 with a mean number of SNPs per gene of 17.5. 
Four of these genes are phospholipases. Although PLCL2 is not enzymatically active, it 
may have an inhibitory role in phospholipase signalling as a decoy receptor. PH domains 
were present in six CMP-predicted genes: SH2B3, RASA1, PREX1, DEPDC2, PLCL2, & 
SBF2, with a mean number of SNPs per gene of 36.9. Two of these are RAC guanine 
nucleotide exchange factors (GEF) that contain RhoGEF (PF00621) and DEP (PF00610) 
domains and bind 3,4,5-trisphosphate (PIP3) via their PH domains, which have strong 
support at the genetic level - DEPDC2 is supported by 47 SNPs and PREX1 is supported 
by 15 SNPs. A third GEF with a PH domain, SBF2, which is RAB related, is mentioned 
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above. GEFs activate G-protein signalling. The abundance of these lipid binding domains 
seems to support the theme of lipids and phosphoinositides identified by the independent 
pathway module CPS.   
Four additional genes associated with phosphoinositol were predicted by the CMP 
module: PITPNM3 (supported by 6 SNPs), and three homologous genes:ITPR1 (1 SNP), 
ITPR2 (6 SNPs) and ITPR3 (1 SNP). PITPNM3 catalyzes the transfer of 
phophatidylinositol and phophatidylcholine between membranes. The three ITPR 
receptors were independently predicted by CPS. 
Other domains found repeatedly in the CMP ab initio predictions with good 
genetic support, and in excess of a mean of 20 SNPs associated with the resident genes, 
are BAH domains described above (PF01426, 44 SNPs/gene); SH2 domains, adaptor 
domains allowing proteins containing those domains to dock to phosphorylated tyrosine 
residues on other proteins (PF00017, 33 SNPs/gene), the LNS2 domain (PF08235, 26 
SNPs/gene), an Mg2+-dependent phosphatidate phosphatase involved in adipose tissue 
development and insulin resistance [42].  
Other genes of interest predicted by CMP ai with good genetic support as well as 
support in the literature are EPHA4 (24 SNPs), which has previously been implicated in 
Amyotrophic lateral sclerosis (ALS), a phenotype often displaying blood pressure 
irregularities including HTN and BRAP (30 SNPs) which has previously been associated 
with peripheral artery disease [43]. 
Three single domain candidate gene products were predicted by CMP ai above the 
empirically determined threshold score of χ2 min >100: ACOT8 - an enzyme of fatty acid 
metabolism; and NPPA, NPPB - atrial natriuretic factors A and B previously associated 
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with HTN by the ICBP study [11]. An extended list of single domain candidates with χ2min 
> 80 is given in Supplementary Table 7. The top genes among CMP ai predictions in 
terms of genetic support, both from p-values and number of SNPs supporting are shown in 
Figure 2C. 
 
Figure 4 Domain combinations with tandem repeats. Directed graph representation of domain 
combinations of CMP ab initio-predicted candidates. Domains with * symbol are following abbreviated 
domain names: ASP_1 = ADAM_spacer1, PMP = Pep_M12B_propep, Fib-C*= Fibrinogen _C , INS_rec = 
Ins145_P3_rec, efhand = efhand_like, Laminin E = Laminin_EGF, Laminin G = Laminin_G_1, Lamining = 
Laminin_G_2, Hormer = Hormone_recep, PkinaseT = Pkinase_Tyr, RHSr* = RHS_repeat, Oest_rec = 
Oest_recep, RYDR = RYDR_ITPR, Eph_lb = Ephrin_lbd, Lamin_I = Laiminin_I, Lamin_II = Laminin_II, 
Lamin_B = Laminin_B , Lamin_N = Laminin_N, Helic_C = Helicase_C. 
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Table 3 Top 10 CMP ai predictions by genetic support 
SNPs Gene Protein function Type Literature evidence 
86 MTA3 
DNA methyl transferase with estrogen-
dependent expression 
 
- - 
77 DHX30 
 
 
ATP-dependent helicase 
 
 
 
D 
 
 
[44]. 
 
 
73 HARS 
 
a histidine-tRNA ligase 
 
- 
Mutations leading to reduced tRNA 
levels in mitochondria linked to HTN 
[45]. 
61 RASA1 
 
an inhibitory regulator of the Ras-cyclic 
AMP pathway 
 
Ph 
 
Capillary malformation-arteriovenous 
malformation syndrome (OMIM 
608354). 
60 SBF2 
a guanine-nucleotide exchange factor for 
GPR126, GPR133 
Ph - 
50 DYSF 
 
a gene involved in skeletal muscle repair 
that has been implicated in several types 
of muscular dystrophy 
 
Ph 
 
Dysferlinopathy may exacerbate 
coexisting conditions such as HTN.  
[46]. 
47 DEPDC2 
 
RAC1 guanine nucleotide exchange 
factor (GEF) 
 
D 
 
BP factor in the HyperGEN African 
Americans [47]. 
46 LPIN3 
 
 
Magnesium-dependent phosphatidate 
phosphatase enzyme which catalyzes the 
conversion of phosphatidic acid to 
diacylglycerol 
 
 
 
D 
 
 
Genetic variations in lipin genes in 
common metabolic dysregulation such 
as obesity, hyperinsulinemia, 
hypertension, and type 2 diabetes. [48]. 
37 SH2B3 Intracellular adaptor protein D [49]. 
36 CHD6 
 
TP-dependent helicase chromatin  
remodelling in response to oxidative 
stress 
 
- 
 
- 
D - directly implicated in HTN, Ph - implicated in a potentially related phenotype, CMP ai - Common 
Module Profiling module in ab initio mode, HTN - Hypertension. 
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Six of the 23 known disease genes (Supplementary Table 1) had homologous 
domains in the search space for which the similarity score exceeded the conservative 
threshold of above 0.4 used to predict and rank candidates, as described in our previously 
published study [16], but none of known disease genes were replicated by Gentrepid 
because none were in the 1,016 gene search space associated with the 6,244 ICBP SNPs 
mapped. In seeded mode, CMP predicted 24 gene products as candidates using pair-wise 
similarity scores calculated between matching domains in a gene of the search space and a 
known disease gene (Table 4), The only multiple domain matches were four nuclear 
receptors with weak genetic support, identified based on Hormone_recep (PF00104) and 
zf-C4 (PF00105) domains matched with the NR3C2 seed gene. Of the single domain 
matches, the candidate with the most underlying SNPs was SERPINB8 (20 SNPs), an 
inhibitor of furin with a role in inflammation/remodeling in cardiometabolic diseases [50] 
based on the disease gene AGT. Other single domain predictions with good genetic support 
include WDFY3 (13 SNPs) and BRWD2 (16 SNPs) matched with the GEsignalling protein 
GNB3 based on the WD40 domain, and ADRB2 (12 SNPs). WDFY3 is a 
phosphatidylinositol 3-phosphate-binding protein involved in aggregate clearance by 
autophagy [51]. The involvement of the ADRB2 gene with HTN, which is also predicted 
by CPS, was discussed above. 
Common themes that are present in the CMP data are G-coupled receptor (GPCR), 
signalling and Zn-binding proteins. GPCRs implicated include the adhesion receptor 
LPHN2 (22 SNPs) as well as several members of family A GPCRs, the most significant of 
which are the 5-HT 4 receptor HTR4 (6 SNPs), the neuropeptide Y receptor NPY2R (4 
SNPs) and the oxoglutarate receptor OXGR1 (5 SNPs). Zn-binding domains are found in 
BRAP (30 SNPs), ZCCHC11 (14 SNPs), ADAMTS18 (3 SNPs) and several nuclear 
receptors. ZCCHC11 uridylates microRNAs to relieve their repressive activities. 
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Table 4 Predicted candidates using CMP module in seeded mode 
1 describes seed genes retrieved from OMIM database. Abbreviation: OMIM - Online Mendelian Inheritance 
in Man. 
Comparison of predicted candidates with previous studies  
A comparison of the 151 predicted candidate genes in this study with the 44 genes 
reported in the original ICBP study, revealed an overlap of nine genes (Supplementary 
Figure S3) In the 29 highly significant ICBP loci in question, Gentrepid previously 
replicated 12 of the ICBP genes using the adjacent mapping with limited bioinformatics 
support.[1] With the more conservative thresholds for bioinformatics support employed 
here, only nine of the ICBP predictions are replicated: CYP1A2, CYP17A1, ATP2B1, 
GUCY1A3, NPPB, NPPA, PLCE1, SH2B3 and NFKB1. These nine overlapping genes, 
independently predicted by both Gentrepid and the ICBP working group from the same 
dataset, should be considered robust, with both genetic and bioinformatic support in their 
favour. Within this subgroup of 9 genes are five Gentrepid-predicted candidate genes that 
were among the 151 candidates predicted by Gentrepid in this study using the 6,244 SNPs 
with p < 1x10-3 and the 19 candidates previously predicted using only the 29 highly 
significant ICBP SNPs: PLCE1, GUCY1A2, ATP2B1, CYP1A2, NFKB1 (Supplementary 
Domains Candidates OMIM 
seeds 
Genes SNPs Scores Ranks 
Hormone_recep, 
zfC4 
4 NR3C2 NR2F6, ESR1, 
NR3C1, NR1D2 
2, 1, 1,1 0.58,0.41, 
0.58, 0.46 
4, 14, 4, 11 
p450 5 CYP11B2, 
CYP3A5, 
PTGIS 
CYP1A1, CYP1A2, 
CYP4A11, 
CYP17A1, CYP21A2 
24, 3, 1, 
3, 4 
0.68, 0.61, 
0.58,0.57,0.40 
1, 2, 4, 5, 15 
Serpin 1 AGT SERPINB8 20 0.48 9 
WD40 7 GNB3 WDFY3, GEMIN5, 
EML4, STRN3, 
WDR55, BRWD2, 
WDR76 
13, 3, 2, 
6, 4, 16,1 
0.48, 0.58, 
0.48, 0.46, 
0.41,0.45,0.59 
9, 4, 9, 1, 13, 
12, 3 
7tm_1 7 AGTR1 ADRB2, CCBP2, 
HTR4, NPY2R, 
OPRM1, P2RY11, 
OXGR1 
12, 1, 6, 
4, 1, 1, 5 
0.52, 0.54, 
0.58, 0.56, 
0.47, 0.46, 
0.47 
8, 7, 4, 6, 10, 
11, 10 
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Figure S3).  The 35 candidate genes predicted solely by the ICBP (Supplementary Figure 
S3) are likely good genetic predictions for which there is currently limited or no 
bioinformatic data in support which would enable Gentrepid to make a prediction.  The 
142 novel predictions made by Gentrepid should be considered plausible predictions 
retrieved by using a combination of SNPs of slightly lower significance, a different SNP 
mapping technique to that usually employed in GWAS, and bioinformatic data to make 
statistically significant predictions.  
The use of the adjacent mapping technique, where each SNP is mapped to the four 
nearest genes rather than just the nearest gene is valid because although the implicated 
SNPs in GWAS are likely to be either the causal SNP, or in linkage disequilibrium with 
the causal SNP, genomic architecture is unknown, complicated, and the relevant locus 
may be distal to the gene it controls. We have previously shown that the adjacent mapping 
technique, where four genes on the plus and minus strands and in the 5’and 3’ directions 
are associated with the SNP, retrieves more disease genes with fewer false positives than 
any other mapping we have explored. Using the more generous 1Mbp mapping, which 
was designed to capture genes which are near but not immediately adjacent to the 
significant SNP with only the 29 highly significant SNPs, Gentrepid previously predicted 
a total of 108 candidate genes [12]. Comparison of these 108 candidate genes predicted 
with the 1Mbp mapping of 29 SNPs at p < 1*10-7 with the 151 predicted candidate genes 
predicted in this study from 6244 SNPs at p < 1*10-3 revealed 21 overlapping genes 
between these two datasets (Supplementary Figure S4). The twelve additional genes 
replicated in this study in common with those predicted using the more generous 1Mbp 
mapping of the 29 highly significant SNPs but not adjacent mapping of these SNPs 
Ballouz et al, 2014 were close to but not immediately adjacent to the highly significant 
SNPs. In this study, they were implicated by nearby less significant SNPs using the 
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adjacent mapping. This supports the notion that the 1Mbp mapping does produce credible 
predictions but other work we have done shows that it also tends to produce more false 
positives than the adjacent mapping [9].  
Further, we also compared the 151 candidate gene predictions made in this study, 
based on the ICBP data from 200,000 patients, with the 219 candidates predicted by our 
reanalysis of the WTCCC GWAS data, based on only 2,000 patients using a similar 
protocol [9]. We found 10 of the 219 previously predicted candidates genes were 
replicated in this study: BCL2 (supported by 1 SNP in this study), PLCE1 (14 SNPs), 
LAMA2 (1 SNP), CTNNA3 (5 SNPs), TJP1 (1 SNP), GUCY1A3 (4 SNPs), PRKG1 (18 
SNPs), NPY2R (14 SNPs), LAMA1 (1 SNP) & WDFY3 (13 SNPs) (Supplementary Figure 
S5). Although the consensus between the two independently analysed datasets give some 
confidence in these candidates, some of them still only have very weak genetic support in 
the more powerful ICBP study, suggesting there is still considerable heterogeneity in the 
data. Although the number of consensus genes was small, Gentrepid was clearly able to 
extract credible candidates from the lower quality WTCCC data where there was only an 
average of 2 SNPs in each locus.  
Given the demonstrated heterogeneity in data for the HTN phenotype, the lack of 
substantial overlap between the two sets of Gentrepid predictions and also with other 
genetic data for the phenotype is not entirely surprising. Until molecular markers and 
better criteria are developed to allow more precise definition of cohorts, there is likely to 
continue to be substantial variation between the results from different GWAS studies and 
other patient-derived data. Obviously the larger number of SNPs supporting some of the 
candidates in this analysis gives more confidence that these particular genes are involved 
and are important in the ICBP cohort. 
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Prediction of therapeutic targets 
Using the 151 unique candidate disease genes predicted by Gentrepid for HTN, we 
searched for potential drug-targets with therapeutics in the three drug databases utilized, 
finding 35 candidate genes (23%) are potential therapeutic targets for HTN (Figure 1). 
Each drug database made significant contributions to therapeutic target identification, with 
the maximum contribution from DrugBank (32), followed by TTD (12) and PharmGKB 
(5).  
Further, we performed a classification of 35 predicted therapeutic targets to 
identify replicated and novel therapeutic targets for HTN. Only two predicted targets 
(ITPR1, ADRB2) are already associated with drugs which are approved or in clinical trials 
for HTN (Table 5).Novel therapeutic targets are genes targeted by therapeutics already 
approved or in human clinical trials for diseases other than HTN. We found 33 novel 
therapeutic targets comprising almost 93% of the targets identified in our analysis.  
. 
 
(1 These drugs mentioned here are examples because one therapeutic target may be associated  
with multiple drugs); (2 Drug databases mentioned here are examples because one drug-target  
association may be described in more than one drug database). Abbreviations - HTN - Hypertension; TTD - 
Therapeutic Target Database. 
 Target 1Drug name Status 2Database 
 
ADRB2 Betaxolol Approved DrugBank 
 Metoprolol Approved DrugBank 
 Carteolol Approved DrugBank 
 Labealol Approved DrugBank 
 Bisoprolol Approved DrugBank 
 Alprenolol Approved DrugBank 
 Pindolol Approved DrugBank 
ITPR1 Nitroprusside Approved TTD 
Table 5 Replicated therapeutics for HTN 
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Identification of novel therapeutics 
We identified 392 unique drugs that target the 35 predicted therapeutic targets. The 
majority of drugs were contributed by DrugBank (332) with the remainder from TTD (91) 
and PharmGKB (8). 374 of the 392 predicted drugs are novel therapeutics. Table 6 shows 
some examples of novel therapeutics identified for HTN. The percentage of drugs that 
may be repositioned towards treatment of HTN was around 5% of the total number of 
drugs extracted from the three databases (374 of 7,252 extracted drugs). For example, the 
drug “Palifermin", which acts upon the FGFR1 gene product, is approved as a therapeutic 
for oral mucositis (Table 6). Our study predicts FGFR1 as a predicted candidate gene and 
a novel therapeutic target for HTN, suggesting that the drug Palifermin may be repurposed 
as a novel therapeutic for HTN, provided that inhibition of FGFR1 is associated with 
lower rather than higher blood pressure. In our previously published reanalysis of the 
WTCCC-GWAS data, Gentrepid predicted a total of 219 candidate genes, 73 of those 
were novel therapeutic targets for HTN [13].  
Validation of predicted therapeutic targets 
We used two different benchmarks to assess the validity of targets predicted by Gentrepid 
for HTN. In the first benchmark, we validated association of targets with HTN based on 
whether they are designated as known targets for HTN in the drug databases or not. In the 
second benchmark, we retrieved the number of Pubmed citations, citing both the 
phenotype of interest (HTN) and the gene name to validate the association of the predicted 
gene-target with HTN. 
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Table 6 Selected novel therapeutics potentially suitable for repositioning for HTN 
 (1 These drugs mentioned in the table are only selected examples because one therapeutic target may be 
associated with multiple drugs in a drug database), (2 Drug databases mentioned here are only selected 
examples because one drug-target association may be retrieved from more than one drug database). 
Abbreviations -TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase; 
HTN - Hypertension. 
For the first benchmark, we classified genes in the search space as “HTN 
candidates” or “HTN non-candidates”. Targets with known therapeutic drugs for HTN 
were considered “true positives” (Table 7). Targets which were not predicted by 
Gentrepid, but present in the search space and targeted by currently registered therapeutics 
for HTN were considered as “false negatives”. Genes that were not predicted for HTN and 
not targetable by HTN drugs were regarded as “true negatives”, while Gentrepid-predicted 
novel therapeutic targets for HTN were considered “false positives” (Table 7). A ROC 
curve was plotted considering targets present in search space (Table 6, Supplementary 
data - Figure S6 (A)). The Area Under Curve (AUC) values of this ROC curve was greater 
than 0.5 (p < 0.05). It suggests that our predictions of therapeutic targets for HTN are 
significant. 
 
 
 
 Target 1Drug name Disease Status 2Database 
 FGFR1 Palifermin Oral mucositis Approved DrugBank 
 AKR1C1 NADH Parkinson's disease Approved DrugBank 
 CYP17A1 Progestrone Infertility in women Approved DrugBank 
 ESR1 Levonorgestrel Menopausal disorder Approved DrugBank 
 BCL2 Docetaxel Breast Cancer Approved DrugBank 
 HSD17B7 NADH Parkinson's disease Approved DrugBank 
 OPRM1 Diphenoxylate Diarrhoea Approved TTD 
 CRHR1 Glucocorticoids Asthma Unknown PharmGKB 
 ABCC2 Adenotriphosphate Dietary imbalance Approved DrugBank 
 CFTR Glyburide 
Blood glucose 
imbalance Approved DrugBank 
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Table 7 Binary classification of HTN targets present in adjacent search space 
 
 Known Drug Targets Novel Drug Targets 
HTN candidates T.P. = 2 F.P. = 149 
HTN non-candidates F.N. = 1 T.N. = 864 
                   Σ1,016 
Abbreviations: HTN - Hypertension, TP - True Positives; FP - False Positives; TN - True Negatives; FN - 
False Negatives. 
 
For the second benchmark, a ROC curve for HTN was created by considering four 
thresholds for targets with at least one, five, ten and fifteen Pubmed citations as HTN true 
positives and targets with less than five, ten and fifteen citations or without any citations 
as HTN false positives. Genes with at least one, five, ten and fifteen article citations not 
predicted by Gentrepid, but present in the search space were considered as “false 
negatives”. Genes neither cited nor predicted for HTN were regarded as “true negatives”. 
The AUC value for this ROC curve was also significantly greater than 0.5 (p < 0.05). It 
ensures that our results are not generated by chance and our predictions of therapeutic 
targets for HTN are significant (Supplementary data - Figure S6 (B)). 
Performance of the system 
The primary aim of our work was to predict novel anti-hypertensive therapeutics which 
may provide immediate translation opportunities of genetic findings to treatments. In total, 
Gentrepid was able to successfully predict 54 unique candidate genes using known disease 
genes as the seeds and 134 unique genes de novo from the ICBP GWAS data using both 
the CMP and CPS modules (Figure 1).  
We have shown there are shared pathways and homology between genes 
implicated by the ICBP SNPs that have not been previously reported. Using the adjacent 
mapping technique, several of the genes such as MTA3 (86 SNPs, CMP ai) and ABCG8 
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(46 SNPs CPS, ai) have much stronger SNP support in the data than any of the genes 
reported by the ICBP (PLCE1 - 15 SNPs).  
Our results show that both the CMP and CPS modules were effective in predicting 
candidates with CMP predicting 108 unique candidates and CPS predicting 71 unique 
candidates with a significant overlap of 28 genes (Figure 1). The ability of both modules 
to make credible independent predictions is consistent with the behaviour of the system on 
data from complex diseases. In contrast, when confronted with data from Mendelian 
diseases, CPS was the major contributor of the predictions [52]. 
However, Gentrepid predictions are fundamentally limited by the biological data 
they are based on. Candidate gene predictions based on both CMP and CPS “seeded” 
mode are limited by known genotype-phenotype data available in the OMIM database. 
The more powerful ab initio mode, which extracts similar candidates directly from the 
GWAS data, is still limited by the underlying pathway and domain databases utilized by 
CPS and CMP. It is estimated that coverage of pathways in current knowledgebases is 
only 10-25% of existing pathways. Although domain coverage is better, with 70% of the 
genes in the genome having a least one parseable Pfam domain, other regions of the 
protein sequence are completely unrepresented in the Pfam library [52]. Reliant as they are 
on the underlying biological information, Gentrepid predictions are not complete and our 
lack of knowledge of the full extent of human protein-protein interactions and complete 
characterization of the underlying domains in proteins precludes the system predicting 
more candidates that are lurking in the data. 
Despite these limitations, Gentrepid predicted a total of 374 novel therapeutics as 
potential drugs which might be repositioned towards HTN. These predicted novel 
therapeutics provide a promising repositioning strategy for translational medicine of HTN. 
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However, although they target the appropriate candidates, they may not do so in the 
correct direction. For example, several agonists of 5-HT 4 receptor HTR4 are suggested 
but an antagonist of this GPCR might be required. Further assessment is then needed to 
assess whether the drug ameliorates or worsens the phenotype. In some cases, the 
literature might be informative, but in others, testing in an animal model may be needed 
before phase II trials are attempted in patients.  
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Conclusion 
HTN is a growing epidemic at national and global levels. Identification of novel anti-
hypertensive treatments can help to decrease this epidemic. In this study, we found novel 
therapeutic targets and therapeutics by integrating with the detailed drug data currently 
available in drug databases, with predicted candidate genes for HTN. We found 22% (n = 
33) of the predicted candidate genes could serve as novel therapeutic targets and 5% (n = 
374) of the extracted drugs as potential novel therapeutics for HTN in our study. 
This study shows Gentrepid is a useful tool for reanalysis of GWAS data by 
finding common features in the data based on pathways and functional domains. As such 
it is a valuable way of extracting more information from these extremely complicated 
datasets on complex diseases. Not only does the system potentially provide translational 
data for the clinic; the drugs predicted via this approach provides an alternate approach to 
benchmarking the candidate gene predictions in a knowledge discovery scenario. Because 
of our lack of knowledge of the genotype-phenotype relationship in complex disease, 
candidate gene prediction systems are typically benchmarked against genotype-phenotype 
information that is biased towards data from Mendelian diseases [22, 53] potentially 
leading to overconfidence in systems that are “tuned” to perform well on this type of data.  
Gentrepid provides a useful alternate method to meta-analysis studies for sifting 
GWAS data, and can be particularly valuable when it is not possible to enrol more patients 
to expand a study. This study allows not only identification of novel therapeutic targets 
but also novel therapeutics that may be feasible to reposition against HTN. Clinical testing 
of the predicted 374 novel therapeutics in this study may help to identify potential anti-
hypertensive treatments, saving valuable time and money spent on preclinical studies and 
phase I clinical trials for HTN drug discovery. Hence, Gentrepid, a free public webserver 
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for GWAS data post-analysis, can be utilized as a tool for clinical translation of genetic 
data to identify drug repositioning opportunities for HTN patients in need. 
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Supplementary Table 1 - Hypertension associated genes used as seeds for the seeded 
approach 
 
Gene symbols Entrez IDs OMIM IDs 
   
HSD11B2, NR3C2, PNMT, AGTR1, PTGIS, NPR3, 3291, 4306, 5409, 185, 5740, 4883, 145500, 108962, 124080, 
BMPR2, ACSM3, KCNMB1, ADD1, AGT, ECE1, 659, 6296, 3779, 118, 183, 1889, 125853, 145505, 178600, 
GNB3, RETN, NOS3, NOS2A, CYP3A5, CYP11B2, 2784, 56729, 4846, 4843, 1577, 189800, 218030, 265380, 
CPS1, SELE, ATP1B1, RGS5, EPHX1 1585, 1373, 6401, 481, 8490, 2052 605115, 608622 
 
Abbreviations: OMIM: Online Mendelian Inheritance in Man  [1]. 
 
Supplementary Table 2 - Pathway information and significant SNPs associated with 
40 predicted candidate genes for HTN identified using the CPS module in seeded 
mode. 
 
Significant Reported gene Candidate gene Chromosomal Pathways  SNPs locations     
 
24 na MYL2 12q24.11 AM 
 
24 na CYP1A1 15q24.1 SHB 
 
18 na PRKG1 10q11.2 CE, IFVE, SS, CPS 
 
14 PLCE1 (rs932764) PLCE1 10q23 CSP 
 
12 na ADRB2 5q31-q32 CPS, CAC, IFVE, CSP 
 
8 na ATP2B2 3p25.3 SS, CPS, CSP 
 
7 na PLCD3 17q21 CSP 
 
6 na HTR4 5q31-q33 CSP 
 
6 na ITPR2 6p21.3 SS, GSP, CSP, ESP, CPS 
 
5 na PLCB1 8q22.1 SS, CE, ESP, CPS 
 
4 GUCY1A3, GUCY1B3 GUCY1A3 4q32.1 IFVE, SS, VSC, CE, CPS  (rs1313957)      
 
4 na CYP21A2 6p21.3 SHB 
 
4 na HBEGF 5q23 ESP 
 
4 na HSD17B7 1q23 SHB 
 
4 na NFKB1 4q24  
 
3 na CALML6 1p36.33 GSP, ESP, CPS 
 
3 CYP1A2,CSK (rs1378942) CYP1A2 15q24.1 SHB 
 
3 na GNAI1 7q21.11 GSP, CPS 
 
3 na CYP17A1 10q24.3 SHB 
 
3 na ATP2B1 12q21.3 CSP 
 
2 na AKR1C1 10p15-p14 SHB 
 
2 na NPPB 1p36.2 AM, CPS 
 
2 na NPPA 1p36.21 AM 
 
2 na HSPA1L 10p11.1 ESP 
 
1 na AKT3 1q44 ESP, SAL, CPS 
 
1 na NR3C1 5q31-q32 CAC 
 
1 na CFTR 7q31.2 GSP 
 
1 na ITPR3 6p21.31 CSP, CE, GSP, SS, CPS,  ESP      
 
1 na ESR1 6q24-q27 ESP 
 
1 na DRB2 6p21.3 SS 
 
1 na LAMB1 7q22 SAL 
 
1 na BCL2 18q21.3 SAL 
 
1 na ITPR1 3p26.1 SS, GSP, CSP, ESP, CPS 
 
1 na LAMA1 18p11.3 SAL 
 
1 na CYP4A11 1p33 VSC 
 
1 na CCNE2 12p11.23 SAL 
 
1 na LAMA2 1q24 SAL 
 
1 na INS 6q22-q23 CPS 
 
1 na VDAC2 11p15.5 CSP, CPS 
 
1 na OPRM1 10q22 ESP 
  
Abbreviations: Estrogen signalling pathway: ESP, cGMP-PKG signalling pathway: CSP, Salivary secretion: SS, Steroid 
hormone biosynthesis: SHB, Calcium signalling pathway: CSP, Circadian entrainment: CE, Ion channels and their functional 
role in vascular endothelium: IFVE, Corticosteroids and cardio protection: CAC, Alk in cardiac myocytes , AM, Small cell lung 
cancer : SAL, Vascular smooth muscle contraction: VSC, Gastric acid secretion: GSP, CPSs – CPS seeded 
Supplementary Table 3 - Pathway information and SNPs associated with CPS ai based predictions 
 
Significant  Predicted   
 
SNPs Reported genes genes Chromosomal locations Pathways 
 
46 na ABCG8 2p21 ABCT 
 
42 na MITF 3p13 MG 
 
40 na PTTG2 4p14 OM 
 
31 na WNT2B 1p13 MG, PC 
 
24 na CYP1A1 15q24.1 SHB 
 
24 na MYL2 12q24.11 TJ 
 
23 na PIK3C3 18q12.3 PIS 
 
18 na PRKG1 10q11.2 LTD, GJ 
 
14 PLCE1 (rs932764) PLCE1 10q23 PC, IPM, PIS 
 
12 na CDC27 17q21.32 OM 
 
12 na ADRB2 5q31-q32 SS, CSP 
 
10 na FGFR1 8p11.23-p11.22 AJ, PC 
 
8 na ATP2B2 3p25.3 SS, CSP 
 
7 na EPB41L2 6q23 TJ 
 
7 na ABCC2 10q24 ABCT 
 
7 na PLCD3 17q21 IPM, PIS 
 
6 na ITPR2 12p11.23 ESP, GJ, PIS 
 
5 na TUBB1 20q13.32 GJ 
 
5 na CTNNA3 10q21 AJ, TJ 
 
5 na CLDN20 6q25 TJ 
 
5 na PLCB1 20p12 IPM, GS, LTD, GJ, PIS, ESP, CSP 
 
5 na PTPN11 12q24.1 PC 
 
4 na CYP21A2 6p21.3 SHB 
 
4 na HBEGF 5q23 ESP 
 
4 GUCY1A3, GUCY1B3 GUCY1A3 4q32.1 LTD, CSP  (rs13139571)       
4 na HSD17B7 1q23 SHB 
 
3 na DNAJB6 7q36.3 PP 
 
3 na CALML6 1p36.33 GS, PIS, ESP, CSP 
 
3 na ACTN2 1q42-q43 AJ, TJ 
 
3 CYP1A2,CSK (rs1378942) CYP1A2 15q24.1 SHB 
 
3 na ABCG5 2p21 ABCT 
 
3 na GNAI1 7q21.11 MG, ESP, CSP 
 
3 na CYP17A1 10q24.3 SHB 
 
3 na MAD2L2 1p36 OM 
 
3 na MAGI2 7q21 TJ 
 
2 na AKR1C1 10p15-p14 SHB 
 
2 na CAV3 3p25 PC 
 
2 na ABCC10 6p12.3 ABCT 
 
2 na FZD8 10p11.2 MG, PC 
 
2 na NPPB 1p36.2 CSP 
 
2 na CSNK2B 6p21.33 AJ, TJ 
 
2 na WNT3 17q21.31 MG, PC 
 
2 na HSPA1L 6p21.3 ESP 
 
1 na AKT3 1q44 ESP, CSP, TJ 
 
1 na TJP1 15q13 AJ, TJ, GJ 
 
1 na LAMA1 18p11.3 PP 
 
1 na ITPR3 6p21.31 ESP, PIS 
 
1 na INPPL1 11q23 IPM, PIS 
 
1 na LAMA2 6q22-q23 PP 
 
1 na PTPRJ 11p11.2 AJ 
 
1 na CFTR 7q31.2 GS 
 
1 na WNT9A 1q42 MG, PC 
 
1 na LAMB1 7q22 PP 
 
1 na CCNE2 8q22.1 OM 
 
1 na BCL2 18q21.3 PP 
 
1 na ITPR1 3p26.1 ESP, GJ, PIS 
 
1 na INS 11p15.5 OM, CSP 
 
1 na PIK3C2A 11p15.5-p14 IPM, PIS 
 
1 na ESR1 6q24-q27 ESP, PC 
 
1 na OPRM1 6q24-q25 ESP 
 
1 na CRHR1 17q21.31 LTD 
 
1 na WASL 7q31.3 AJ 
 
1 na VDAC2 10q22 CSP 
 
1 na MAD2L1 4q27 OM 
  
Abbreviations: Prion pathway: PP, Phosphatidylinositol signalling system: PIS, Estrogen signalling pathway: ESP, Long-
term depression: LTD, cGMP-PKG signalling pathway: CSP, Gap junction: GJ, Salivary secretion: SS, Oocyte meiosis: OM, 
Adherens junction: AJ, Steroid hormone biosynthesis: SHB, Proteoglycans in cancer: PC, ABC transporters: ABCT, Inositol 
phosphate metabolism: IPM, Tight junction: TJ, Melanogenesis: MG, CPSai – CPS ab initio. 
Supplementary Table 4 – Pathways predicted by CPS in seeded (light grey) and ab initio (dark) mode. 
 
 
 Pathways  
Total SNPs in 
the dataset 
supporting 
that pathway  
Number of 
genes in 
the 
pathway 
implicated  
Mean 
number of 
SNPs per 
implicated 
gene    
Correspo-
nding rank 
of pathway 
 
            
 ABC transporter  59  5  11.8  1  
 
 Ion channels and their functional role in  34  3  11.3  2    vascular endothelium                 
 
 Melanogenesis  89  8  11.1  3  
 
 Alk in cardiac myocytes  28  3  9.3  4  
 
 Inositol phosphate metabolism  51  6  8.5  5  
 
 Oocyte meiosis  69  10  6.9  6  
 
 Steroid hormone biosynthesis  40  6  6.7  7  
 
 Steroid hormone biosynthesis  40  6  6.7  7  
 
 Corticosteroids and cardioprotection  13  2  6.5  8  
 
 Vascular smooth muscle contraction  50  8  6.3  9  
 
 Proteoglycans in cancer  81  13  6.2  10  
 
 Phosphatidyl inositol signalling  62  10  6.2  10  
 
 Calcium signalling pathway  64  11  5.8  11  
 
 Tight junction  54  10  5.4  12  
 
 Circadian entrainment  42  8  5.3  13  
 
 Salivary secretion  46  9  5.1  14  
 
 Salivary secretion  46  9  5.1  14  
 
 Gap junction  44  9  4.9  15  
 
 Long-term depression  39  8  4.9  15  
 
 cGMP-PKG signalling pathway  66  14  4.7  16  
 
 cGMP-PKG signalling pathway  66  14  4.7  16  
 
 Adherens junction  23  7  3.3  17  
 
 Gastric acid secretion  20  7  2.9  18  
 
 Gastric acid secretion  20  7  2.9  18  
 
 Estrogen signalling pathway  28  11  2.5  19  
 
 Estrogen signalling pathway  28  11  2.5  19  
 
 Small cell lung cancer  14  7  2  20  
 
 Prion pathway  7  5  1.4  21  
 
            
Dark shaded region – CPS ab initio approach, Light shaded region – CPS seeded approach 
Supplementary Table 5 - Domain information and significant SNPs associated with 
88 predicted candidate genes for Hypertension based on CMP ab initio module 
 
SNP Gene Domain combination X
2max Rank  count Symbol unique    
 
86 MTA3 BAH|ELM2|GATA|Myb_DNA-binding 3.00E+10 18 
 
77 DHX30 DEAD|DUF1605|HA2|Helicase_C 3.00E+09 23 
 
73 HARS HGTP_anticodon|tRNA-synt_2b|WHEP-TRS 3.00E+08 27 
 
61 RASA1 C2|PH|RasGAP|SH2|SH3_1 8.00E+09 20 
 
60 SBF2 dDENN|DENN|GRAM|Myotub-related|PH|uDENN 1.00E+16 5 
 
50 DYSF C2|FerA|FerB|FerI 3.00E+11 15 
 
47 DEPDC2 DEP|PH|RhoGEF 1.00E+06 38 
 
46 LPIN3 Lipin_N|LNS2 3.00E+05 40 
 
37 SH2B3 PH|Phe_ZIP|SH2 1.00E+06 38 
 
36 CHD6 Chromo|Helicase_C|SNF2_N|TCH 6.00E+09 21 
 
30 BRAP BRAP2|zf-C3HC4|zf-UBP 3.00E+07 31 
 
24 EPHA4 Ephrin_lbd|fn3|Pkinase|SAM_2 2.00E+07 31 
 
23 PIK3C3 PI3_PI4_kinase|PI3K_C2|PI3Ka 1.00E+08 28 
 
22 LPHN2 7tm_2|Gal_Lectin|GPS|HRM|Latrophilin|OLF 1.00E+18 2 
 
22 NT5E 5_nucleotid_C|Metallophos 1.00E+05 42 
 
20 PTPRD fn3|I-set|ig|Y_phosphatase 1.00E+05 42 
 
19 RPL6 Ribosomal_L6e|Ribosomal_L6e_N 2.00E+05 41 
 
17 MARK2 KA1|Pkinase|UBA 2.00E+06 37 
 
16 ANTXR2 Ant_C|Anth_Ig|VWA 1.00E+08 28 
 
15 PREX1 DEP|PH|RhoGEF 1.00E+06 38 
 
14 PLCE1 C2|PI-PLC-X|PI-PLC-Y|RA 2.00E+09 24 
 
14 ZCCHC11 NTP_transf_2|PAP_assoc|zf-CCHC 2.00E+07 31 
 
14 ACAD10 Acyl-CoA_dh_1|Acyl-CoA_dh_M|APH|Hydrolase 1.00E+11 16 
 
14 SNX14 Nexin_C|PX|PXA|RGS 8.00E+10 17 
 
13 WDFY3 Beach|FYVE|WD40 8.00E+05 39 
 
13 FMNL1 Drf_FH3|Drf_GBD|FH2 1.00E+08 28 
 
12 NMT1 NMT|NMT_C 1.00E+06 38 
 
11 JARID2 ARID|JmjC|JmjN|zf-C5HC2 4.00E+11 14 
 
11 CTPS CTP_synth_N|GATase 3.00E+05 40 
 
8 ATP2B2 Cation_ATPase_C|Cation_ATPase_N|E1-E2_ATPase|Hydrolase 4.00E+09 22 
 
7 PLCD3 C2|efhand_like|PI-PLC-X|PI-PLC-Y 1.00E+10 19 
 
7 EPB41L2 4_1_CTD|FA|FERM_C|FERM_M|FERM_N|SAB 3.00E+17 3 
 
7 NUDT13 NUDIX|NUDIX-like|zf-NADH-PPase 2.00E+09 24 
 
7 FARSLB B3_4|B5 5.00E+06 34 
 
7 ERP29 ERp29|ERp29_N 5.00E+06 34 
 
6 DCBLD1 CUB|F5_F8_type_C|LCCL 3.00E+06 36 
 
6 PITPNM3 DDHD|LNS2 1.00E+05 42 
 
6 MOCS3 MoeZ_MoeB|Rhodanese|ThiF 5.00E+08 26 
 
6 ITPR2 Ins145_P3_rec|Ion_trans|MIR|RIH_assoc|RYDR_ITPR 5.00E+15 7 
 
5 PLCB1 C2|efhand_like|PI-PLC-X|PI-PLC-Y|PLC-beta_C 1.00E+14 8 
 
4 TNXB EGF|EGF_2|Fibrinogen_C|fn3 2.00E+06 37 
 
4 NSF AAA|CDC48_2|CDC48_N 7.00E+08 25 
 
4 IK RED_C|RED_N 5.00E+06 34 
 
4 BLM BDHCT|DEAD|Helicase_C|HRDC|RQC 8.00E+15 6 
 
3 ADAMTS18 ADAM_spacer1|Pep_M12B_propep|Reprolysin|TSP_1 5.00E+08 11 
 
3 DLG2 Guanylate_kin|PDZ|SH3_2 3.00E+05 40 
 
3 ADAMTS18 ADAM_spacer1|Pep_M12B_propep|PLAC|Reprolysin|TSP_1 2.00E+12 11 
 
3 SEC14L1 CRAL_TRIO|CRAL_TRIO_N|PRELI 8.00E+07 29 
 
3 ACTN2 CH|efhand|efhand_Ca_insen|Spectrin 1.00E+08 28 
 
3 PTN PTN_MK_C|PTN_MK_N 3.00E+05 40 
 
3 LOC653702 Ribosomal_L30|Ribosomal_L30_N 1.00E+05 42 
 
3 MSH3 MutS_I|MutS_II|MutS_III|MutS_V 4.00E+13 9 
 
3 SKIV2L DEAD|DSHCT|Helicase_C 1.00E+07 32 
 
2 EPHB4 Ephrin_lbd|fn3|Pkinase_Tyr|SAM_1 3.00E+07 31 
 
2 ODZ3 EGF|EGF_2|NHL|RHS_repeat|Ten_N 7.00E+11 13 
 
2 NR2F6 Hormone_recep|zf-C4|zf-C4_C 9.00E+06 33 
 
2 ORC1L AAA|BAH|Cdc6_C 1.00E+08 28 
 
2 DCP2 DCP2|NUDIX 1.00E+05 42 
 
2 NOC3L CBF|NOC3p 1.00E+06 38 
 
2 TCF1 HNF-1_N|HNF-1A_C|HNF-1B_C|Homeobox 7.00E+12 10 
 
2 NPPA ANP 1.00E+02 42 
 
2 NPPB ANP 1.01E+02 42 
 
1 MYO9B C1_1|IQ|Myosin_head|RA|RhoGAP 1.00E+11 16 
 
1 INPPL1 Exo_endo_phos|SAM_1|SH2 5.00E+05 40 
 
1 SMURF2 C2|HECT|WW 2.00E+05 41 
 
1 NRXN1 EGF|Laminin_G_1|Laminin_G_2 1.00E+05 42 
 
1 TNKS Ank|PARP|SAM_2 2.00E+05 41 
 
1 FRMD5 FA|FERM_C|FERM_M|FERM_N 6.00E+09 21 
 
1 WASL PBD|WH1|WH2 3.00E+07 31 
 
1 TJP1 PDZ|SH3_2|ZU5 3.00E+05 40 
 
1 PLCL2 C2|efhand_like|PH|PI-PLC-X|PI-PLC-Y 1.00E+12 12 
 
1 MEP1A Astacin|EGF|MAM|MATH 2.00E+09 24 
 
1 NR3C1 GCR|Hormone_recep|zf-C4 4.00E+06 35 
 
1 PIK3C2A C2|PI3_PI4_kinase|PI3K_C2|PI3K_rbd|PI3Ka|PX 2.00E+17 4 
 
1 DDHD2 DDHD|SAM_1|WWE 4.00E+07 30 
 
1 THBS4 EGF|EGF_CA|TSP_C 2.00E+05 41 
 
1 DBH Cu2_monoox_C|Cu2_monooxygen|DOMON 2.00E+09 24 
 
1 EIF2C2 DUF1785|PAZ|Piwi 5.00E+08 26 
 
1 AMT GCV_T|GCV_T_C 2.00E+05 41 
 
1 SUCLG2 ATP-grasp_2|Ligase_CoA 1.00E+05 42 
 
1 MRPL2 Ribosomal_L2|Ribosomal_L2_C 5.00E+05 40 
 
1 PTD004 DUF933|MMR_HSR1 1.00E+05 42 
 
1 RPA2 RPA_C|tRNA_anti 2.00E+05 41 
 
1 LAMA1 Laminin_B|Laminin_EGF|Laminin_G_1|Laminin_G_2 8.00E+20   Laminin_I|Laminin_II|Laminin_N 1     
 
1 LAMA2 Laminin_B|Laminin_EGF|Laminin_G_1|Laminin_G_2 8.00E+20   |Laminin_I|Laminin_II|Laminin_N 1     
 
1 ESR1 Hormone_recep|Oest_recep|zf-C4 3.00E+07 31 
 
1 ITPR1 Ins145_P3_rec|Ion_trans|MIR|RIH_assoc|RYDR_ITPR 5.00E+15 7 
 
1 ITPR3 Ins145_P3_rec|Ion_trans|MIR|RIH_assoc|RYDR_ITPR 5.01E+15 7 
 
1 ACOT8 Acyl_CoA_thio 1.02E+02 42 
  
List of single and multi-domains of predicted candidate gene products predicted by CMP module in ab-initio mode. In 
total, there are 88 candidate gene-products including 85 multi-domain and three single domain gene products. 
Supplementary Table 6 - Domain information and significant SNPs associated with two or more predicted 
 
candidate genes for Hypertension based on CMP ab initio module 
 
    Mean 
 
 Number   number of 
 
Domains of genes Genes SNPs per gene SNPs 
 
AAA 2 NSF, ORC1L 4,2 3.0 
 
ANP 2 NPPA,NPPB 2,2 2.0 
 
BAH 2 MTA3, ORC1L 86,2 44.0 
 
C2 8 PIK3C2A, PLCB1, PLCL2, DYSF, PLCD3, 1,5,1,50,   RASA1, PLCE1, SMURF2 7,61,14,1 17.5    
 
DDHD 2 DDHD2, PITPNM3 1,6, 3.5 
 
DEAD 3 DHX30, SKIV2L, BLM 77,3,4 28.0 
 
DEP 2 PREX1,DEPDC2 15,47 31.0 
 
efhand_like 3 PLCB1, PLCL2, PLCD3 5,1,7 4.3 
 
EGF 5 ODZ3, TNXB, THBS4, NRXN1, MEP1A 2,4,1,1,1 1.8 
 
EGF_2 2 ODZ3, TNXB 2,4, 3.0 
 
Ephrin_lbd 2 EPHB4, EPHA4 2,24 13.0 
 
FA 2 FRMD5, EPB41L2 1,7 4.0 
 
FERM_C 2 FRMD5, EPB41L2 1,7 4.0 
 
FERM_M 2 FRMD5, EPB41L2 1,7 4.0 
 
FERM_N 2 FRMD5, EPB41L2 1,7 4.0 
 
fn3 4 PTPRD, EPHB4, EPHA4, TNXB 20,2,24,4 12.5 
 
Helicase_C 4 CHD6, BLM, SKIV2L, DHX30 36,4,3,77 30.0 
 
Hormone_recep 3 ESR1, NR2F6, NR3C1 1,2,1 1.3 
 
Hydrolase 2 ACAD10, ATP2B2 14,8, 11.0 
 
Ins145_P3_rec 3 ITPR1,ITPR2, ITPR3 1,6,1 2.7 
 
Ion_trans 3 ITPR1,ITPR2, ITPR3 1,6,1 2.7 
 
Laminin_B 2 LAMA1,LAMA2 1,1, 1.0 
 
Laminin_EGF 2 LAMA1,LAMA2 1,1, 1.0 
 
Laminin_G_1 3 NRXN1, LAMA1,LAMA2 1,1,1 1.0 
 
Laminin_G_2 3 NRXN1, LAMA1,LAMA2 1,1,1 1.0 
 
Laminin_I 2 LAMA1,LAMA2 1,1, 1.0 
 
Laminin_II 2 LAMA1,LAMA2 1,1, 1.0 
 
Laminin_N 2 LAMA1,LAMA2 1,1, 1.0 
 
LNS2 2 LPIN3, PITPNM3 46,6 26.0 
 
MIR 3 ITPR1,ITPR2, ITPR3 1,6,1 2.7 
 
NUDIX 2 NUDT13, DCP2 7,2 4.5 
 
PDZ 2 TJP1, DLG2 1,3 2.0 
 
PH 6 SH2B3, RASA1, PREX1,DEPDC2, PLCL2, SBF2 37,61,15,47,1,60 36.8 
 
PI3_PI4_kinase 2 PIK3C3, PIK3C2A 23,1 12.0 
 
PI3K_C2 2 PIK3C3, PIK3C2A 23,1 12.0 
 
PI3Ka 2 PIK3C3, PIK3C2A 23,1, 12.0 
 
PI-PLC-X 4 PLCE1, PLCB1, PLCD3, PLCL2 14,5,7,1 6.8 
 
PI-PLC-Y 4 PLCE1, PLCB1, PLCD3, PLCL2 14,5,7,1 6.8 
 
Pkinase 2 MARK2, EPHA4 17,24 20.5 
 
PX 2 SNX14, PIK3C2A 14,1 7.5 
 
RA 2 MYO9B, PLCE1 1,14 7.5 
 
RhoGEF 2 PREX1,DEPDC2 15,47, 31.0 
 
RIH_assoc 3 ITPR1,ITPR2, ITPR3 1,6,1 2.7 
 
RYDR_ITPR 3 ITPR1,ITPR2, ITPR3 1,6,1 2.7 
 
SAM_1 3 DDHD2, INPPL1, EPHB4 1,1,2 1.3 
 
SAM_2 2 TNKS, EPHA4 1,24, 12.5 
 
SH2 3 SH2B3, INPPL1, RASA1 37,1,61 33.0 
 
SH3_2 2 TJP1, DLG2 1,3 2.0 
 
zf-C4 3 NR2F6, ESR1, NR3C1 2,1,1 1.3 
  
List of domains associated with two or more candidate gene products predicted by CMP module in ab-initio mode. 
Supplementary table 7 - List of 33 single domain proteins identified by CMP 
 
Gene 
Implicated Pfam 
domain 
 Estimate 
of support 
based on 
rarity of the 
domain 
X2min  
 
Genetic 
support 
(SNPs)  
    
ACOT8 Acyl_CoA_thio 1 111.3418 
 
NPPA ANP 2 111.3418 
 
NPPB ANP 2 111.3418 
 
BAMBI BAMBI 9 84.49174 
 
CFDP1 BCNT 45 84.49174 
 
CSNK2B CK_II_beta 2 84.49174 
 
LOC134147 DLH 1 84.49174 
 
FAM64A DUF1466 6 84.49174 
 
C6orf96 DUF155 1 84.49174 
 
C10orf22 DUF1637 8 84.49174 
 
PRO1853 DUF185 14 84.49174 
 
CCHCR1 HCR 7 84.49174 
 
IKBKAP IKI3 1 84.49174 
 
MTHFR MTHFR 34 84.49174 
 
NDUFB8 NDUF_B8 1 84.49174 
 
PEX14 Pex14_N 6 84.49174 
 
MPI PMI_typeI 12 84.49174 
 
PLVAP PV-1 1 84.49174 
 
DOM3Z RAI1 1 84.49174 
 
RCSD1 RCSD 2 84.49174 
 
RPL28 Ribosomal_L28e 2 84.49174 
 
POLR3F RNA_pol_Rpc34 3 84.49174 
 
AYP1 RNase_H1_sml 3 84.49174 
 
SYCP1 SCP-1 1 84.49174 
 
SPCS3 SPC22 1 84.49174 
 
SRA1 SRA1 2 84.49174 
 
SUFU SUFU 7 84.49174 
 
GTF2E2 TFIIE_beta 1 84.49174 
 
C6orf66 UPF0240 8 84.49174 
 
MAD2L2 HORMA 3 82.52655 
 
MAD2L1 HORMA 1 82.52655 
 
PTPLAD2 PTPLA 3 82.52655 
 
PTPLA PTPLA 48 82.52655 
  
 
List of single domain gene products identified at x2min > 80 for the HTN phenotype. These proteins were 
identified using the CMP module of Gentrepid. In total, there are 33 single domain gene products in this list. 
Figure S1(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted candidate genes and drug targets for HTN based on CPS ab initio approach - 
Specific chromosomal locations of 436 significant SNPs/SNP clusters associated with 64 predicted 
candidate genes, 22 of which predicted as drug targets for HTN phenotype. Red arrow shows 
specific location of SNP/SNP clusters, blue colour symbols show predicted candidate gene and 
green colour symbols show candidate genes predicted as drug targets. These results were obtained 
by reanalysis of 6,244 SNPs (p < 1*10-3) extracted from ICBP study. 
Figure S1(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted candidate genes and drug targets for HTN based on CMP ab initio approach - Specific 
chromosomal locations of 1,021 significant SNPs/SNP clusters associated with 88 predicted candidate genes 
using CMP ai module, 14 of which predicted as drug targets for HTN phenotype. Red arrow shows specific 
location of SNP/SNP clusters, blue colour symbols show predicted candidate gene and green colour symbols 
show candidate genes predicted as drug targets.* symbol shows known HTN drug targets. These results 
were obtained by reanalysis of 6,244 SNPs (p < 1*10-3) extracted from the ICBP study. 
Figure S2(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interaction network of predicted candidate gene products using CPS ab initio approach - 
Interaction network between CPS ai module based 64 predicted candidate gene products retrieved 
from the STRING database ( http://string-db.org) [2]. Nodes are gene products coloured for visual 
aids and edges refer to each type of associated evidence described in database and mentioned in 
the figure. Abbreviation: CPS ai: Common Pathway Scanning in ab initio mode. 
Figure S2 (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interaction network of predicted candidate gene products using CPS seeded approach - 
Interaction network between CPS s module based 40 predicted candidate gene products retrieved 
from the STRING database ( http://string-db.org) [2]. Nodes are gene products coloured for visual 
aids and edges refer to each type of associated evidence described in database and mentioned in 
the figure. Abbreviation: CPS s: Common Pathway Scanning in seeded mode. 
Figure S3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of Gentrepid predicted candidate genes from the ICBP data in this study with 
predictions from other studies - Of the 151 candidate genes for HTN (green circle) predicted in this 
study, 9 overlap with the 44 predicted genes in the original ICBP study  [3] (yellow circle): PLCE1, 
CYP1A2, GUCY1A3, CYP17A1, NPPB, NPPA, SH2B3, ATP2B1, NFKB1 (blue and pink shaded 
area); and 5 overlap with genes predicted by Gentrepid in the 29 highly significant loci (Ballouz et al, 
2013)  [4] (cyan circle): CYP1A2, PLCE1, GUCY1A3, ATP2B1, NFKB1 (pink shaded area). 
Abbreviations: HTN – Hypertension, ICBP – International Consortium of Blood Pressure.
Figure S4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of predicted candidate genes for HTN obtained by reanalysis of ICBP SNPs in 
two different studies - 151 genes in this study using adj approach (green circle) and 108 genes in 
Ballouz et al, 2013 using 1Mbp approach (cyan circle)  [4]. We found 21 overlapping genes 
(CYP17A1, NFKB1, GUCY1A3, CYP1A1, CYP1A2, ATP2B1, NPPA, NPPB, MAD2L2, WNT3, 
CDC27, BLM, WNT2B, BRAP, SH2B3, PIK3C2A, TUBB1, CYP21A2, TNXB, CSNK2B, PLCE1) 
between these two datasets (pink area). Bolded genes were not in the adjacent mapping of the 29 
highly significant SNPs but were nearby and captured by the more generous 1Mbp mapping used in 
Ballouz et al, 2013 or supported by less significant SNPs using the adjacent mapping in this study. 
Abbreviations: HTN – Hypertension, ICBP – International Consortium of Blood Pressure. 
 
Figure S5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of predicted candidate genes for HTN obtained by reanalysis of WTCCC SNP 
data and ICBP SNP data - Comparison of 219 genes obtained by reanalysis of the WTCCC GWAS 
data (Green circle) [5], and 151 genes obtained by reanalysis of ICBP data (Brown circle). We found 
10 overlapping genes (BCL2, PLCE1, LAMA2, CTNNA3, TJP1, GUCY1A3, PRKG1, NPY2R, 
LAMA1, WDFY3) between these two datasets (purple colour intersection area). Abbreviations: HTN 
– Hypertension, WTCCC – Wellcome Trust Case Control Consortium.
Figure S6 (A) ROC Curve for HTN 
based on known drug targets  
Figure S6 (B) ROC curve for HTN based 
on PubMed citations 
 
 
Figure S6 A) ROC curve for HTN based on thresholds obtained using targets present in search 
space. Figure S6 B) ROC curve for HTN based on thresholds obtained using cut-off of Pubmed 
citations (at least one, five, ten and fifteen). Abbreviations: HTN – Hypertension, ROC curve – 
Receiver Operation Characteristic curve. 
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Chapter 5: Discussion 
In this thesis, we developed a computational pipeline for mapping candidate genes to therapeutics, 
thus extending the Gentrepid candidate gene prediction system. This system (described in detail in 
chapter one), was benchmarked using the WTCCC-GWAS study that identifying loci associated with 
seven complex diseases. We were able to find both known and novel therapeutic targets for the seven 
complex diseases investigated (T1D, T2D, CAD, CAD, RA, HT and BD) (see page viii for 
abbreviations) (chapter 2). Our system (Gentrepid) was capable to replicate both known disease genes 
and therapeutics as well as suggest novel candidates and potential therapeutics for the seven complex 
diseases (see chapter two). We used two benchmarks to validate our results: firstly, the ability to 
retrieve known drug targets for the seven complex diseases (T1D, T2D, CAD, CAD, RA, HT and BD) 
directly from the genetic data using three drug databases (Drug Bank, TTD, PharmGKB) was 
assessed. Secondly, we searched for research articles citing both the gene and the disease name in 
question (e.g. T1D, T2D) from PubMed to assess literature support for the association between the 
gene in question and the phenotype of interest. The first benchmark based on known targets showed 
that 24 known targets (i.e. true positives) of seven complex diseases were replicated in this study 
(p<0.05) and the second benchmark based on literature search of studies related to seven diseases in 
PubMed, showed there was a significant association (p<0.05) between mentions of the seven 
phenotypes and the predicted target gene in literature abstracts. The PubMed benchmark, however, is 
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not conclusive because the association might be a negative one between the phenotype and the 
predicted target gene. 
In chapter three, we applied the new Gentrepid pipeline to the latest GWAS data for CAD to 
produce a more extensive bioinformatics analysis of the latest data from CARDIoGRAMplusC4D 
study (Ballouz S et al. 2013). We utilized the CPS and CMP modules as well as three additional 
modules based on protein-protein interaction data (PPI), miRNA (MIR) and Common Regulatory 
Targets (CRT), which identified 647 candidate genes and 194 therapeutic targets associated with 993 
drugs, from these we were able to identify 184 novel therapeutic targets associated with 981 novel 
drugs which might be directed towards CAD. We compared the therapeutic targets obtained for CAD 
in this study and our previously published study based on the WTCCC data, described in chapter 2 
(Grover, MP et al. 2014). In total, 113 additional targets not identified in our earlier study were 
discovered using the new data in this study (Grover, MP et al. 2015), 79 therapeutic targets were 
common to both studies and 23 targets were not replicated in this study (Grover, MP et al. 2015). We 
validated the results of the study using known CAD targets in the drug databases and literature search 
of CAD studies in PubMed. The first benchmark based on known CAD targets showed that eight 
known CAD targets i.e. true positives were replicated in this study (p<0.05) and the second benchmark 
based on literature search of CAD studies in PubMed, showed there was a significant association 
(p<0.05) between mentions of the CAD phenotype and the predicted target gene in literature abstracts. 
The PubMed benchmark, however, is not conclusive because the association might be a negative one 
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between the CAD phenotype and the predicted target gene. In chapter four, we asked whether 
reanalysis of the more recent ICBP-Hypertension GWAS study (6,244 SNPs, p<1*10-3) could improve 
upon predicted candidate genes and therapeutic targets for the Hypertension phenotype made using the 
WTCCC-GWAS data. We found a total of 151 predicted candidate genes and 35 therapeutic targets 
associated with 392 drugs. From those we were able to identify 33 novel therapeutic targets associated 
with 374 novel therapeutics which might be directed towards HTN. We also found 21 overlapping 
genes between 151 predicted candidate gene dataset predicted in this study and 108 candidate genes 
predicted with the 1Mbp mapping of 29 SNPs (ICBP GWAS data, p < 1*10-7) in our previous study 
(Ballouz S. et al. 2014). We further compared the 151 candidate gene predictions made in this study, 
based on the ICBP data, with the 219 candidates predicted by our reanalysis of the WTCCC GWAS 
data (Ballouz S et al. 2011). We found only 10 of the 219 previously predicted candidate genes were 
replicated in this study and 141 new candidates were identified in this study i.e. there was much poorer 
alignment of the Gentrepid-predicted results based on the older WTCCC data compared to the newer, 
more powerful studies for the HT phenotype compared to the CAD phenotype. As the quantile-
quantile plots had already suggested that the HT data was of much lower quality that the CAD data, 
this suggests that while Gentrepid is a valuable tool for investigating SNPs of lower significance, very 
noisy data will still produce an unacceptably high number of what are likely to be false positives. We 
further validated our results using known HTN targets in the drug databases and literature search of 
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HTN studies in PubMed. The first benchmark based on known HTN targets showed that two known 
HTN targets i.e. true positives were replicated in this study (p<0.05) and the second benchmark based 
on literature search of HTN studies in PubMed, showed there was a significant association (p<0.05) 
between mentions of the HTN phenotype and the predicted target gene in literature abstracts. The 
PubMed benchmark, however, is not conclusive because the association might be a negative one 
between the HTN phenotype and the predicted target gene. 
The implications of all our results in this thesis on the prediction of candidate genes, 
identification of novel therapeutics for complex diseases will now be discussed. The relevance of the 
results in pharmaceutical industries, drug-repositioning approach and development of future medicines 
will also be discussed.  
5.1 Gentrepid as a candidate gene prediction and drug repositioning tool – 
Implications and Limitations  
We used Gentrepid as a candidate gene prediction tool in this thesis. Gentrepid chiefly uses CMP and 
CPS modules to predict candidate genes and it is reflect on how our views of the performance of these 
two modules have changed over time. When we originally benchmarked Gentrepid on a set of 
oligogenic diseases in 2006, we found that most of the predictions came from CPS whereas the results 
from complex diseases had roughly equal contributions from CMP and CPS (George RA et al. 2006). 
CMP predicts results based on domains that are frequently associated with the phenotype. Some of the 
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CMP results came from duplicated genes in the genome eg. ITPR1 on 3p26.1 (1 SNP), ITPR2 on 
12p11 (6 SNPs) and ITPR3 on 6p21 (1 SNP) were predicted as candidate genes for HTN (see Chapter 
4 - Research study 3), suggesting that duplicated genes may play a larger role in complex diseases than 
they do in Mendelian diseases. This makes sense in terms of their non-Mendelian inheritance. 
However, not all CMP predictions came from homologs, with repeated domains in mosaic genes also 
being predicted. These genes may have a common function (eg the helicases BLM, SK1V21 & 
DHX30 predicted in HTN) or, when they are adaptor units, may be involved in mediating homophilic 
protein interactions (C2, PH and EGF domains in HTN) (see Chapter 4 - Research study 3). Other 
domains found repeatedly in the CMP predictions with good genetic support are BAH domains (44 
SNPs) and SH2 domains (33 SNPs) which are adaptor domains allowing proteins to dock to 
phosphorylated tyrosine residues and the LNS2 domain (26 SNPs), involved in adipose tissue 
development and insulin resistance (see Chapter 4 - Research study 3).  
 We also found that both the CMP and CPS modules were effective in predicting significant 
number of candidates for complex diseases. In our previously published study for seven complex 
diseases, CMP and CPS modules predicted a total of 1,497 candidate genes for seven complex 
diseases in seeded and ab initio modes. CPS module predicted between 59-100% of total seeded 
predictions and 14-100 % of total ab initio predictions, while CMP module predicted between 12-43% 
of total seeded predictions and 27-88% of total ab initio predictions (Ballouz S. et al. 2011). In both 
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seeded and ab initio modes, there was at most 12% overlap of predictions from both CMP and CPS 
modules predictions (Ballouz S. et al. 2011). In the specific case study for HTN (chapter 4), CMP 
module predicted 108 candidate genes and CPS module predicted 71 candidate genes with a 
significant overlap of 28 genes. In seeded mode, both CMP and CPS module predicted 54 unique 
candidate genes, while in ab initio mode both CMP and CPS module predicted 134 unique genes (see 
Chapter 4 - Research study 3). These results suggest that the ability of CMP and CPS modules to make 
credible independent predictions is consistent with the behaviour of the system on data from complex 
diseases. However, Gentrepid predictions are limited by the biological databases they are rely on. In 
“seeded” mode of CPS and CMP modules, candidate gene predictions are limited by known genotype-
phenotype data available in the OMIM database. In “ab initio” mode of CMP and CPS modules, 
candidate gene predictions are limited by the underlying pathway (e.g. KEGG, Biocarta) and domain 
databases (e.g. Pfam) utilized. It is estimated that coverage of pathways in current knowledgebases is 
only 10-25% of existing pathways. Although domain coverage is better, with 70% of the genes in the 
genome having a least one parseable Pfam domain, other regions of the protein sequence are 
completely unrepresented in the Pfam library (George RA et al. 2006, Finn RD et al. 2015). Hence, 
Gentrepid predictions using CMP and CPS modules are incomplete because we still lack complete 
understanding of human protein interactome and complete characterization of all the protein domains. 
 In the three research studies described in this thesis, we extended Gentrepid as a drug 
repositioning tool to predict potential novel therapeutics for complex diseases suitable for 
Mani Grover 
95 
 
 
 
 
 
 
repositioning in clinical trials. The skyrocketing prices of drug development and the high failure rate 
of several drug compounds in clinical trials constantly drive pharmaceutical industries to explore new 
drug development strategies. Drug repositioning is a drug development approach which adds great 
value to the revenue of the pharmaceutical companies by bringing novel and affordable treatments for 
a number of serious diseases using already approved compounds (see section 1.1.4 Drug repositioning 
of chapter one for more details). In recent years, various Informational Technology (IT) based 
methods such as data mining, bioinformatics, and the use of novel screening platforms have been used 
for the identification and screening of potential drug candidates at low cost. Similarly, our approach 
used Gentrepid to identify novel therapeutic targets and associated therapeutics suitable for 
repositioning towards seven complex diseases by combining genetic information from GWAS studies 
with already known drug data from three drug databases (DrugBank, PharmGKB, and TTD). In our 
study, we extracted a total of 7,252 drugs from three drug databases. Gentrepid identified 2,192 drugs 
(29% of extracted 7,252 drugs) mapped to 452 potential therapeutic targets for seven complex diseases 
(see Chapter 2- Research study 1), 993 drugs mapped to 192 potential therapeutic targets for CAD (see 
Chapter 3 - Research study 2), 392 drugs mapped to 35 potential therapeutic targets for HTN (see 
Chapter 4 - Research study 3). We also found 2,130 novel therapeutics mapped to 428 novel 
therapeutic targets for seven complex diseases (see Chapter 2- Research study 1), 981 novel 
therapeutics mapped to 184 novel therapeutic targets for CAD (see Chapter 3 - Research study 2), 374 
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drugs mapped to 33 novel therapeutic targets for HTN (see Chapter 4 - Research study 3). Our results 
have important implications for the pharmaceutical industry because novel therapeutics suitable for 
repositioning can provide a starting point in the long and difficult journey of drug discovery. By 
identifying these drugs which are likely to respond to novel targets, it will be easier to demonstrate 
efficacy and safety of such drugs. This would lead to smaller, more effective clinical trials with 
corresponding cost savings.   
Successful repositioning of a drug depends on integration of both intellectual property (IP) and 
regulatory laws. Patent strategies directed to protect repositioned formulations, and methods of use can 
be effective only when the original formulations, and methods of use are off-patent (Smith 2012). 
Repositioning strategies that include IP and legal input strategies can help more readily transform an 
apparently non-viable drug repurposing project into a successful project. However, drug repositioning 
will not be successful in all cases. For example, the kinase inhibitor bevacizumab failed to show 
efficacy in a human clinical trial (phase III) for gastric cancer despite already being repurposed 
towards many other different cancers (Kang & Kauh 2011). In another example, the multi-kinase 
inhibitor sunitinib also failed human clinical trials for breast cancer, colorectal cancer, Non-small cell 
lung cancer (NSCLC) and prostate cancer, but was approved for the treatment of renal cell carcinomas 
and pancreatic tumors (Highlights 2011). In another study, the combination of bupropion and 
naltrexone, previously approved for depression and opioid addiction, seemed to regulate appetite in 
obese people, however, the FDA later rejected this combination due to adverse cardiovascular effects 
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(Caveney et al. 2011; Plodkowski et al. 2009). Therefore, even repurposed drugs that have passed 
clinical safety standards (e.g. phase I/II) might still be found to have adverse effects. Hence, it is 
important for pharmaceutical companies to consider the limitations related to adverse side effects of a 
drug before repurposing in human clinical trials. 
5.2 Implications in future medicine  
 
Preclinical trials and human clinical trials are often the largest source of Research and Development 
(R&D) in the pharmaceutical sector. As drug regulatory requirements continue to be tightened and 
research and development costs continue to rise, there is an ever-growing need to improve R&D 
productivity. It requires large clinical trials and a focus on data gathering, collection and analysis 
based on rigorous preclinical and clinical testing done to establish safety and efficacy of a drug. This 
approach increases costs but does not consistently improve outcomes. Therefore, R&D organizations 
have already started improving productivity by developing large data analytical capabilities focused on 
specific patient cohorts. Gentrepid as a bioinformatics tool, predicts large number of predicted 
therapeutic targets by reanalyzing population based GWAS data and identifies novel therapeutics 
suitable for repositioning in human clinical trials (Grover, Mani P. et al. 2015; Grover, Mani P et al. 
2014). In future, Gentrepid can also be integrated in the large data analytics by the pharmaceutical 
industry to design more efficient clinical trials, and speed up the drug discovery and the approval 
process while reducing the costs for R&D. 
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In recent years, a number of pharmaceutical researchers and physicians have proposed the 
concepts of ‘Personalised medicine’ and ‘P4 medicine’ to describe future of medicine (Hamburg & 
Collins 2010; Weston & Hood 2004) . This ‘P4 Medicine’ approach relates to using predictive, 
preventive, personalised and participatory medicine approaches (Khoury et al. 2012). A number of 
researchers have suggested adding ‘a fifth P’, which relates to a population perspective as many 
disease-associated genetic variants (SNPs) discovered in population based association studies (e.g. 
GWAS) need to be validated in real clinical settings (Khoury et al. 2012). 
Personalised medicine involves the prediction, prevention and treatment of illness by 
prioritizing individuals’ needs (Khoury et al. 2012). This results in a patient-centric approach for 
therapeutic development unlike the currently used drug-centric and target-centric approaches (Chawla 
& Davis 2013) (see Introduction chapter one for details). Patient-centric approaches prioritize patients’ 
needs compared to the drug-centric and target-centric approaches in which selection of an effective 
drug compound or therapeutic target is the first and foremost priority. However, in combination with 
the drug-centric and target-centric approaches, a patient-centric approach can overcome challenges to 
develop personalised medicines for real-life patients. 
In the three research studies described in this thesis (Chapter 2- 4), we identified novel 
treatments suitable for repositioning for complex diseases using a system-based approach. Our 
bioinformatics analysis of GWAS data of population studies, certainly contribute to the vision of 
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patient- centred P4/P5 medicine in the treatment of complex diseases. In future, such systems based 
approaches will be able to transform conventional costly medicines to more affordable P4/ P5 
medicines focused on personalised patient data resulting in a decrease in the time and costs associated 
with drug development. The integration of ‘P4’and ‘P5’ medicines with genomic and bioinformatics 
approaches will emphasize personalised health monitoring, molecular symptom, early detection and 
preventative medicine, which will bring a paradigm shift from conventional medicine. However, the 
real-time genomic data of patients will be enormous, which will need to be handled carefully.  
In future, the applications of personalised medicine in many aspects of health care will increase 
due to the rapid decline in the cost of genomic profiling and availability of web based bioinformatic 
tools such as Gentrepid (www.gentrepid.org), which analyses genomic data quickly and efficiently 
(Ballouz, S. et al. 2011; Grover, Mani P. et al. 2015; Grover, Mani P et al. 2014). However, this can 
only be accomplished by creating harmonisation between scientific researchers, healthcare 
professionals and the wider society. Altogether, medical scientists, governments, pharmaceutical 
companies and patients themselves can ensure the success of this new transformation of medicine. 
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Chapter 6: Conclusion 
In conclusion, we have identified novel therapeutics for seven complex diseases suitable for 
repositioning in human clinical trials by integrating genetic, bioinformatic and drug data. Our results 
demonstrate how powerful data mining and analysis can be used by the pharmaceutical industry to 
identify novel therapeutics from existing approved drug data. Genetic association studies that correlate 
gene variants with already known drugs can aid the development of more efficacious therapeutics for 
complex diseases. However, combining gene-variant and drug information using bioinformatics 
approaches to deliver effective therapies is still a major challenge. This study demonstrates an 
approach for efficiently identifying possible novel therapeutic targets and alternative applications of 
existing therapeutics. In the first research study, we found 22% of predicted candidate genes as novel 
therapeutic targets from the predicted candidate gene dataset and ~29% of drugs as novel therapeutics 
from the drug dataset for the seven complex diseases. In the second research study for CAD, we have 
specifically identified 30% of predicted candidate genes as therapeutic targets and 14% of retrieved 
drugs as therapeutics specific to repurpose towards CAD. In our third and final study for HTN 
phenotype, we have identified 23% of candidate genes as novel therapeutic targets 5% of extracted 
drugs feasible to repurpose towards HTN. We have utilized both FDA approved drugs and drugs in 
clinical trials. Hence, these drugs may potentially be repurposed against the seven phenotypes of 
interests, quickly taking advantage of prior work in pharmaceutics to translate ground - breaking 
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results in genetics to clinical treatments. Gentrepid, thus, can be utilized as a drug repositioning tool to 
save time and money spent on initial stages of drug discovery.   
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Appendix 
 
This section consists thesis errata for chapter 2 and chapter 3 described in this thesis. This section also 
consists award certificates, course certificates obtained in conferences and symposia.  
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Thesis Errata 
 
Chapter 2 p. 9 of research article: Benazapril is not a therapeutic for AGT, it targets ACE. There is only 
an interaction between Benazapril and AGT, but the drug does not act on AGT.  
 
Chapter 2 p. 9 of research article: Repaglinide is not a therapeutic for TCF7L2. There is only an 
interaction between Repaglinide and TCF7L2, but the drug does not act on TCF7L2. 
 
Chapter 2 p. 10 of research article: Lithium is not a novel therapeutic for GSK3B. There is only an 
interaction between Lithium and GSK3B, but the drug does not act on GSK3B. 
 
Chapter 2 p. 10 of research article: Methotrexate is not a novel therapeutic for ABCC1. There is only 
an interaction between Methotrexate and ABCC1, but the drug does not act on ABCC1. 
 
Chapter 3 p. 6 of research article: Fluvoaxamine is not a novel therapeutic for HTR1A. There is only 
an interaction between Fluvoaxamine and HTR1A, but the drug does not act on HTR1A. 
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